,date,information,related
0,2022-09-22,"Headline: AstraZeneca Gets EU Approval for Ultomiris Drug, source:MarketWatch, summary: By Sabela Ojea AstraZeneca PLC said Friday that its Ultomiris drug has been approved in the European Union for the treatment of adults with the rare disease..., Headline: LONDON BRIEFING: Smiths annual revenue rises; Made.com up for sale, source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca's Ultomiris approved in EU for myasthenia gravis, source:Alliance News, summary: No summary",AZN
1,2022-09-23,"Headline: Ionis Pharmaceuticals announces AstraZeneca decision to not advance ION449 trial, source:Thefly.com, summary: Ionis Pharmaceuticals (IO... IONS, AZN, Headline: AstraZeneca's Ultomiris approved in Europe in gMG treatment, source:Thefly.com, summary: The company states: ""... AZN, Headline: VGK: Deutsche Bank Sees Brutal EU Economic Contraction In 2023, Yet It May Still Be Overly Optimistic, source:SeekingAlpha, summary: Deutsche Bank expects EU economy to contract 2.2%. Read more to see why EU as a whole will underperform and VGK ETF's significant headwinds., Headline: AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med, source:Yahoo, summary: Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels). Ionis said that although the candidate met the primary endpoint, its partners at AstraZeneca Plc (NASDAQ: AZN) have decided not to move it into Phase III studies because the ""results did not achieve pre-specified efficacy criteria."" The trial showed that 60mg of ION449 (AZD8233) administered monthly achieved a statistically signifi, Headline: Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test, source:Yahoo, summary: Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing., Headline: Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK, source:Yahoo, summary: Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 3.07% to $54.58 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: ADRs End Lower, Alibaba and AstraZeneca Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed lower on Friday. The S&P/BNY Mellon index of American depositary receipts dropped 3.4% to..., Headline: Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III, source:Yahoo, summary: Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.",AZN
2,2022-09-24,"Headline: 3 Medical Stocks Displaying Remarkable Relative Strength In 2022, source:TalkMarkets, summary: 3 medical stocks that displayed a substantial amount of relative strength year-to-date.",AZN
3,2022-09-25,"Headline: GSK Appoints Julie Brown as New CFO, source:MarketWatch, summary: By Ian Walker GSK PLC said Monday that it has appointed Julie Brown as its new chief financial officer, replacing Iain Mackay, from May 2023. The..., Headline: LONDON BRIEFING: Unilever CEO to step down; RPS backs new takeover bid, source:Alliance News, summary: No summary, Headline: TOP NEWS: GSK names Burberry's Julie Brown as new CFO from May, source:Alliance News, summary: No summary",AZN
4,2022-09-26,"Headline: 10 Best Diabetes Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss the 10 best diabetes stocks to buy now. If you want to read about some more diabetes stocks, go directly to 5 Best Diabetes Stocks To Buy Now. The diabetes market has grown in the past few years as organizations and individuals in the private and public domains make significant […], Headline: AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication, source:Yahoo, summary: AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.",AZN
5,2022-09-27,"Headline: TOP NEWS: AstraZeneca's Tezspire and Koselugo approved in Japan, source:Alliance News, summary: No summary, Headline: 7 Vaccine Stocks to Sell ASAP Now That the 'Pandemic's Over', source:InvestorPlace, summary: Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over., Headline: AstraZeneca's Tezspire approved in Japan for severe asthma treatment, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca's Koselugo approved in Japand for pediatric plexiform neurofibromas, source:Thefly.com, summary: The company states: ""... AZN, Headline: Wall Street Breakfast: Dollar Vs. Stocks, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Dollar vs. Stocks The U.S., Headline: Adding $100 to These 7 Stocks Would Be a Genius Move Right Now, source:Yahoo, summary: You don't need a mountain of cash to build wealth on Wall Street -- especially with deals like these., Headline: 7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’, source:Yahoo, summary: As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected with the less fatal strain, Omicron, people would isolate themselves for a few days and then return to work. By shifting away from its reliance on drug companies, investors must recognize there are vaccine stocks that it’s time to sell. The government cut orders for vaccines and antivira, Headline: Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer, source:Yahoo, summary: Japan's health agency has approved AstraZeneca Plc's (NASDAQ: AZN) Koselugo (selumetinib) for pediatric patients with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms and which cannot be entirely removed by surgery without the risk of substantial morbidity. The approval is based on positive results from the SPRINT Stratum 1 Phase 2 trial that showed Koselugo reduced the size of inoperable tumors in children. The SPRINT Stratum 1 Phase 2 trial showed Koselugo",AZN
6,2022-09-28,"Headline: 7 Large-Cap Stocks With Sustained Dividend Growth Potential, source:InvestorPlace, summary: Large-cap stocks with dividend growth potential have robust cash flows and are likely to increase their dividends in the coming years., Headline: Covid vaccination linked to slight increase in menstrual cycle, NIH study confirms, source:CNBC, summary: A change in menstrual cycle length of eight days or less is considered within the normal range of variation, according to NIH., Headline: Cantor Fitzgerald healthcare analysts to hold KOL luncheon panel, source:Thefly.com, summary: In conjunction with Canto... AZN, AMGN, MRTX, GILD, IMAB, NVS, SURF, PFE, ALXO, RHHBY, MRK, Headline: PhaseBio Might Have To Return Global Rights To Its Lead Program, source:Yahoo, summary: PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition. Formerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc's (NASDAQ: AZN) blood thinner Brilinta (ticagrelor) In January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights., Headline: AZN vs. LLY: Which Stock Is the Better Value Option?, source:Yahoo, summary: AZN vs. LLY: Which Stock Is the Better Value Option?, Headline: Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise, source:SeekingAlpha, summary: APLS' flagship product was rolled out last year, is pursuing other indications, and could eventually achieve blockbuster status. Read more on the stock here.",AZN
7,2022-09-29,"Headline: LONDON BROKER RATINGS: GSK raised to 'outperform'; RBC cuts THG, source:Alliance News, summary: No summary, Headline: GLOBAL BROKER RATINGS: Nordisk and GSK raised; BofA cuts Apple, source:Alliance News, summary: No summary",AZN
8,2022-09-30,"Headline: 5 Dividend Growth Stocks to Beat Market Volatility, source:Yahoo, summary: Coca-Cola (KO), General Dynamics (GD), AstraZeneca (AZN), Boise Cascade (BCC), and Insperity (NSP) that offer dividend growth could be compelling picks amid market volatility.",AZN
9,2022-10-02,"Headline: Investors shouldn't have to choose between 'growth' and 'safety' – this stock offers both, source:Yahoo, summary: Investing in shares is a tough task at the best of times. The stock market’s continual ebb and flow between joy and despair means that investors can frequently find themselves on the wrong side of consensus views for extended periods.",AZN
10,2022-10-03,"Headline: Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio , source:TalkMarkets, summary: Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio., Headline: Alexion, AstraZeneca Rare Disease to acquire LogicBio Therapeutics for $2.07 p/s, source:Thefly.com, summary: LogicBio Therapeutics (LO... LOGC, AZN, Headline: Alexion, AstraZeneca Rare Disease to acquire LogicBio for $2.07 per share, source:Thefly.com, summary: Alexion (ALXN), AstraZene... ALXN, AZN, LOGC, Headline: nan, source:TipRanks, summary: nan, Headline: AstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGC, source:MarketWatch, summary: By Colin Kellaher LogicBio Therapeutics Inc. on Monday said it agreed to be acquired by AstraZeneca PLC for about $68 million in a deal supporting the..., Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: Myovant Sciences soars following acquisition proposal from Sumitovant Biopharma LOGC, MYOV, VSAT, BOX, WFC, APRN, CS, TSLA, DOCU, AZN, Headline: Zacks.com featured highlights include Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity, source:Yahoo, summary: Coca-Cola, General Dynamics, AstraZeneca, Boise Cascade and Insperity have been highlighted in this Screen of The Week article., Headline: Why Is LogicBio (LOGC) Stock Up 600% Today?, source:InvestorPlace, summary: LogicBio (LOGC) stock is seeing massive gains on Monday following news that AstraZeneca (AZN) subsidiary Alexion is acquiring the company., Headline: LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGC, source:MarketWatch, summary: By Colin Kellaher Shares of LogicBio Therapeutics Inc. skyrocketed Monday after the genetic-medicine company agreed to be acquired by Anglo-Swedish pharma..., Headline: Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine, source:Yahoo, summary: WILMINGTON, Del., October 03, 2022--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development., Headline: Why Are LogicBio Therapeutics Shares Skyrocketing Today?, source:Yahoo, summary: AstraZeneca Plc's (NASDAQ: AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ: LOGC) for $2.07 per share. Both boards have unanimously approved the transaction. Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock. It plans to retain LogicBio employees at their current location. Also Read: LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatri, Headline: LogicBio's stock skyrockets after buyout bid for a 667% premium, source:Yahoo, summary: Shares of LogicBio Therapeutics Inc. skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company announced an agreement to be acquired by AstraZeneca PLC's Alexion, AstraZeneca Rare Disease in a deal that values LogicBio at about $68.23 million. The stock had closed Friday at a record low of 27 cents, representing a market capitalization for LogicBio of about $8.9 million. Under terms of the buyout deal, Alexi, Headline: ADRs End Higher, ABB and AstraZeneca Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed higher Monday. The S&P/BNY Mellon index of American depositary receipts edged up 2.6% to..., Headline: AstraZeneca acquires local startup at 660% premium, source:Yahoo, summary: AstraZeneca Rare Disease, the local division formed when the British pharma giant acquired Alexion Pharmaceuticals Inc. last year, has scooped up a struggling local biotech at a significant premium.  AstraZeneca plc (Nasdaq: AZN) is buying LogicBio Therapeutics Inc. (Nasdaq: LOGC) for $2.07 per share, a 660% premium that values the total acquisition at $68 million.  Lexington-based LogicBio has been struggling since February, when the U.S. Food and Drug Administration ordered a halt to an early-stage trial testing a drug in pediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats., Headline: Astrazeneca (AZN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $55.55 in the latest trading session, marking a +1.29% move from the prior day.",AZN
11,2022-10-04,"Headline: FDA approves Roche breast cancer detection test eligible for ENHERTU, source:Thefly.com, summary: Roche (RHHBY) ""annou... RHHBY, AZN, DSNKY",AZN
12,2022-10-05,"Headline: FOCUS-Fresenius taps pre-dialysis kidney care as drugs promise treatment change, source:Yahoo, summary: The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.  For decades, Germany's Fresenius Medical Care (FMC) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function.  The company’s 17.6 billion euros ($17.6 billion) in annual revenue has been sustained for decades by high rates of obesity and diabetes, which contribute to kidney damage., Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly LOGC, CALA, MYOV, ACOR, CDXC, AZN, Headline: 10 Healthcare Stocks to Watch in Light of Biden’s ‘60 Minutes’ Interview, source:Yahoo, summary: In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […]",AZN
13,2022-10-06,"Headline: GSK: Some Upside Likely, source:SeekingAlpha, summary: GSK's price might have underwhelmed recently, but it's picking up now. Read more to know why GSK stock looks like a buy to me., Headline: FTSE 100 to pay £81.5bn to investors in dividend bonanza, source:Yahoo, summary: FTSE 100 set for record cash returns to investors but dividend forecasts stall., Headline: AZN November 25th Options Begin Trading, source:Stock Options Channel, summary: Staff article entitled AZN November 25th Options Begin Trading, about stock options, from Stock Options Channel., Headline: Top 20 Drug Companies in the World in 2022, source:Yahoo, summary: In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […], Headline: HONEYWELL BEGINS PRODUCTION OF NEAR-ZERO GLOBAL-WARMING-POTENTIAL MEDICAL PROPELLANT, source:Yahoo, summary: Honeywell (Nasdaq: HON) today announced the opening of a plant in Baton Rouge, La., that is the company's first large-scale manufacturing site for Solstice® Air (HFO-1234ze(E) cGMP), a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers.",AZN
14,2022-10-07,"Headline: Home - The Fly, source:Thefly.com, summary: The Fly is a leading digital publisher of real-time financial news. The Fly team scours all sources of company news and delivers short-form stories consisting of only market moving content., Headline: Omicron BA.4.6 subvariant makes up nearly 14% of COVID variants in U.S. - CDC, source:Yahoo, summary: The U.S. Centers for Disease Control and Prevention (CDC) on Friday estimated that by Oct. 8 nearly 14% of the circulating coronavirus variants in the United States were of the BA.4.6 subvariant of Omicron.  The subvariant has been slowly increasing in prevalence across the U.S., even as the BA.5 subvariant of Omicron remains the dominant strain with 79.2% of the cases.  The BA.4.6 subvariant has been found to be better at evading COVID-19 antibody therapies, with the U.S. Food and Drug Administration in early October warning healthcare providers that AstraZeneca's Evusheld had the risk of being ineffective against some variants it cannot neutralize., Headline: Here’s Why AstraZeneca PLC (AZN) Benefited in the Second Quarter, source:Yahoo, summary: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. Since 2015, for the first time, the market witnessed two consecutive quarterly losses. During the second quarter, the S&P 500 Index continued its decline, trading at -16.1%. […]",AZN
15,2022-10-09,"Headline: Have $2,000? 2 Market Crash-Ready Stocks to Buy, source:Yahoo, summary: Specifically, there are a pair of pharmaceutical companies whose roster of in-demand medicines makes their prospects better than most in the face of market turbulence of any kind, so let's analyze each and see why they could be a smart pickup for some downside protection.  Pfizer (NYSE: PFE) is a company that needs no introduction, especially not after its rapid development and commercialization of Comirnaty, its coronavirus vaccine.  Furthermore, Pfizer has a veritable cornucopia of other medicines that people rely on, too.",AZN
16,2022-10-10,"Headline: Strong Dollar Means Buy Abroad - Assessing Foreign Assets, source:SeekingAlpha, summary: Investors are flocking to USD, and most foreign currencies are now weak. Click here to know about the ways that a strong USD influences foreign assets., Headline: Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe, source:Yahoo, summary: Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang., Headline: AstraZeneca's COVID vaccine suffers a setback in nasal spray trial, source:Yahoo, summary: Attempts by Oxford University researchers and AstraZeneca Plc  to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection.  An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement on Tuesday.  Also, the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination., Headline: Nasal version of Oxford/AstraZeneca Covid vaccine fails in trial, source:Yahoo, summary: A nasal version of the Oxford/AstraZeneca Covid-19 vaccine has failed in an early-stage trial, dealing a blow to hopes for a more effective way to prevent transmission of the virus.  Oxford university said on Tuesday a nasal formulation of the vaccine elicited mucosal antibody responses in a “minority of participants” and systemic immune responses were weaker compared with intramuscular vaccination.  The setback highlights the complexity of designing a nasal formulation against coronavirus, which spreads through tiny particles in the air., Headline: AstraZeneca call volume above normal and directionally bullish, source:Thefly.com, summary: Bullish option flow detec... AZN",AZN
17,2022-10-11,"Headline: AstraZeneca price target lowered to 11,800 GBp from 12,000 GBp at Guggenheim, source:Thefly.com, summary: Guggenheim analyst Seamus... AZN, Headline: Illumina launches strategic research collaboration with AstraZeneca, source:Thefly.com, summary: Illumina (ILMN) announced... ILMN, AZN, Headline: AstraZeneca Looks to Cancer, RSV Drugs for Growth as Covid-Vaccine Demand Wanes, source:Yahoo, summary: The British drugmaker is reducing production of its Covid-19 vaccine and betting on new therapies for other conditions., Headline: AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. The AstraZeneca-funded phase 1 trial tested the efficacy of the Oxford vaccine when delivered through a simple device that sprays droplets up the nose. In a statement, the University of Oxford said that an antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial. While the trial raise, Headline: Oxford/AstraZeneca COVID vaccine nasal spray fails in trial, source:Yahoo, summary: The nasal version of the Oxford/AstraZeneca COVID vaccine failed to elicit an antibody response in an early trial and the company is shelving its development, Headline: GSK to Hire Top AstraZeneca Dealmaker After Agreement Reached, source:Yahoo, summary: (Bloomberg) -- GSK Plc is free to hire a top dealmaker from AstraZeneca Plc after reaching an agreement with its rival, which had sued to block the sharing of sensitive information.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketThis Is What 7% Mortgages Will Do to the Housing MarketIt’s Official: The Fed’s in the RedThe Most Powerful Buyers in Treasuries Are All Bailing at OnceScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyChris Sheldon w, Headline: Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery, source:Yahoo, summary: Illumina Inc (NASDAQ: ILMN) entered a strategic research collaboration with AstraZeneca plc (NASDAQ: AZN) on drug target discovery. Financial and other details of the partnership were not disclosed. Under the terms of the agreement, the firms will join forces on artificial intelligence-based genome interpretation and genomic analysis and evaluate whether a combined framework can increase the yield of and confidence in target discovery. AstraZeneca's Center for Genomics Research will use the comb, Headline: Illumina collaborates with AstraZeneca on AI-focused research, source:Alliance News, summary: No summary",AZN
18,2022-10-12,"Headline: AstraZeneca's  Alexion to present new data on advancement in treating NMOSD, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca to show 'exceptional' data on neuromyelitis drug Ultomiris, source:Alliance News, summary: No summary, Headline: Alexion, AstraZeneca Rare Disease to present new Ultomiris data, source:Thefly.com, summary: Alexion (ALXN), AstraZene... ALXN, AZN, Headline: Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022, source:Yahoo, summary: WILMINGTON, Del., October 12, 2022--Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26 to 28, 2022., Headline: LONDON MARKET CLOSE: Stocks down as BoE confirms end to bond-buying, source:Alliance News, summary: No summary, Headline: U.K. stocks drop for sixth day, source:MarketWatch, summary: U.K. stocks fell Wednesday, as the FTSE 100 Index finished down 0.86% at 6,826.15. Of the FTSE 100 constituents, clothing retail company JD Sports Fashion..., Headline: 2 No-Brainer Stocks to Buy Right Now for Less Than $100, source:Yahoo, summary: Here are two excellent companies to consider: AstraZeneca (NASDAQ: AZN) and Roku (NASDAQ: ROKU).  U.K.-based AstraZeneca has a rich and diversified lineup of drugs.  The company's best-selling therapeutic area is oncology., Headline: 10 Best Cancer Stocks to Buy Now, source:Yahoo, summary: In this article, we discuss the 10 best cancer stocks. To skip the detailed analysis of the oncology market, go directly to 5 Best Cancer Stocks to Buy Now. Due to the COVID-19 pandemic, the oncology segment of the market saw a slight impact. The screening and oncology care services saw a decline in priority […], Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slumped 0.42% to $55.07 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $55.07, marking a -0.42% move from the previous day.",AZN
19,2022-10-13,"Headline: 3 Incredibly Cheap Blue Chip Stocks to Buy Right Now, source:Yahoo, summary: Bear markets are never fun.  Good news often fails to land with investors, blue chip stocks rarely prove to be rock-solid safe havens, and important sources of passive income, such as dividends, can dry up as companies rethink their capital allocation strategies.  History has shown, however, that bear markets are some of the best times to buy equities and hold them for long periods., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.84% higher to $55.53 Thursday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Astrazeneca (AZN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $55.53, marking a +0.84% move from the previous day.",AZN
20,2022-10-14,"Headline: 2 Top Biotech Stocks to Buy Right Now, source:Yahoo, summary: Healthcare is a reliable sector of the economy for those looking to create wealth over the long haul., Headline: AstraZeneca PLC ADR falls Friday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 1.01% to $54.97 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite...",AZN
21,2022-10-17,"Headline: Is This Monster Stock on the Verge of a Home Run?, source:Yahoo, summary: Ultomiris was just approved in the European Union to treat patients with generalized myasthenia gravis., Headline: Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern, source:SeekingAlpha, summary: The FDA announced a surprise advisory committee meeting for Cytokinetics' omecamtiv. Read why I have grave doubts whether omecamtiv will be approved easily., Headline: 10 Best FTSE Dividend Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss 10 best FTSE dividend stocks to buy now. If you want to see more stocks in this selection, check out 5 Best FTSE Dividend Stocks To Buy Now. The Office for National Statistics reported that the U.K. economy contracted by 0.3% in August, potentially initiating a long recession that can […], Headline: Moderna CEO talks competition with J&J, Novavax, AstraZeneca, source:Yahoo, summary: Moderna CEO Stephane Bancel on competing with traditional players in the drug and vaccine space., Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 2.20% to $56.18 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",AZN
22,2022-10-18,"Headline: iKena Oncology provides research, development update on IK-930 program, source:Thefly.com, summary: Ikena Oncology (IKNA) pro... IKNA, AZN, Headline: 7 Stocks to Buy When There's Blood in the Streets, source:InvestorPlace, summary: For investors looking for high-quality stocks to buy when there is blood in the streets, there happen to be plenty of companies to pick., Headline: What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?, source:InvestorPlace, summary: AVEO stock jumped on the news that LG Chem will pay $15/share for Aveo Oncology and make it the centerpiece of a new oncology division., Headline: Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway, source:Yahoo, summary: Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today provided a research & development update on the Company’s lead ta, Headline: Should You Invest in AstraZeneca PLC (AZN)?, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor […], Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.37% to $55.97 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: ADRs End Mostly Stronger; AstraZeneca, atai Life Sciences Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed mostly higher Tuesday. The S&P/BNY Mellon index of American depositary receipts edged up 0.3%..., Headline: AstraZeneca price target lowered to 118 GBp from 120 GBp at Berenberg, source:Thefly.com, summary: Berenberg analyst Luisa H... AZN, Headline: 7 Stocks to Buy When There’s Blood in the Streets, source:Yahoo, summary: In general, the last quarter of the year is good for equity markets. However, it’s too early to assume that the markets are automatically headed higher. From the perspective of most investors, Q4 is set up to provide both opportunities and challenges. The upside is that the best time to look for stocks to buy is when there is blood in the streets. The bad news is that stocks may continue to struggle, given the current macro backdrop. So, what’s the reason for concern? Well, inflation remains hig",AZN
23,2022-10-19,"Headline: LONDON BROKER RATINGS: HSBC lifts Marston's; Barclays cuts Flutter, source:Alliance News, summary: No summary, Headline: GLOBAL BROKER RATINGS: Deutsche Bank and JPMorgan upgrade Netflix, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 2.61% to $54.51 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...",AZN
24,2022-10-20,"Headline: TOP NEWS: AstraZeneca says Evusheld shows promise on Covid variants, source:Alliance News, summary: No summary, Headline: Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports, source:Thefly.com, summary: Under the Inflation Reduc... BMY, JNJ, LLY, MRK, PFE, SNY, AZN, GSK, RHHBY, NVS, Headline: AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards, source:Yahoo, summary: WILMINGTON, Del., October 20, 2022--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the fourth annual Cancer Community Awards (C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate and recognize inspiring work that exemplifies the full promise of community partnerships in advancing equitable access to quality cancer care., Headline: AstraZeneca PLC ADR falls Thursday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slumped 0.29% to $54.35 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Moves -0.29%: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $54.35, moving -0.29% from the previous trading session.",AZN
25,2022-10-21,"Headline: 3 Alzheimer's Therapy Stocks to Invest in, source:Yahoo, summary: Alzheimer's therapies are big news lately.  The disease is the leading cause of dementia and memory loss.  The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.14% to $54.97 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Top Stock Reports for AstraZeneca, Caterpillar & Crown Castle, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), Caterpillar Inc. (CAT) and Crown Castle Inc. (CCI).",AZN
26,2022-10-23,"Headline: AstraZeneca treatment gets FDA approval for US liver cancer patients, source:Alliance News, summary: No summary",AZN
27,2022-10-24,"Headline: AstraZeneca's Imjudo+Imfinzi approved in U.S. for unresectable liver cancer, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer, source:Yahoo, summary: The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the combination includes a single dose of the anti-CTLA-4 antibody Imjudo 300mg added to the anti-PD-L1 antibody Imfinzi 1500mg, followed by Imfinzi every four weeks, dubbed the STRIDE regimen. The approval was based on positive results from the HIMALAYA Phase 3 tri, Headline: IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer, source:Yahoo, summary: WILMINGTON, Del., October 24, 2022--AstraZeneca’s IMJUDO® (tremelimumab) in combination with IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the combination, which includes a single dose of the anti-CTLA-4 antibody IMJUDO 300mg added to the anti-PD-L1 antibody IMFINZI 1500mg followed by IMFINZI every four weeks, is called the STRIDE regimen, Headline: Merck (MRK) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings., Headline: The Zacks Analyst Blog Highlights AstraZeneca, Caterpillar, Crown Castle, Nasdaq and American Water Works, source:Yahoo, summary: AstraZeneca, Caterpillar, Crown Castle, Nasdaq and American Water Works are part of the Zacks top Analyst Blog., Headline: AstraZeneca's Fasenra Treatment Passed One of Two Endpoints in Trial, source:MarketWatch, summary: By Joe Hoppe AstraZeneca PLC said Tuesday that a Phase 3 trial of its Fasenra treatment for eosinophilic esophagitis passed one dual-primary endpoint but..., Headline: TOP NEWS: AstraZeneca's Fasenra fails to meet trial's primary endpoint, source:Alliance News, summary: No summary",AZN
28,2022-10-25,"Headline: AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra (benralizumab) in Eosinophilic esophagitis (EoE) patients aged 12 years or older. Eosinophilic esophagitis (EoE) is characterized by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus. Patients experience difficulty swallowing (dysphagia), pain, food getting stuck, and anxiety. The data showed that Fasenra (benralizumab) did not meet one of the two du, Headline: 12 Best Value Dividend Stocks To Buy, source:Yahoo, summary: In this article, we will take a look at 12 best value dividend stocks to buy. If you want to see more of the best value dividend stocks to buy, go directly to 5 Best Value Dividend Stocks To Buy. Inflation remains a headwind for the markets in 2022. In terms of inflation, the annual […], Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.30% to $55.90 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: ADRs End Mostly Higher, AstraZeneca and atai Life Sciences Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed mostly higher on Tuesday. The S&P/BNY Mellon index of American depositary receipts edged up..., Headline: LONDON MARKET OPEN: Sterling climbs above USD1.15, euro above parity, source:Alliance News, summary: No summary",AZN
29,2022-10-26,"Headline: TOP NEWS: AstraZeneca hails survival rates of breast cancer drugs, source:Alliance News, summary: No summary, Headline: AstraZeneca phase 3 study shows Capivasertib+Faslodex improves breast cancer PFS, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints, source:Yahoo, summary: The Anglo-Swedish pharma giant said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations., Headline: Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer, source:Yahoo, summary: WILMINGTON, Del., October 26, 2022--Positive high-level results from the CAPItello-291 Phase III trial showed that AstraZeneca’s capivasertib in combination with FASLODEX® (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus FASLODEX in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer, following re, Headline: Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer, source:Yahoo, summary: WILMINGTON, Del., October 26, 2022--Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca’s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at both 75mg and 150mg dose levels versus FASLODEX® (fulvestrant) 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or meta, Headline: AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) shared positive topline data from the CAPItello-291 Phase 3 trial of capivasertib in combination with Faslodex (fulvestrant) in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer patients, following recurrence or progression on or after endocrine therapy. The capivasertib + Faslodex combo demonstrated a statistically significant and clinically meaningful improvement in progress, Headline: GLOBAL BRIEFING: Meta quarterly revenue drops; Xi wants US cooperation, source:Alliance News, summary: No summary, Headline: Study confirms AstraZeneca jab's higher risk of very rare clot, source:Alliance News, summary: No summary",AZN
30,2022-10-27,"Headline: AstraZeneca's Ultomiris showed zero relapses in adults with NMOSD, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca's Ultomiris treatment gets good results from Phase 3 trial, source:Alliance News, summary: No summary, Headline: Invitae announces collaboration with AstraZeneca, source:Thefly.com, summary: Invitae (NVTA) announced ... NVTA, AZN, Headline: Omicron subvariants are resistant to key antibody treatments, putting people with weak immune systems at risk of Covid , source:CNBC, summary: President Biden cautioned that the immunocompromised are at heightened risk this winter and should talk to their physician about precautions., Headline: ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks, source:Yahoo, summary: WILMINGTON, Del., October 27, 2022--Detailed positive results from the Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS® (ravulizumab-cwvz) significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), compared to the external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. Data were presented today at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress., Headline: Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research, source:Yahoo, summary: Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to use Invitae's Ciitizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer. This partnership will enable sharing of high-quality, patient-consented data from the patient community of the Cholangiocarcinoma Foundation (CCF), a leading patient advocacy group whose mission is to find a cure, Headline: AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves. The data showed that Ultomiris significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD, compared to the external placebo arm from the pivotal Soliris PREVENT clinica, Headline: AstraZeneca PLC ADR falls Thursday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.60% to $57.61 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: 11 Best UK Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss 11 best UK stocks to buy now. If you want to see more stocks in this selection, click 5 Best UK Stocks To Buy Now. On October 22, Moody’s downgraded the United Kingdom’s economic outlook from “stable” to “negative”, citing political instability and skyrocketing inflation. However, Moody’s credit rating for […]",AZN
31,2022-10-28,"Headline: 3 Perfect Stocks Retirees Can Buy Hand Over Fist Right Now, source:Yahoo, summary: For many investors, 2021 was ideal.  The benchmark S&P 500 endured no more than a 5% correction for the entirety of the year, and the major stock indexes finished higher by a double-digit percentage.  All three major U.S. stock indexes have plunged into a bear market, with volatility hitting levels not seen since 2009., Headline: U.K. stocks break two-day climbing streak, source:MarketWatch, summary: U.K. stocks finished lower Friday, with the FTSE 100 Index decreasing 0.37% at 7,047.67. Of the FTSE 100 constituents, banking company NatWest Group PLC saw..., Headline: Why Invitae Stock Was So Healthy This Week, source:Yahoo, summary: Even though the genetics testing specialist didn't divulge the financial details of a new partnership, investors nevertheless were happpy about the news., Headline: Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod, source:Yahoo, summary: Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.91% to $58.71 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...",AZN
32,2022-10-29,"Headline: AstraZeneca PLC's (LON:AZN) Intrinsic Value Is Potentially 99% Above Its Share Price, source:Yahoo, summary: In this article we are going to estimate the intrinsic value of AstraZeneca PLC ( LON:AZN ) by taking the forecast...",AZN
33,2022-10-30,"Headline: AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing, source:SeekingAlpha, summary: Big pharma investment is about the long term, and AstraZeneca has that focus. Read more on how investors should look for emerging companies that fit with big pharma or partner interests.",AZN
34,2022-10-31,"Headline: AstraZeneca to present over 60 abstracts at ASN and AHA events this week, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca to present new cardiovascular, renal drug data in US, source:Alliance News, summary: No summary, Headline: Top 5 3rd Quarter Trades of ST - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: ClearBridge Value Equity Strategy Q3 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge Value Equity Strategy outperformed its Russell 1000 Value Index during the third quarter 2022. Click here to read the full fund letter., Headline: AstraZeneca's Vaxzevria Gets Full Marketing Authorization in EU for Prevention of Covid-19, source:MarketWatch, summary: By Kyle Morris AstraZeneca PLC said Tuesday that its Covid-19 vaccine Vaxzevria has been granted full marketing authorization in the European Union. The..., Headline: Biotech And XBI: The Bottom Is In, source:SeekingAlpha, summary: XBI is a widely diversified ETF comprised of myriad small and midcap biotech stocks. Read how I've built up a large position in the ETF since mid-June., Headline: LONDON BRIEFING: FTSE 100 to open higher; BP swings to profit, source:Alliance News, summary: No summary",AZN
35,2022-11-01,"Headline: TOP NEWS: AstraZeneca's Vaxzevria wins full market authorisation in EU, source:Alliance News, summary: No summary, Headline: JPMorgan Chase hires OrbiMed Advisors executive for new life sciences venture capital unit, source:MarketWatch, summary: JPMorgan Chase & Co. undefined said Tuesday its J.P. Morgan Asset Management unit is launching a new private capital team aimed at investments in life..., Headline: European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine, source:Yahoo, summary: The European Medicines Agency (EMA) has granted full Marketing Authorisation to AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]). Vaxzevria was initially granted a conditional Marketing Authorisation due to the urgency of the COVID-19 pandemic. As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the EMA has now granted full approval. The approval covers the use of Vaxzevria in both a primary vaccination se, Headline: Hospitalizations on the rise in New York City as new COVID strains spread rapidly, source:Yahoo, summary: Hospitalizations are rising again in New York City with the spread of new COVID-19 subvariants that are better at evading immunity, along with flu and respiratory syncytial virus, or RSV., Headline: Roche Needs Some Wins, source:SeekingAlpha, summary: Roche has enjoyed strong reputation, but it can sometimes outrun or outlast underlying facts. Read why I'm getting more concerned that that may be the case here., Headline: AstraZeneca PLC ADR rises Tuesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 1.77% to $59.85 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite..., Headline: ADRs End Higher, Alibaba and AstraZeneca Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed higher on Tuesday. The S&P/BNY Mellon index of American depositary receipts edged up 0.9% to..., Headline: ClearBridge Global Growth Strategy Q3 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: During the third quarter of 2022, the ClearBridge Global Growth Strategy outperformed its MSCI ACWI benchmark. Click here to read the full fund letter.",AZN
36,2022-11-02,"Headline: U.K. stocks break two-day winning streak, source:MarketWatch, summary: U.K. stocks decreased Wednesday, as the FTSE 100 Index finished down 0.58% at 7,144.14. Among FTSE 100 constituents, tobacco company British American Tobacco..., Headline: AstraZeneca PLC ADR falls Wednesday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.25% to $59.70 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Moves -0.25%: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $59.70, marking a -0.25% move from the previous day.",AZN
37,2022-11-03,"Headline: AstraZeneca PLC ADR rises Thursday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.39% higher to $59.93 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Will AstraZeneca PLC (AZN) Deliver Promising Return?, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron International Growth Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 11.51% (Institutional Shares), compared to a 9.91% decline for its principal benchmark, the MSCI ACWI ex USA Index. Due to global weakness in […], Headline: AstraZeneca's Nirsevimab Approved in the EU, source:MarketWatch, summary: By Anthony O. Goriainoff AstraZeneca PLC said Friday that nirsevimab, a treatment for the prevention of respiratory syncytial virus, a..., Headline: LONDON BRIEFING: Stocks called higher; US job growth expected to slow, source:Alliance News, summary: No summary",AZN
38,2022-11-04,"Headline: TOP NEWS: AstraZeneca's Beyfortus wins EU approval for RSV in newborns, source:Alliance News, summary: No summary, Headline: LONDON MARKET OPEN: FTSE 100 boosted by miners as commodities rise, source:Alliance News, summary: No summary, Headline: Sanofi, Astra win EU approval for prevention of infant RSV, source:Yahoo, summary: The European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.  The long-acting therapy, also known as nirsevimab, was given EU marketing authorisation for the prevention of disease from infections caused by the respiratory syncytial virus (RSV), Sanofi said in a statement., Headline: Cowen biotech/pharma analysts hold an analyst/industry conference call, source:Thefly.com, summary: Biotech Analysts Werber &... AZN, ALXN, ARGX, Headline: EMEA Earnings to Watch: Ryanair, Bayer, AstraZeneca, Richemont, source:Yahoo, summary: (Bloomberg) -- A glance at the Stoxx Europe 600 Index’s performance at the sector level gives an indication of the winners and losers of the third-quarter earnings cycle, with travel and leisure stocks streaking ahead, and food, beverage and tobacco bringing up the rear, the only group in the red. Next week will be a test for both as the current reporting season nears a close.Most Read from BloombergTwitter Sued for Mass Layoffs by Musk Without Enough NoticeMusk Plans to Eliminate Half of Twitte, Headline: Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants, source:Yahoo, summary: The European Commission has approved AstraZeneca plc (NASDAQ: AZN) and Sanofi SA’s (NASDAQ: SNY) Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. In the pivotal MELODY efficacy trial, B, Headline: Global company events calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Europe OK's 1st one-dose drug to protect babies against RSV, source:Associated Press, The, summary: No summary, Headline: Lilly, Boehringer say Jardiance slows kidney disease progression in trial, source:Yahoo, summary: Boehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was shown to slow the progression of chronic kidney disease (CKD), as they seek to catch up with market segment leader AstraZeneca.  In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people with and without diabetes., Headline: Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View, source:Yahoo, summary: Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges., Headline: AstraZeneca PLC ADR rises Friday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.77% to $60.99 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: ADRs End Higher, Alibaba and AstraZeneca Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed higher Friday. The S&P/BNY Mellon index of American depositary receipts rose 3.7% to 128.80...., Headline: 12 Best Non-REIT Dividend Stocks To Buy, source:Yahoo, summary: In this article, we discuss 12 best non-REIT dividend stocks to buy. If you want to see more stocks in this selection, go see 5 Best Non-REIT Dividend Stocks To Buy. A well-proven way to fight inflation is to look for investments that have categorically outperformed during times of high inflation. Dividends have contributed nearly […]",AZN
39,2022-11-07,"Headline: AstraZeneca presents data on Farxiga and importance of earlier screening for CKD, source:Thefly.com, summary: The company states: ""... AZN, Headline: UK earnings, trading statements calendar - next 7 days, source:Alliance News, summary: No summary, Headline: AstraZeneca notes positive phase III analysis for heart failure drug, source:Alliance News, summary: No summary, Headline: AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?, source:Yahoo, summary: Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs., Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.18% higher to $61.10 Monday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Most Promising Pharmaceutical Company During A Recession, source:SeekingAlpha, summary: AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Click here to read more., Headline: GLOBAL BRIEFING: Trump teases 2024 run ahead of US midterms, source:Alliance News, summary: No summary",AZN
40,2022-11-08,"Headline: IN BRIEF: Beximco Pharmaceuticals revenue up thanks to domestic sales, source:Alliance News, summary: No summary, Headline: FDA Pulmonary-Allergy Drugs Advisory Committee to hold a virtual meeting, source:Thefly.com, summary: The Committee discusses A... AZN, Headline: Why Investors Need to Take Advantage of These 2 Medical Stocks Now, source:Yahoo, summary: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.38% higher to $61.33 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Options Action: A bet against AstraZeneca, source:CNBC, summary: Optimize Advisors' Mike Khouw looks at what's going on in the biotech space, including a bet against AstraZeneca ahead of earnings. With CNBC's Melissa Lee and the Fast Money traders, Carter Worth, Dan Nathan, Guy Adami and Jeff Mills., Headline: AstraZeneca celebrates asthma treatment recommendation by US FDA, source:Alliance News, summary: No summary",AZN
41,2022-11-09,"Headline: AstraZeneca Expected to Report Higher 3Q Earnings With Key Drugs in Focus -- Earnings Preview, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC is scheduled to report results for the third quarter on Nov. 10. Here's what you need to know: SALES: Sales at the..., Headline: UK earnings, trading statements calendar - next 7 days, source:Alliance News, summary: No summary, Headline: PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma, source:Yahoo, summary: WILMINGTON, Del., November 09, 2022--The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older. In adolescents aged 12 to 17 years, the Committee voted 9 to 8 that the data do not support a favorable benefit risk assessment for the use of PT027 for the treatment of asthma. In childre, Headline: LONDON MARKET CLOSE: European stocks tread water amid US midterms, source:Alliance News, summary: No summary, Headline: Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023, source:MarketWatch, summary: Clovis Oncology Inc. shares undefined plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain..., Headline: Why AstraZeneca (AZN) Might Surprise This Earnings Season, source:Yahoo, summary: AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: Is AstraZeneca PLC (AZN) a Solid Long-Term Investment?, source:Yahoo, summary: ClearBridge Investments, an investment management company, released its “ClearBridge Value Equity Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark, the Russell 1000 Value Index, in the third quarter. Sector allocation effects and overall stock selection contributed positively to the strategy’s relative performance in the […], Headline: FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids, source:Yahoo, summary: The FDA's Pulmonary-Allergy Drugs Advisory Committee has voted 16 to 1 that the data support a favorable benefit-risk assessment for AstraZeneca Plc's (NASDAQ: AZN) PT027 (albuterol/budesonide) for asthma in people aged 18 years and older. In adolescents aged 12 to 17 years, the Committee voted 9 to 8, and for children aged 4 to 11 years, the Committee voted 16 to 1 that the data do not support a favorable benefit-risk assessment for PT027 for asthma. The FDA is slated to decide in the first hal, Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.46% to $61.05 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Fisherâs 13F portfolio value decreased from ~$141B to ~$133B in Q3 2022. Read more to see Fisher Asset Management's holdings and trades for Q3 2022., Headline: AstraZeneca Q3 Preview: Can Shares Stay Strong?, source:Yahoo, summary: AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and widely outperforming the general market., Headline: GLOBAL BRIEFING: Biden hails ""strong"" midterm election in US, source:Alliance News, summary: No summary, Headline: AZN Crosses Above Key Moving Average Level, source:Market News Video, summary: In trading on Thursday, shares of AstraZeneca plc (AZN) crossed above their 200 day moving average of $62.56, changing hands as high as $65.92 per share - AstraZeneca plc shares are currently trading up about 5.4% on the day. - AZN., Headline: GET READY: AstraZeneca, National Grid and WH Smith at 0700 BST, source:Alliance News, summary: No summary, Headline: LONDON MARKET EARLY CALL: FTSE 100 called lower ahead of US inflation, source:Alliance News, summary: No summary, Headline: LONDON BRIEFING: AstraZeneca and Haleon lift annual guidance, source:Alliance News, summary: No summary, Headline: AstraZeneca Lifts 2022 Guidance After Swing to 3Q Profit, Higher Sales -- Update, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC on Thursday lifted its guidance for the full year after reporting a swing to net profit and higher sales for the third..., Headline: AstraZeneca raises 2022 earnings outlook after Q3 results beat estimates, source:Yahoo, summary: By Scott Kanowsky, Headline: FDA approves tremelimumab combo for metastatic non-small cell lung cancer, source:Thefly.com, summary: On November 10, the Food ... AZN, Headline: LONDON MARKET OPEN: Centrica helps FTSE 100 outperform ahead of US CPI, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street On Thursday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. RIVN, MQ, SIX, RNG, NIO, ATVI, RBLX, TJX, PANW, CTMX, AMZN, COIN, AZN, TSLA, IBEX, RPAY, RDFN, MGNI, APPS, TGTX, EGIO, VCSA, CANO, VERU, YETI, BYND, DSP, RL, DGII, Headline: Dow scores 1,200-point gain as stocks log biggest one-day advance since 2020 on signs inflation is softening, source:MarketWatch, summary: U.S. stocks finished sharply higher on Thursday, logging their biggest single-session rally in more than two years as the Dow soared more than 1,200 points...",AZN
42,2022-11-10,"Headline: AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28, source:Thefly.com, summary: YTD Total Revenue increas... AZN, Headline: Astrazeneca: Q3 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: AstraZeneca drops plans to submit COVID-19 vaccine to U.S. FDA, WSJ reports, source:Thefly.com, summary: AstraZeneca said it has d... AZN, Headline: TOP NEWS: AstraZeneca swings to third-quarter profit and ups guidance, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC 2022 Q3 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q3 earnings call., Headline: AstraZeneca (NASDAQ:AZN) Stock Rises on Upbeat Q3 Results, Guidance Lift, source:TipRanks, summary: Shares of the pharma giant AstraZeneca (NASDAQ:AZN) advanced in Thursday’s early trading hours on better-than-expected third-quarter results, fueled by cancer drugs..., Headline: AstraZeneca lifts 2022 earnings outlook as cancer drugs boost results, source:Yahoo, summary: (Reuters) -AstraZeneca raised its full-year earnings outlook on Thursday after strong sales of its key cancer drugs helped it beat quarterly profit and revenue forecasts, driving its shares to a 2-1/2 month high.  The Anglo-Swedish company said it managed to grow its business in China despite protracted COVID lockdowns and was no longer pursuing U.S. approval for its COVID-19 vaccine.  AstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year., Headline: Viatris wins court decision invalidating AstraZeneca's Symbicort patent, source:Thefly.com, summary: Viatris (VTRS), a global ... VTRS, AZN, Headline: Stocks making the biggest moves premarket: Tapestry, WeWork, Rivian and others, source:CNBC, summary: These are the stocks posting the largest moves before the bell., Headline: AstraZeneca lifts guidance after forecast-beating profit and sales, source:Yahoo, summary: After tax, profit was $1.64 billion compared with a loss of $1.65 billion the year prior. Analysts had expected the company to post a net profit of $629 million., Headline: AstraZeneca drops submission to US regulators for Covid-19 vaccine approval, source:Yahoo, summary: AstraZeneca has abandoned its submission for US regulatory approval for the Covid-19 vaccine it developed with Oxford university, almost two years after it was initially approved in the UK and Europe.  Pascal Soriot, AstraZeneca’s chief executive, said the company had decided to focus its regulatory team’s efforts on areas with larger unmet medical need, pointing to 19 regulatory approvals since the last earnings call., Headline: AstraZeneca Lifts Profit Guidance on Cancer, Diabetes Drugs, source:Yahoo, summary: (Bloomberg) -- AstraZeneca Plc raised its profit guidance for this year, saying drugs like Farxiga for diabetes and Tagrisso for cancer are fueling demand.Most Read from BloombergMusk’s First Email to Twitter Staff Ends Remote WorkSam Bankman-Fried’s $16 Billion Fortune Is Eviscerated in DaysUS Inflation Slows More Than Forecast, Gives Fed Downshift RoomFTX Warns of Bankruptcy Without Rescue for $8 Billion ShortfallMeta to Cut 11,000 Jobs; Zuckerberg Says ‘I Got This Wrong’Core earnings per shar, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: Yeti surges following Q3 results SIX, USFD, YETI, NIO, AZN, RNG, ZIP, BDX, WE, TTGT, BMBL, VERU, MO, Headline: AstraZeneca Raises 2022 Guidance After Swing to 3Q Profit -- Earnings Review, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC reported third-quarter earnings on Thursday. Here is what we watched. SALES: Sales at the Anglo-Swedish pharma major rose..., Headline: UPDATE 3-European stocks scale 11-week high after soft U.S. inflation data, source:Yahoo, summary: European shares clocked an 11-week closing high on Thursday as a slower-than-expected rise in U.S. consumer prices strengthened hopes of less aggressive interest rate hikes from the Federal Reserve going ahead.  The pan-European STOXX 600 jumped 2.8%, notching its biggest percentage gain in five weeks.  A U.S. Labor Department report showed consumer prices rose less than expected in October, pushing the annual increase below 8% for the first time in eight months., Headline: FTSE 100: AstraZeneca raises profit guidance amid strong demand, source:Yahoo, summary: AstraZeneca returns to profit on higher drugs revenue., Headline: AstraZeneca Drops Plan to Sell Covid-19 Vaccine in U.S., source:Yahoo, summary: AstraZeneca  PLC said it had dropped plans to submit its Covid-19 vaccine to the Food and Drug Administration for approval, ending a long-running ambition to eventually sell the shot in the U.S. despite initial setbacks.  The Cambridge, England-based pharmaceutical company said Thursday that there would likely be a lack of demand in the U.S., where it said primary vaccination needs had been met.  It would continue to focus its efforts on ensuring the availability of the vaccine, called Vaxzevria, elsewhere, including seeking its approval as a booster shot, the company said., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. ATVI, RBLX, TJX, PANW, CTMX, RIVN, MQ, SIX, RNG, NIO, AMZN, MSFT, AZN, ZM, TSLA, BTC, BITCOIN, $BTC, RPAY, RDFN, MGNI, APPS, TGTX, EGIO, VCSA, CANO, VERU, YETI, BYND, DSP, RL, DGII, Headline: AstraZeneca CFO on Profit Guidance, Expansion, Vaccine Demand, source:Yahoo, summary: Astrazeneca's Chief Financial Officer Aradhana Sarin discusses the UK drugmaker's earnings for this quarter. Profit surged to $1.67 per share in the third quarter, beating the $1.52 analysts had estimated. The company benefited from sales of cancer drugs as diagnoses progressively return to pre-pandemic levels., Headline: AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) has reported Q3 core EPS of $1.67, up 55% Y/Y (+70 constant currency), beating the consensus of $0.72. The company clocked Q3 sales of $10.98 billion, +11% (+19% CC), beating the consensus of $10.91 billion. Sales of AstraZeneca's key cancer medicines — Tagrisso and Imfinzi — helped the company's revenue beat, with sales of its broader oncology portfolio rising 24%. Tagrisso generated nearly $1.4 billion, and Imfinzi brought in $737 million in the quarter. Related:, Headline: AstraZeneca: Q322 Earnings Boost Share Price, Narrowing The Long-Term Upside Opportunity, source:SeekingAlpha, summary: AZN reported Q322 results today. Revenues grew 37% year-on-year and from a core reporting perspective at least the Pharma looks very profitable. Read more here., Headline: Stocks making the biggest moves midday: Six Flags, Rivian, Bumble, Coinbase, Dutch Bros and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks, source:Yahoo, summary: Two stocks that risk-averse investors should consider today are AstraZeneca (NASDAQ: AZN) and Coca-Cola (NYSE: KO).  AstraZeneca is a top healthcare company with solid financials, a bright future, and a terrific dividend.  Sales rose 43% year over year to $22.2 billion as AstraZeneca benefited from growth in multiple segments as well as the acquisition of rare disease company Alexion Pharmaceuticals, which it completed last year., Headline: Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11, source:Yahoo, summary: Bloomberg FTX 'Urgently Needs' $8B To Avoid Bankruptcy, Bankman-Fried Reportedly Tells Investors FTX (FTT/USD) CEO Sam Bankman-Fried reportedly told investors on Wednesday that he urgently needs $8 billion in emergency funding to cover withdrawal requests and avert bankruptcy. In a call with investors, Bankman-Fried said he hoped to raise as much as $3 billion to $4 billion in equity and some debt. FTX Stares At More Trouble As Justice Department Reportedly Joins SEC Probe Into Liquidity Crisis, Headline: AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up, source:Yahoo, summary: AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged., Headline: AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022, source:Yahoo, summary: WILMINGTON, Del., November 10, 2022--Today, TIME named AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab) on their 2022 list of Best Inventions. Their selection of EVUSHELD reflects its impact as the first and only long-acting monoclonal antibody to receive emergency use authorization in the US for the prevention of COVID-19 in immunocompromised people., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 6.62% to $65.09 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth, source:Yahoo, summary: AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock., Headline: Why AstraZeneca Stock Shot Higher Today, source:Yahoo, summary: The company trounced analyst profitability estimates for its latest quarter and raised its guidance., Headline: AstraZeneca's Combined Imfinzi-Imjud Lung Cancer Treatment Gets Approval for Use in US, source:MarketWatch, summary: By Michael Susin AstraZeneca PLC said Friday that U.S.'s Food and Drug Administration has approved the use of its combined treatment Imfinzi with Imjud for..., Headline: AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript, source:Yahoo, summary: Before I hand it over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements., Headline: TOP NEWS: AstraZeneca wins US FDA approval for lung cancer drugs, source:Alliance News, summary: No summary",AZN
43,2022-11-11,"Headline: AstraZeneca's Imfinzi and Imjudo approved in U.S. for NSCLC patients, source:Thefly.com, summary: The company states: ""... AZN, Headline: AstraZeneca announces availability of Alexion rare disease therapy in China, source:Thefly.com, summary: The company states: ""... AZN, Headline: FDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination Treatment, source:TipRanks, summary: U.K.-based drugmaker AstraZeneca’s (NASDAQ:AZN) metastatic non-small cell lung cancer treatment, which is a combination of Imjudo and Imfinzi along with platinum-ba..., Headline: Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Ayr Wellness (OtherAYRWF) and Privia Health Group (PRVA), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on AstraZeneca (<a..., Headline: AstraZeneca put volume heavy and directionally bearish, source:Thefly.com, summary: Bearish flow noted in Ast... AZN, Headline: LONDON MARKET CLOSE: FTSE 100 lags behind peers in risk-on mood, source:Alliance News, summary: No summary, Headline: U.K. stocks weaken Friday, source:MarketWatch, summary: U.K. stocks finished lower Friday, with the FTSE 100 Index falling 0.78% at 7,318.04. Among FTSE 100 constituents, defense equipment/products company BAE..., Headline: IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer, source:Yahoo, summary: WILMINGTON, Del., November 11, 2022--AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC)., Headline: FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer, source:Yahoo, summary: The FDA has approved AstraZeneca plc’s (NASDAQ: AZN) Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy for Stage IV (metastatic) non-small cell lung cancer (NSCLC). The approval was based on the results from the POSEIDON Phase 3 trial. Patients treated with a limited course of five cycles of the anti-CTLA-4 antibody Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range, Headline: Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine, source:Yahoo, summary: Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe., Headline: Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort, source:Yahoo, summary: Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 3.56% to $62.77 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",AZN
44,2022-11-12,"Headline: AstraZeneca Third Quarter 2022 Earnings: Beats Expectations, source:Yahoo, summary: AstraZeneca ( LON:AZN ) Third Quarter 2022 Results Key Financial Results Revenue: US$11.0b (up 11% from 3Q 2021). Net..., Headline: 15 Most Valuable NASDAQ Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 most valuable NASDAQ companies in the world. If you want to see more of the most valuable NASDAQ companies in the world, go directly to 5 Most Valuable NASDAQ Companies in the World. When most people hear NASDAQ, they think of technology given that […]",AZN
45,2022-11-13,"Headline: ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer, source:Business Wire, summary: No summary, Headline: AstraZeneca: Lynparza Combo Recommended in EU for Prostate Cancer, source:MarketWatch, summary: By Kyle Morris AstraZeneca PLC said Monday that a Lynparza combination has been recommended for marketing authorization in the European Union for the..., Headline: AstraZeneca's Imfinzi Plus Chemotherapy Recommended for Market Authorization in EU, source:MarketWatch, summary: By Joe Hoppe AstraZeneca PLC said Monday that its Imfinzi product has been recommended for marketing authorization in the European Union for treating adults..., Headline: AstraZeneca Says Enhertu Recommended for EU Approval for Gastric Cancer, source:MarketWatch, summary: By Kyle Morris AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer. The..., Headline: LONDON MARKET OPEN: Informa lifts FTSE 100; pound above USD1.18, source:Alliance News, summary: No summary, Headline: LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral', source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca receives three recommendations for EU approval, source:Alliance News, summary: No summary",AZN
46,2022-11-14,"Headline: AstraZeneca Lynparza+biraterone recommended for E.U. approval in mCRPC, source:Thefly.com, summary: The company states: ""... AZN, MRK, Headline: Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Halozyme (HALO), source:TipRanks, summary: There&#8217;s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (<span class='tr-stock-ticker' style='color:blue; f..., Headline: GLOBAL BROKER RATINGS: HSBC cuts Azimut to 'hold' from 'buy', source:Alliance News, summary: No summary, Headline: European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs, source:Yahoo, summary: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approving AstraZeneca Plc (NASDAQ: AZN) - Merck & Co Inc (NYSE: MRK) partnered Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for prostate cancer setting. The opinion covers metastatic castration-resistant prostate cancer (mCRPC) patients for whom chemotherapy is not clinically indicated. The CHMP also backed the approval of AstraZeneca’s Imfinzi (durvalu, Headline: Tango Therapeutics: Behind The Recent Momentum, source:SeekingAlpha, summary: Shares of early clinical-stage biotech Tango Therapeutics, Inc. (TNGX) are down ~50% since going public in August 2021 â primarily victimized by a lack of catalysts and a tough market., Headline: AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod, source:Yahoo, summary: AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication., Headline: LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform', source:Alliance News, summary: No summary",AZN
47,2022-11-15,"Headline: BECKER CAPITAL MANAGEMENT INC  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: GLOBAL BROKER RATINGS: Liberum initiates ConvaTec with 'buy', source:Alliance News, summary: No summary, Headline: Top 5 3rd Quarter Trades of Ca - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: BRIDGER MANAGEMENT, LLC Buys 1 - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use, source:Yahoo, summary: The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.06% higher to $63.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines, source:Yahoo, summary: Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.",AZN
48,2022-11-16,"Headline: Compugen to receive $7.5M milestone payment from AstraZeneca, source:Thefly.com, summary: Compugen (CGEN) expects t... CGEN, AZN, Headline: Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics, source:Yahoo, summary: WILMINGTON, Del., November 16, 2022--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company., Headline: Investor AB: Not Cheap Enough, source:SeekingAlpha, summary: Investor AB is a Swedish holding company that invests both in listed and unlisted European companies., Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.23% to $63.80 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",AZN
49,2022-11-17,"Headline: Key Factors Driving Amgen's (AMGN) Outperformance This Year, source:Yahoo, summary: Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets., Headline: Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?, source:Yahoo, summary: Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.41% higher to $64.06 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...",AZN
50,2022-11-18,"Headline: Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo, source:Yahoo, summary: Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe., Headline: 2 Stocks to Buy Whether or Not a Recession Is Coming, source:Yahoo, summary: Let's look at two pharma giants that could help investors navigate the next recession and beyond: Bristol Myers Squibb (NYSE: BMY) and AstraZeneca (NASDAQ: AZN).  Bristol Myers' top-line growth seems unimpressive right now.  During the third quarter, the company's revenue declined by 3% year over year (YoY) to $11.2 billion., Headline: AstraZeneca PLC ADR rises Friday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.58% to $65.07 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...",AZN
51,2022-11-19,"Headline: Billionaire Steve Cohen’s Top 10 Dividend Stocks, source:Yahoo, summary: In this article, we will take a look at billionaire Steve Cohen’s top dividend stocks. If you want to see more of billionaire Steve Cohen’s top dividend stocks, go directly to Billionaire Steve Cohen’s Top 5 Dividend Stocks. Billionaire Steve Cohen is the founder of Point72 Asset Management which as of the end of September […]",AZN
52,2022-11-21,"Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.55% higher to $65.43 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Here’s Why AstraZeneca PLC (AZN) Declined in the Third Quarter, source:Yahoo, summary: Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund delivered negative returns. The market continued its decline in the third quarter and the S&P 500 Index fell -4.9%. In addition, […]",AZN
53,2022-11-22,"Headline: Merck Vs. AbbVie: Which Is Better Buy As The Patent Cliffs Approach?, source:SeekingAlpha, summary: I will be comparing AbbVie and Merck to see which is better positioned for its patent cliff. Read to know why I like AbbVie more than Merck., Headline: AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022, source:Yahoo, summary: WILMINGTON, Del., November 22, 2022--AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022., Headline: Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharma, source:SeekingAlpha, summary: Regeneron Pharmaceuticals is hoping to establish itself as a major oncology player. See why I no longer see REGN stock price upside in the near term., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.87% higher to $66.00 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Alexion's new U.S. head is looking for 'the next generation of medicines to unpack', source:Yahoo, summary: A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in ""the best of both worlds"" as the official rare disease unit of the U.K. pharma giant.",AZN
54,2022-11-23,"Headline: 15 Biggest European Pharmaceutical Companies, source:Yahoo, summary: In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […], Headline: AstraZeneca PLC ADR rises Wednesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.18% higher to $66.12 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...",AZN
55,2022-11-24,"Headline: Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?, source:Yahoo, summary: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores., Headline: AstraZeneca Thailand Wins Two ACES Awards 2022: ""Industry Champions of the Year"" and ""Community Initiative"", source:Yahoo, summary: AstraZeneca (Thailand) Co., Ltd., was recently honoured with two accolades in the categories of Industry Champions of the Year and Community Initiative at the Asia Corporate Excellence & Sustainability Awards 2022 (ACES Awards 2022).",AZN
56,2022-11-25,"Headline: Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why, source:Yahoo, summary: Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term., Headline: 10 Best Biotech Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we discuss 10 best biotech stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy According To Hedge Funds. In 2023, digitalization will increase in the biotech industry as the possibility of online and remote assessment, diagnosis, […]",AZN
57,2022-11-27,"Headline: 11 Best Diabetes Stocks To Buy Now, source:Yahoo, summary: In this article, we discuss 11 best diabetes stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Diabetes Stocks To Buy Now. The global diabetes market is segmented based on the type, drug class, and devices used to treat the condition. Based on the type, the […], Headline: C4X Discovery Signs Licensing Deal with AstraZeneca Worth up to $402 Mln, source:MarketWatch, summary: By Joe Hoppe C4X Discovery Holdings PLC said Monday that it has signed a worldwide licensing deal with AstraZeneca PLC worth up to $402 million for the...",AZN
58,2022-11-28,"Headline: C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca  for the development and commercialisation of NRF2 Activator programme, source:Yahoo, summary: C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with, Headline: AstraZeneca Bets On UK Listed Firm For Lung Diseases, source:Yahoo, summary: Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) worth up to $402 million for its NRF2 Activator program. C4X Discovery is listed on the London Stock exchange, and the deal is the third significant deal with a major pharmaceutical company. AstraZeneca will develop and commercialize an oral therapy for inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). Re, Headline: AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M, source:Yahoo, summary: The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases., Headline: AstraZeneca PLC ADR rises Monday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.06% higher to $66.21 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: BOE: Global Exposure, Call Writing Strategy, ~7.6% Distribution Yield, source:SeekingAlpha, summary: BlackRock Enhanced Global Dividend Trust's discount is attractive and leads to an enticing distribution yield. See the factors that make BOE CEF a Buy., Headline: AstraZeneca to Buy Neogene Therapeutics for $320 Mln, source:MarketWatch, summary: By Ian Walker AstraZeneca PLC said Tuesday that it is buying biotechnology company Neogene Therapeutics Inc. for up to $320 million. The pharmaceutical giant...",AZN
59,2022-11-29,"Headline: AstraZeneca acquires biotech Neogene for $320M in bid to expand cancer treatments, source:Yahoo, summary: By Scott Kanowsky, Headline: UPDATE 2-AstraZeneca boosts cancer portfolio with $320 mln Neogene deal, source:Yahoo, summary: AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments.  Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead.  ""Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years,"" said Susan Galbraith, AstraZeneca's executive vice president of oncology research., Headline: ADC Therapeutics: Running Through A Stretch Of Bad Luck, source:SeekingAlpha, summary: ADC Therapeutics faced the brunt of the FDA's new policy against rampant accelerated approvals. See why ADCT stock remains something of a risky bet., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.20% to $66.08 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",AZN
60,2022-11-30,"Headline: AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022, source:Yahoo, summary: WILMINGTON, Del., November 30, 2022--AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022., Headline: AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal, source:Yahoo, summary: The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies., Headline: Mirati Therapeutics: Is There A Big Pharma Buyout In Play And What's The Price Tag?, source:SeekingAlpha, summary: Mirati Therapeutics will find out in December if the FDA will approve its lead drug candidate Adagrasib in NSCLC. Read why the company also is part of acquisition speculation., Headline: Why Shares of Compugen Rose 16.5% on Wednesday, source:Yahoo, summary: Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday.  The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and closing at $1.20.  The stock has been volatile, with a 52-week low of $0.51 and a 52-week high of $4.88.",AZN
61,2022-12-01,"Headline: 2 Stocks That Could Surprise Investors in 2023, source:Yahoo, summary: The healthcare industry can make for a safe place to invest regardless of the macroeconomic conditions.  A couple of healthcare stocks that are diversified and that could be good buys heading into the new year are AstraZeneca (NASDAQ: AZN) and PetMed Express (NASDAQ: PETS).  AstraZeneca's business performed well in 2022, but its stock isn't doing as well as perhaps it should be., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.54% higher to $68.34 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the...",AZN
62,2022-12-02,"Headline: Vaxxinity Covid-19 Booster Candidate Matches Rivals At Trial, source:MarketWatch, summary: By Dean Seal Vaxxinity Inc. said Friday that UB-612, its Covid-19 booster candidate, achieved at trial similar results to Pfizer Inc.'s Covid-19 vaccine and..., Headline: Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal, source:Yahoo, summary: Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.19% higher to $68.47 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",AZN
63,2022-12-04,"Headline: Arvinas: Promising Science, Poor Data, source:SeekingAlpha, summary: Arvinas produced underwhelming data for the second time. Read more to see why I sold out my position in ARVN stock recently.",AZN
64,2022-12-05,"Headline: Ocugen: Still Struggling, source:SeekingAlpha, summary: Ocugen introduces its mucosal COVID vaccine, but can it compete with the mRNA vaccine technology of Moderna and BioNTech/Pfizer? Read more here., Headline: 10 Best Foreign Stocks to Buy Now, source:Yahoo, summary: In this article, we will take a look at 10 best foreign stocks to buy now. If you want to see more best foreign stocks to buy, go directly to 5 Best Foreign Stocks to Buy Now. Although it has the largest economy in the world, the United States doesn’t have a monopoly on good companies. […], Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.07% to $68.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...",AZN
65,2022-12-07,"Headline: ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03, source:Yahoo, summary: WILMINGTON, Del., December 07, 2022--Updated results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. These results and primary results from the DESTINY-Breast02 Phase III trial wi, Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.42% higher to $68.85 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the Dow..., Headline: AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine (T-DM1) in previously treated patients with HER2-positive unresectable and/or metastatic breast cancer. Enhertu demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to T-DM1. In the key secondary endpoint analysis of overall survival for DESTINY-Breast03, Enhertu demonstrated a 36% reduction in risk o",AZN
66,2022-12-08,"Headline: IOO: We're Thinking A Soft Landing, source:SeekingAlpha, summary: iShares Global 100 ETF is mostly just a value weighted US portfolio. Click here to read more about the fund., Headline: Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer, source:Yahoo, summary: WILMINGTON, Del., December 08, 2022--Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca’s capivasertib in combination with FASLODEX® (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus FASLODEX in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative, locally advanced or metastatic breast cancer, following recurrence or pr, Headline: Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant), source:Yahoo, summary: WILMINGTON, Del., December 08, 2022--Detailed results from the SERENA-2 Phase II trial showed AstraZeneca’s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels versus FASLODEX® (fulvestrant) 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer, previously trea, Headline: Lexicon Continues To Drift Ahead Of An Expected FDA Approval And A High-Risk Commercialization Effort, source:SeekingAlpha, summary: Lexicon shares have drifted lower since the summer, with little news of consequence to sway investor opinions. Read the outlook here., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.46% higher to $69.17 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer. The data showed that camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in patients previously treated with endocrine therapy. In t",AZN
67,2022-12-09,"Headline: AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low, or HER2-negative (IHC 0) unresectable or metastatic breast cancer. Safety results were consistent with previous trials of datopotamab deruxtecan. Also see: AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials. In this cohort of, Headline: Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say, source:Yahoo, summary: The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.  Enhertu, which won U.S. approval in late 2019, is used in patients with advanced breast, gastric and lung cancers whose tumor cells carry a protein called HER2.  Early this year, researchers found that Enhertu could also benefit certain breast cancer patients whose HER2 levels were previously thought to be too low for the drug to have a meaningful effect., Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.34% to £113.54 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100..., Headline: Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy, source:Yahoo, summary: Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients., Headline: AstraZeneca PLC ADR rises Friday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.55% higher to $69.55 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: ADRs End Lower; AstraZeneca, British American Tobacco Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed lower on Friday. The S&P/BNY Mellon index of American depositary receipts ticked down 0.3% to..., Headline: UPDATE 1-Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say, source:Yahoo, summary: The rush to use AstraZeneca and Daiichi-Sankyo's drug Enhertu to treat certain types of breast cancer has far outpaced doctors' ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.  Enhertu, which won U.S. approval in late 2019, is used in patients with advanced breast, gastric and lung cancers whose tumor cells carry a protein called HER2.  Early this year, researchers found that Enhertu could also benefit certain breast cancer patients whose HER2 levels were previously thought to be too low for the drug to have a meaningful effect.",AZN
68,2022-12-10,"Headline: Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen's favorites for 2023, source:MarketWatch, summary: Across the market, Cowen & Co. analysts see undervalued stocks., Headline: Eli Lilly: What To Do When The Market Doesn't Care About Valuation, source:SeekingAlpha, summary: Eli Lilly is one of the best performing pharmaceutical stocks in 2022. Click here to see why LLY stock is overvalued according to me.",AZN
69,2022-12-12,"Headline: Pfizer: The Best Long-Term Investment Setup Since 2009, source:SeekingAlpha, summary: Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here., Headline: AstraZeneca falls Monday, still outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.04% to £113.50 Monday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR underperforms Monday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.39% to $69.28 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...",AZN
70,2022-12-13,"Headline: AstraZeneca falls Tuesday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.21% to £113.26 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity, source:Yahoo, summary: WILMINGTON, Del., December 13, 2022--AstraZeneca is proud to announce $4 million in financial contributions to 52 nonprofit organizations through its second-annual Accelerate Change Together (ACT) on Health Equity: Community Solutions Challenge and National Strategic Collaborations. Building on the learnings and impact from its inaugural year, the 2022 contributions will support community-based, regional and national nonprofit programs working to advance health equity and enhance STEM (Science,, Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.43% higher to $69.58 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone, source:Yahoo, summary: AstraZeneca is breaking out on the strength of its relative strength highs and as profits continue to grow.",AZN
71,2022-12-14,"Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.65% to £114.00 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: 4 Large Drug Stocks to Watch in a Booming Industry, source:Yahoo, summary: Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio., Headline: Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?, source:Yahoo, summary: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service., Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.24% to $70.44 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca price target raised to 13,000 GBp from 12,000 GBp at Deutsche Bank, source:Thefly.com, summary: No summary, Headline: LONDON BRIEFING: Lower open ahead of BoE, ECB; Currys swings to loss, source:Alliance News, summary: No summary, Headline: FDA extends review of AstraZeneca/Merck`s Lynparza`s expanded use in prostate cancer, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca and Merck receive US FDA extension for Lynparza review, source:Alliance News, summary: No summary",AZN
72,2022-12-15,"Headline: Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Investec raises Phoenix Group to 'buy', source:Alliance News, summary: No summary, Headline: Merck, AstraZeneca Receive FDA Extension on Lynparza New Drug Application Date, source:MarketWatch, summary: By Denny Jacob Drugmaker Merck &amp; Co. and pharmaceutical company AstraZeneca PLC on Thursday said the Food and Drug Administration will extend the date..., Headline: C4X Holdings loss widens; outlook strong amid AstraZeneca partnership, source:Alliance News, summary: No summary, Headline: Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca, source:Yahoo, summary: Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca have been highlighted in this Industry Outlook article., Headline: FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza, source:Yahoo, summary: The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) supplemental marketing application for Lynparza (olaparib) by three months. The application seeks approval for Lynparza in combination with abiraterone & prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). Related: AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer. The supplemental application is, Headline: AstraZeneca falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.35% to £113.60 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE..., Headline: Implied Volatility Surging for AstraZeneca (AZN) Stock Options, source:Yahoo, summary: Investors need to pay close attention to AstraZeneca (AZN) stock based on the movements in the options market lately., Headline: U.S. Commerce removes Wuxi Biologics from unverified list, source:Yahoo, summary: The Commerce Department also removed nine Russian entities from the unverified list and addded them to the entity list because the United States has been unable to conduct site visits.  Companies are added to the unverified list if the United States cannot complete on-site visits to determine if they can be trusted to receive sensitive U.S. technology exports, inspections which in China require approval from the commerce ministry., Headline: FibroGen: Growth Prospects Are Not Worth Current Valuations, source:SeekingAlpha, summary: Amid strong headwinds, FibroGen has achieved a high market valuation. Click here to read my analysis on why I think investors should avoid FGEN stock., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slumped 0.99% to $69.74 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Primecap Odyssey Funds` 2022 Annual Shareholder Letter, source:GuruFocus, summary: No summary",AZN
73,2022-12-16,"Headline: HealthBeacon appoints new interim CFO, permanent CFO process ongoing, source:Alliance News, summary: No summary, Headline: AstraZeneca`s Imjudo combo gets EMA panel nod to treat liver, lung cancers in EU, source:Seeking Alpha, summary: No summary, Headline: Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results, source:InvestorPlace, summary: No summary, Headline: AstraZeneca`s cancer, heart drugs gets EMA panel nod for expanded use in EU, source:Seeking Alpha, summary: No summary, Headline: Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology, source:Yahoo, summary: Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and moreExpects ACT to contribute US$25-30 million in revenues in 2023Positions Prenetics solidly within the US$80+ billion global precision oncology ma, Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slid 1.80% to £111.56 Friday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index..., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 2.58% to $67.94 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA, source:Yahoo, summary: The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.",AZN
74,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF., Headline: AstraZeneca (AZN) Gets a Buy from SVB Securities, source:TipRanks, summary: No summary, Headline: AstraZeneca`s Imfinzi plus Imjudo recommended for approval in the EU, source:MarketWatch, summary: No summary, Headline: ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer, source:Business Wire, summary: No summary, Headline: ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer, source:Business Wire, summary: No summary, Headline: AstraZeneca`s Forxiga gets EU approval recommendation for symptomatic chronic heart failure, source:MarketWatch, summary: No summary, Headline: AstraZeneca`s Enhertu wins EU approval for advanced gastric cancer, source:Seeking Alpha, summary: No summary, Headline: LONDON BRIEFING: Stocks called up, but prospect of Santa rally fades, source:Alliance News, summary: No summary, Headline: LONDON MARKET OPEN: Stocks higher as China begins shaky reopening, source:Alliance News, summary: No summary, Headline: AstraZeneca, Daiichi Sankyo announce Enhertu recommended for approval in the EU, source:Thefly.com, summary: No summary, Headline: TOP NEWS: AstraZeneca receives host of EU approvals or recommendations, source:Alliance News, summary: No summary",AZN
75,2022-12-19,"Headline: AstraZeneca slips after Imfinzi falls short in cancer trial, source:Yahoo, summary: By Geoffrey Smith, Headline: AstraZeneca reports Forxiga recommended for extend indication in EU by CHMP, source:Thefly.com, summary: No summary, Headline: AstraZeneca reports Enhertu approved in EU for previously treated gastric cancer, source:Thefly.com, summary: No summary, Headline: AstraZeneca says Imfinzi plus Imjudo recommended for approval in EU by CHMP, source:Thefly.com, summary: No summary, Headline: AstraZeneca says PEARL trial didn`t achieve statistical significance on endpoint, source:Thefly.com, summary: No summary, Headline: AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU, source:Yahoo, summary: The Anglo-Swedish pharma giant said the Committee for Medicinal Products for Human Use of the European Medicines Agency based its opinion on results from the Himalaya Phase 3 trial, and results from the Poseidon Phase 3 trial., Headline: AstraZeneca’s Forxiga gets EU approval recommendation for symptomatic chronic heart failure, source:Yahoo, summary: The recommendation covers heart failure with reduced ejection fraction--a measure of the amount of blood the heart's left ventricle pumps with each heartbeat., Headline: AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) announced topline data from the PEARL Phase 3 trial of Imfinzi (durvalumab) monotherapy versus platinum-based chemotherapy (investigator's choice) as a 1st-line treatment in patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The study did not achieve statistical significance for the primary endpoints of improving overall survival (OS) versus platinum-based chemotherapy as a monotherapy treatment for metastatic NSCLC whose tumor cells express hig, Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.43% to £111.08 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs, source:Yahoo, summary: The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) - Daiichi Sankyo’s (OTC: DSKYF) (OTC: DSNKY) Enhertu (trastuzumab deruxtecan) for advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval covers patients who have received a prior trastuzumab-based regimen. Concurrently, the Committee for Medicinal Products (CHMP) for Human Use (CHMP) of the European Medicines Agency has backed the approval for Enhertu for unresectable or metastatic HER2-low, Headline: AstraZeneca PLC ADR falls Monday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.69% to $67.47 Monday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: ADRs End Mixed; AstraZeneca, atai Life Sciences Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed mixed on Monday. The S&P/BNY Mellon index of American depositary receipts ticked down 0.1% to..., Headline: Astrazeneca (AZN) Stock Moves -0.69%: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $67.47, moving -0.69% from the previous trading session.",AZN
76,2022-12-20,"Headline: AstraZeneca, G42 Healthcare enter strategic partnership agreement, source:Thefly.com, summary: No summary, Headline: FTSE 100 lower as Bank of Japan's surprise move sparks fear, source:Yahoo, summary: Bank of Japan unexpectedly tweaks its ultra loose monetary policy., Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.16% to £111.26 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs, source:Yahoo, summary: The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure., Headline: Could AstraZeneca's Asthma Drug Candidate Generate Billions?, source:Yahoo, summary: AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults., Headline: AstraZeneca PLC ADR rises Tuesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.37% higher to $67.72 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: LONDON BRIEFING: UK public sector borrowing shoots up in November, source:Alliance News, summary: No summary, Headline: AstraZeneca, Merck`s Lynparza gets approval in EU for expanded use in prostate cancer, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca Imfinzi combo for biliary tract cancer gets approval in EU, source:Seeking Alpha, summary: No summary, Headline: LONDON MARKET OPEN: European markets make gains in early trade, source:Alliance News, summary: No summary, Headline: AstraZeneca wins two new approvals in EU for cancer drugs, source:Alliance News, summary: No summary",AZN
77,2022-12-21,"Headline: AstraZeneca`s Imfinzi+chemotherapy approved in E.U. in BTC patients, source:Thefly.com, summary: No summary, Headline: Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU, source:Thefly.com, summary: No summary, Headline: AstraZeneca`s Lynparza approved in E.U. as first line treatment in mCRPC, source:Thefly.com, summary: No summary, Headline: Madrigal: Next Steps After `Wow` Data In NASH, source:Seeking Alpha, summary: No summary, Headline: Madrigal: Next Steps After 'Wow' Data In NASH, source:SeekingAlpha, summary: On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. Click here to read why I think his opens up a Huge market for MDGL., Headline: AstraZeneca rises Wednesday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares advanced 1.06% to £112.44 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings, source:Yahoo, summary: The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) plus abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC) for patients for whom chemotherapy is not clinically indicated. The approval was based on results from the PROpel Phase III trial. In the trial, Lynparza combo therapy reduced the risk of disease progression or death by 34% versus abiraterone and prednisone or prednisolon, Headline: AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs, source:Yahoo, summary: The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use., Headline: AstraZeneca PLC ADR rises Wednesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.27% higher to $67.90 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: ADRs End Higher, AstraZeneca and Carnival Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed higher on Wednesday. The S&P/BNY Mellon index of American depositary receipts ticked up 1.5%...",AZN
78,2022-12-22,"Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (AZN) and ContraFect (CFRX), source:TipRanks, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.55% to £113.06 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: The Top Healthcare Stocks to Buy With $100, source:Yahoo, summary: AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are two pharmaceutical stocks that investors can buy with less than a $100 bill.  AstraZeneca's $219 billion market capitalization makes it the eighth-largest pharmaceutical company in the world and the third-biggest international-based drugmaker.  Perhaps unsurprisingly, the $44.6 billion in revenue that analysts expect the company to generate in 2022 is well-diversified., Headline: Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?, source:Yahoo, summary: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores., Headline: AstraZeneca PLC ADR rises Thursday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.27% higher to $68.08 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Top Research Reports for Novo Nordisk, AstraZeneca & Accenture, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AstraZeneca PLC (AZN) and Accenture plc (ACN).",AZN
79,2022-12-23,"Headline: VEU: An Ex-U.S. Fully Diversified Passive ETF With A Low But Decent Yield, source:SeekingAlpha, summary: VEU is a good option for investors seeking geographical and sectoral diversification. Read why the fund has a higher chance of successfully generating strong returns in the long run., Headline: The Zacks Analyst Blog Highlights Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies, source:Yahoo, summary: Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies are part of the Zacks top Analyst Blog., Headline: AstraZeneca PLC ADR falls Friday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.15% to $67.98 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite...",AZN
80,2022-12-24,"Headline: HQH: 50 Big-Yield Healthcare Stocks, These 3 Worth Considering, source:SeekingAlpha, summary: We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds (CEFs) and bonds. Learn about our 3 top picks here.",AZN
81,2022-12-26,"Headline: Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang, source:Yahoo, summary: The ageless Dow Jones Industrial Average, broad-based S&P 500, and growth-dependent Nasdaq Composite, have tumbled as much as 22%, 28%, and 38%, respectively, from their all-time highs.  For those of you keeping score at home, it means all three indexes are, or were at one point, in a bear market.  Since every bear market throughout history has eventually been recouped (and then some) by a bull market rally, the 2022 bear market represents the ideal time for long-term investors to pounce., Headline: Novavax COVID-19 shot lags in effectiveness in first study of its kind, source:Seeking Alpha, summary: No summary",AZN
82,2022-12-27,"Headline: AstraZeneca PLC (LON:AZN) is a favorite amongst institutional investors who own 88%, source:Yahoo, summary: A look at the shareholders of AstraZeneca PLC ( LON:AZN ) can tell us which group is most powerful. We can see that..., Headline: AstraZeneca PLC ADR falls Tuesday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.07% to $67.93 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: LONDON BRIEFING: UK strikes continue; AstraZeneca wins Japan approvals, source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca wins approvals for cancer treatments in Japan, source:Alliance News, summary: No summary, Headline: AstraZeneca`s Imjudo/Imfinzi combo gets approval in Japan for liver, lung cancers, source:Seeking Alpha, summary: No summary, Headline: Japan approves AstraZeneca`s blood cancer drug Calquence, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca announces Imfinzi, Imjudo approved in Japan to treat three cancers, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces Calquence approved in Japan to treat CLL, source:Thefly.com, summary: No summary",AZN
83,2022-12-28,"Headline: LONDON MARKET MIDDAY: FTSE 100 rises with positive 2022 in sight, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Wednesday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.11% to £112.50 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: ADRs End Mostly Lower, AstraZeneca and ABB Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed mostly lower on Wednesday. The S&P/BNY Mellon index of American depositary receipts ticked..., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.54% to $67.56 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca: Our 2023 Growth Pick, source:SeekingAlpha, summary: AstraZeneca's stock price performance is almost flat since our buy rating target released in May. Click here to read our latest analysis of AZN stock.",AZN
84,2022-12-29,"Headline: Novartis: Competitors Take Note, Iptacopan Is Coming, source:SeekingAlpha, summary: Novartis recently reported positive results from two phase 3 trials of iptacopan in PNH patients. Read why iptacopan should become a decent growth product for NVS stock., Headline: February 2023 Options Now Available For AstraZeneca (AZN), source:Stock Options Channel, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.87% to £113.48 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC (NASDAQ:AZN) Q3 2022 Earnings Call Transcript, source:Yahoo, summary: AstraZeneca PLC (NASDAQ:AZN) Q3 2022 Earnings Call Transcript November 10, 2022 AstraZeneca PLC beats earnings expectations. Reported EPS is $0.84, expectations were $0.72. Operator: Good morning to those joining from the U.K. and the U.S., good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and gentlemen, to […], Headline: AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers, source:Yahoo, summary: The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.80% higher to $68.10 Thursday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: GSK on hunt for attractive biotechs ‘hiding in plain sight’, source:Yahoo, summary: GSK’s chief commercial officer is looking to acquire or partner with biotechs “hiding in plain sight”, as the UK drugmaker focuses on replenishing its drug pipeline.  Luke Miels said the company was hoping to avoid “getting into a bidding war” by identifying under-appreciated targets worth $1bn-$2.5bn, such as its acquisition of Sierra Oncology earlier this year.  Earlier this month, Amgen bought Horizon Therapeutics for $28bn.",AZN
85,2022-12-30,"Headline: Diabetes rates in children set to skyrocket by 2060 - study, source:Seeking Alpha, summary: No summary, Headline: Pharma Stock Roundup: FDA Gives Nod to RHHBY's Lunsumio, Accepts PFE Vaccine BLA, source:Yahoo, summary: FDA approves Roche's (RHHBY) Lunsumio for follicular lymphoma and accepts Pfizer's (PFE) BLA for the pentavalent meningococcal vaccine candidate., Headline: AstraZeneca PLC ADR falls Friday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.44% to $67.80 Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite..., Headline: Exclusive-Drugmakers to raise prices on at least 350 drugs in U.S. in January, source:Yahoo, summary: Drugmakers including Pfizer Inc, GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.  The increases are expected to come as the pharmaceutical industry prepares for the Biden Administration's Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices directly for some drugs starting in 2026.",AZN
86,2022-12-31,"Headline: Align, Invitae among healthcare stocks SA contributors correctly said to avoid in 2022, source:Seeking Alpha, summary: No summary, Headline: Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks, source:Yahoo, summary: In this article we take a look at Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks. Click to skip ahead and see Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. Gilead Sciences, Inc. (NASDAQ:GILD), Novo Nordisk A/S (NYSE:NVO), and Molina Healthcare, Inc. (NYSE:MOH) are three of the healthcare companies that Jim Simons’ quant fund has identified as […]",AZN
87,2023-01-02,"Headline: AstraZeneca price target raised to 13,500 GBp from 12,500 GBp at JPMorgan, source:Thefly.com, summary: No summary, Headline: LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH, source:Alliance News, summary: No summary",AZN
88,2023-01-03,"Headline: 4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile, source:SeekingAlpha, summary: FDMT is an undercovered gene therapy developer. It claims certain competitive differences for its vector delivery platform. Read more on FDMT stock here., Headline: Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study, source:Yahoo, summary: Valneva SE (NASDAQ: VALN) reported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001. The data show that a booster dose of VLA2001 was well tolerated in previously vaccinated participants with either Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) or Moderna Inc (NASDAQ: MRNA) shots. The data confirm the favorable safety profile of VLA2001 seen across all studies, including in homologous or heterologous booster setting, Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC advanced 2.82% to £115.34 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day, source:Yahoo, summary: DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day., Headline: 3 Top Healthcare Stocks Defying the Bear Market, source:Yahoo, summary: Let's take a closer look at these three healthcare stocks defying the current bear market.  Shares for TransMedics Group rose 222% in 2022.  The price jump was due in part to the company's financial performance and partly to its extended moat as the only organ transplant system approved by the Food and Drug Administration (FDA) to transport multiple organs., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 2.26% to $69.33 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite..., Headline: IBD 50 Stocks To Watch: Pharmaceutical Leader AstraZeneca Retakes Latest Buy Point, source:Yahoo, summary: Among the top stocks to watch, pharmaceutical leader AstraZeneca is retaking its latest buy point despite Tuesday's stock market weakness., Headline: ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer, source:Business Wire, summary: No summary, Headline: On This Day: Pelosi is 1st woman elected speaker of the House, source:United Press International, summary: No summary",AZN
89,2023-01-04,"Headline: Kymera Therapeutics appoints Chiniara as CLO, Corporate Secretary, source:Thefly.com, summary: No summary, Headline: Stocks making the biggest moves premarket: General Electric, Salesforce, Alibaba and more, source:CNBC, summary: These are the stocks posting the largest moves in early morning trading. , Headline: EMA validates change to Daiichi Sankyo`s application for lung cancer drug Enhertu, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.59% to £116.02 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Wednesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.25% higher to $69.50 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: AstraZeneca Stock Scores Relative Strength Rating Upgrade, source:Yahoo, summary: AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating., Headline: Genomic Vision Announces Successful Beta Testing of FiberSmart®, source:Business Wire, summary: No summary, Headline: TOP NEWS: AstraZeneca's and Sanofi's nirsevimab approved for US review, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR rises Thursday, outperforms market, source:MarketWatch, summary: No summary, Headline: LONDON BROKER RATINGS: Bank of America cuts Pearson to 'underperform', source:Alliance News, summary: No summary, Headline: AstraZeneca initiated with an Outperform at BMO Capital, source:Thefly.com, summary: No summary",AZN
90,2023-01-05,"Headline: AstraZeneca`s BLA for nirsevimab in RSV prevention accepted by FDA for review, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Bernstein raises Schneider to 'outperform', source:Alliance News, summary: No summary, Headline: Sanofi says FDA accepts BLA for nirsevimab, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: AstraZeneca initiated as a buy at BMO as pharma is udvervalued compared to peers, source:Seeking Alpha, summary: No summary, Headline: Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer, source:Yahoo, summary: CHICAGO, January 05, 2023--Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is currently open for enrollment., Headline: AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says, source:Yahoo, summary: BMO Capital Markets initiated coverage on AstraZeneca Plc (NASDAQ: AZN) with an Outperform rating and a price target of $82. The analyst writes that AstraZeneca's growth and margin expansion are undervalued relative to peers as the company continues to migrate to higher-margin programs. AZN trades at a discount to peers through 2026E with top-and-bottom-line growth 2023-2026 of ~6% and ~14%, respectively, based on consensus, and ~7% and ~13% based on BMO estimates. Also see: AstraZeneca Bets On, Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: No summary, Headline: AstraZeneca`s COVID drug Evusheld unlikely to neutralize newest variant, FDA says, source:MarketWatch, summary: No summary, Headline: LONDON BROKER RATINGS: Credit Suisse cuts Next to 'underperform', source:Alliance News, summary: No summary",AZN
91,2023-01-06,"Headline: A pharma partnership that brought a breakthrough in breast cancer, source:Yahoo, summary: Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing, Headline: IN BRIEF: Zoom appoints AstraZeneca Chief Information Officer to board, source:Alliance News, summary: No summary, Headline: AstraZeneca And Daiichi Sankyo`s Zauberkugel (Magic Bullet), source:Seeking Alpha, summary: No summary, Headline: AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet), source:SeekingAlpha, summary: AstraZeneca, Daiichi Sankyo to market HER-2 cancer domain targeting therapy Enhertu. See why I consider accumulating DSKYF stock for Enhertu momentum play., Headline: 1 Stock Defying the Downturn to Buy, and 1 to Avoid, source:Yahoo, summary: AstraZeneca is a U.K.-based pharmaceutical company with a long list of products, many of which are hugely successful and generate well over $1 billion in annual sales.  The company's oncology lineup is particularly impressive, with products such as Tagrisso, Imfinzi, Lynparza, and Calquence, all of which are blockbusters.  AstraZeneca's oncology drugs made up about 35% of the company's revenue in the third quarter., Headline: As the U.S. Gets Older, Some ETFs Bet on Aging in Place, source:Yahoo, summary: A number of thematic funds are focused on companies that help seniors who want to stay in their homes as long as possible., Headline: A Highly Contagious Covid-19 Variant Is Spreading in the U.S. What to Know., source:Yahoo, summary: XBB.1.5 now accounts for the vast majority of Covid-19 cases in northeastern U.S., where hospitalizations are climbing.",AZN
92,2023-01-09,"Headline: Fed Wants Weaker Markets, Investors Want a Bargain. Brace for Earnings Season., source:Yahoo, summary: Wall Street lowers fourth-quarter earnings expectations, AstraZeneca to buy CinCor Pharma in $1.8 billion deal, new Covid-19 strain is the most contagious yet, and other news to start your day., Headline: European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas, source:Yahoo, summary: European drugmakers announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums, Headline: AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire to CinCor Pharma Inc (NASDAQ: CINC) for $26.00 per share in cash plus a contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product. Marc de Garidel, Chief Executive Officer at CinCor, said: ""We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits, Headline: Midday movers: Lululemon Athletica, CinCor Pharma, Exact Sciences and more, source:Yahoo, summary: By Liz Moyer, Headline: CinCor Pharma Stock Surges on AstraZeneca Deal to Buy It, source:Yahoo, summary: AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline, Headline: AstraZeneca to Buy CinCor Pharma for Up to $1.8 Billion, source:Yahoo, summary: (Bloomberg) -- AstraZeneca Plc agreed to buy US biotech CinCor Pharma Inc. for as much as $1.8 billion to gain a promising new treatment for hypertension and kidney disease.Most Read from BloombergUS Safety Agency to Consider Ban on Gas Stoves Amid Health FearsGoldman to Cut About 3,200 Jobs This Week After Cost ReviewCommodity Ship Heads for Inspection After Suez Canal MishapStocks Give Up Rally Above Key Mark After Fedspeak: Markets WrapRental Housing Is Suddenly Headed Toward a Hard LandingTh, Headline: AstraZeneca reaches deal to buy CinCor Pharma for up to $1.8B, source:Yahoo, summary: AstraZeneca entered into a definitive agreement Monday to acquire CinCor Pharma Inc. for up to $1.8 billion.  CinCor (NASDAQ: CINC), based in Waltham, Massachusetts, is developing new treatments for hypertension and chronic kidney disease.  The deal, which still requires shareholder and regulatory approval, is expected to be completed during the first quarter of this year., Headline: Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day, source:Yahoo, summary: Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day., Headline: Ipsen to buy liver disease drugmaker for $952M, source:Yahoo, summary: Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million., Headline: AstraZeneca/CinCor: deal may herald start of biotech buying spree, source:Yahoo, summary: AstraZeneca’s $1.8bn cash acquisition of CinCor should provide a bit of a pick-me-up for biotech investors.  If this finding were to be confirmed in a larger phase 3 trial, baxdrostat would have a huge addressable market.  It is paying $1.3bn upfront, or roughly $800mn excluding the cash on CinCor’s balance sheet., Headline: JPMorgan Health Conference Kicks Off With Predictable Flurry of (Small) Deals, source:Yahoo, summary: The annual JPMorgan Healthcare Conference in San Francisco, which kicked off today, is often a magnet for deal announcements. This year was no exception, though they were all of the smaller variety — mostly European drug companies paying big premiums to fill their pipelines. Among them, AstraZeneca PLC’s announcement that it would purchase CinCor Pharma Inc. for [as much as $1.8 billion](https://www.wsj.com/livecoverage/stock-market-news-today-01-09-2023/card/astrazeneca-to-buy-u-s-drugmaker-cin, Headline: AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal, source:Yahoo, summary: AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion., Headline: Astrazeneca (AZN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $70.90, moving +0.14% from the previous trading session.",AZN
93,2023-01-10,"Headline: AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B, source:Yahoo, summary: AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline., Headline: AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout, source:Yahoo, summary: AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor., Headline: Stock Market Holds Gains; Chip Stock Breaks Out, source:Yahoo, summary: The stock market held afternoon gains as a server and storage stock flashed a sell signal. Air pollution control stock broke out of a base., Headline: 10 Most Fined Pharmaceutical Companies in the World, source:Yahoo, summary: In this article, we will be taking a look at the 10 most fined pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 5 Most Fined Pharmaceutical Companies in the World. Pharmaceutical companies have often been derided by conspiracy theorists who coined the term “Big Pharma”. The […]",AZN
94,2023-01-11,"Headline: FDA approves AstraZeneca’s new treatment for people with asthma, source:Yahoo, summary: MARKET PULSE AstraZeneca (AZN) (UK:AZN) said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee company said Airsupra is a first-in-class treatment that is administered in an inhaler using a combination of albuterol and budesonide., Headline: AIRSUPRA™ (PT027) approved in the US for asthma, source:Yahoo, summary: WILMINGTON, Del., January 11, 2023--AIRSUPRA™ (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older., Headline: Biden administration will select first 10 drugs for Medicare price negotiations by September, source:CNBC, summary: The federal government for the first time has the power to negotiate Medicare drug prices due to the Inflation Reduction Act., Headline: 3 Dividend Growth Stocks To Buy In January 2023, source:SeekingAlpha, summary: Dividend Growth Stocks can contribute significantly to increasing your additional income in the form of dividends year over year. Click to see my picks!, Headline: AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA, source:Yahoo, summary: The FDA approved AstraZeneca Plc's (NASDAQ: AZN) Airsupra, formerly PT027, as the first and only rescue medication for as-needed use to reduce the risk of asthma exacerbations. The drug is only approved in adults after the company and its partner Avillion sought approval in patients four and older. Airsupra is a pressurized metered-dose inhaler containing albuterol and budesonide. Current albuterol rescue inhalers alleviate acute symptoms, but do not treat the underlying inflammation in asthma,, Headline: AstraZeneca Is Acquiring CinCor Pharma: Market Values Interesting CVR At $3.21, source:SeekingAlpha, summary: AstraZeneca is acquiring Cincor Pharma for $26 per share and an interesting CVR. Learn more about the acquisition and my recommendation.",AZN
95,2023-01-12,"Headline: Could This New Drug Launch Be a Hit for Viatris?, source:Yahoo, summary: Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort.",AZN
96,2023-01-13,"Headline: Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns, source:Yahoo, summary: Drug companies say they need to raise prices on cancer drugs and other treatments to fund research. But they already spend more on stock buybacks and dividends.",AZN
97,2023-01-14,"Headline: 3 Growth Stocks Poised for Huge Gains in 2023, source:Yahoo, summary: Pharmaceutical companies Bayer (OTC: BAYR.Y), Eli Lilly (NYSE: LLY), and AstraZeneca (NASDAQ: AZN) had big years last year, bucking the rest of the market, and each stock saw share gains over the past year.  All three companies have new drugs that were either recently launched or are likely to get final regulatory approval in 2023.  Bayer's stock is up more than 4.5% over the past year, thanks to strong financials and an even stronger pipeline.",AZN
98,2023-01-16,"Headline: AstraZeneca rises Monday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.17% to £116.76 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE...",AZN
99,2023-01-17,"Headline: Vaxxinity: Potential Strong Upsides Ahead, source:SeekingAlpha, summary: Vaxxinity shares have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geopolitical. Read more here., Headline: AstraZeneca falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.65% to £116.00 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slumped 0.48% to $70.74 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $70.74 in the latest trading session, marking a -0.48% move from the prior day.",AZN
100,2023-01-18,"Headline: Reunion Neuroscience Taps Robert Alexander as Chief Medical Officer, source:MarketWatch, summary: By Robb M. Stewart Reunion Neuroscience Inc. said Wednesday it appointed industry veteran Robert Alexander as its chief medical officer as the company works..., Headline: One of the greatest cancer drugs ever has suddenly lost its edge. This is why it was vulnerable., source:MarketWatch, summary: Imbruvica seemed invincible in the marketplace. But a new book, “For Blood and Money,” shows how the drug’s creators left a trap door that led to its undoing., Headline: AstraZeneca falls Wednesday, still outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.19% to £115.78 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE..., Headline: HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China, source:Yahoo, summary: HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who, Headline: AstraZeneca PLC ADR rises Wednesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.21% higher to $70.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Indivior: Healthy Defensive In A Difficult Economy, source:SeekingAlpha, summary: Drug addiction is on the rise but so are treatments for it, like those provided by Indivior for opioid usage. Click here to read my analysis of INVVY stock.",AZN
101,2023-01-19,"Headline: AstraZeneca (AZN) Presents At 41st Annual Healthcare Conference - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by AstraZeneca PLC in conjunction with this event., Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slid 1.36% to £114.20 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.56% to $70.49 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...",AZN
102,2023-01-22,"Headline: Incyte: Making Hay While The Sun Shines, source:SeekingAlpha, summary: Incyte should experience strong cash inflows from both JAKAFI and OPZELURA over the next 6 years. Read more to see why INCY stock is a buy., Headline: Global drug spending to reach $1.9T by 2027 ��� IQVIA, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC ADR falls Monday, underperforms market, source:MarketWatch, summary: No summary, Headline: LONDON BROKER RATINGS: Jefferies cuts Berkeley; HSBC cuts St James's, source:Alliance News, summary: No summary",AZN
103,2023-01-23,"Headline: Cantor biotech/biopharma analysts hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share, source:Thefly.com, summary: No summary, Headline: AZN Stock Under Pressure, source:TalkMarkets, summary: No summary, Headline: AstraZeneca starts tender offer to acquire CinCor, source:Seeking Alpha, summary: No summary, Headline: GLOBAL BROKER RATINGS: MS cuts Shell; Netflix gets price target bumps, source:Alliance News, summary: No summary, Headline: CytoSorbents says Canada cleared pivotal study for anti-bleeding technology, source:Seeking Alpha, summary: No summary, Headline: Interesting AZN Put And Call Options For February 17th, source:Stock Options Channel, summary: No summary, Headline: The Top Healthcare Stocks to Buy With $100, source:Yahoo, summary: Bayer Aktiengesellschaft (OTC: BAYR.Y) and AstraZeneca (NASDAQ: AZN) are elite healthcare companies with shares that trade for less than $100 and make excellent long-term investments because of their revenue and earnings growth, promising pipelines, and above-average dividends.  Bayer was down 11.2% in 2022 and currently trades for about $15 a share while AstraZeneca was up 16.4% in 2022 and currently trades for around $70 a share.  Bayer is a huge German life science conglomerate., Headline: AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc., source:Yahoo, summary: WILMINGTON, Del., January 23, 2023--AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product. On 9 January 2023, AstraZeneca announced that it had entered into a definitive agreement to acquire CinCor. Following the successful closing of the, Headline: Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance, source:Yahoo, summary: Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD., Headline: Top Analyst Reports for AstraZeneca, NextEra Energy & Boeing Company, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), NextEra Energy, Inc. (NEE) and The Boeing Company (BA)., Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: LONDON MARKET OPEN: FTSE 100 lags as other indices make headway, source:Alliance News, summary: No summary",AZN
104,2023-01-24,"Headline: Gilead Sciences: What To Do Ahead Of Q4 2022 Financial Report, source:SeekingAlpha, summary: As a leader in various therapeutic areas, Gilead Sciences' total revenue was $7,042 million in Q3 2022, up 12.5% QoQ. Read why I rate GILD stock a Sell., Headline: Thermo Fisher, AstraZeneca team on CDx  test for Tagrisso, source:Thefly.com, summary: No summary, Headline: Wall Street flat as earnings roll while FTSE closes in red, source:Yahoo, summary: UK public borrowing increased by more than expected last month as the government ploughed billions into its subsidies for household bills., Headline: The Zacks Analyst Blog Highlights AstraZeneca, NextEra Energy, The Boeing, The PNC Financial Services Group and Centene, source:Yahoo, summary: AstraZeneca, NextEra Energy, The Boeing, The PNC Financial Services Group and Centene are part of the Zacks top Analyst Blog., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $66.28 in the latest trading session, marking a -1.97% move from the prior day., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens, source:Alliance News, summary: No summary",AZN
105,2023-01-25,"Headline: Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer, source:Business Wire, summary: No summary, Headline: Novartis downgraded to Neutral from Buy at Citi, source:Thefly.com, summary: No summary, Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary, Headline: AstraZeneca, Daiichi Sankyo`s Enhertu gets approval in EU for breast cancer subtype, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca, Daiichi Sankyo receive EU approval for Enhertu, source:Thefly.com, summary: No summary, Headline: TOP NEWS: AstraZeneca's Enhertu approved in EU for breast cancer form, source:Alliance News, summary: No summary",AZN
106,2023-01-26,"Headline: New Jersey Better Educational Savings Trust`s Top 5 Buys of the 4th Quarter, source:GuruFocus, summary: No summary, Headline: CinCor CEO: acquisition by AstraZeneca was more than a year in the making, source:Yahoo, summary: Before CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant., Headline: argenx: Trigger Ready, But Waiting For Stronger Earnings Profile, source:SeekingAlpha, summary: Argenx caught a strong bid in FY22' on the back of advancements in its Efgartigimod [Vyvgart] pipeline for Myasthenia Gravis. Read more here., Headline: FDA announces Evusheld not currently authorized for emergency use in U.S., source:Thefly.com, summary: No summary, Headline: AstraZeneca COVID-19 antibody therapy no longer authorized in U.S., source:Seeking Alpha, summary: No summary, Headline: AstraZeneca COVID-19 therapy no longer authorized in U.S., source:Seeking Alpha, summary: No summary, Headline: AstraZeneca continuing to work with FDA to collect data on Evusheld and variants, source:Thefly.com, summary: No summary, Headline: AstraZeneca`s preventive COVID therapy no longer effective against current variants, source:MarketWatch, summary: No summary, Headline: IN BRIEF: AstraZeneca loses emergency use authorisation for Evusheld, source:Alliance News, summary: No summary, Headline: ADRs End Higher; AstraZeneca, Diageo Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed higher on Thursday. The S&P/BNY Mellon index of American depositary receipts edged up 0.5% to..., Headline: UPDATE 2-U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld, source:Yahoo, summary: The U.S. health regulator has withdrawn emergency-use authorization for AstraZeneca's COVID-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.  The Food and Drug Administration (FDA) had limited Evusheld's use earlier this month for the same reason and the agency's Thursday announcement sent U.S. shares of London-based AstraZeneca down 1.31% to $65.75., Headline: AstraZeneca’s preventive COVID therapy no longer effective against current variants, source:Yahoo, summary: MARKET PULSE AstraZeneca (AZN) (UK:AZN) said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophylaxis of COVID-19, citing its lack of effectiveness against the currently circulating variants., Headline: FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants, source:CNBC, summary: Many take Evusheld as an additional layer of protection because the vaccines do not trigger a strong immune response for them., Headline: AstraZeneca PLC ADR falls Friday, underperforms market, source:MarketWatch, summary: No summary",AZN
107,2023-01-27,"Headline: 7 Dividend Stocks to Buy for a Stable Income Stream, source:Yahoo, summary: A key to successful retirement planning or wealth building is to start early. One critical component of investing is to secure stable cash flows. This is likely through fixed income, rental income, or investment in dividend stocks. With the markets continuing to face macroeconomic headwinds, it’s a good time to look at some dividend stocks to buy for the coming years. I would allocate 50% of my funds toward dividend stocks, though your allocation may vary based on your individual risk profile. I, Headline: Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends, source:Yahoo, summary: J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility., Headline: The Cash King In Big Pharma: Pfizer (Rating Upgrade), source:SeekingAlpha, summary: Wall Street has gone downgrade happy on Pfizer in January, loudly complaining the end of the pandemic has arrived. Click here to read my most recent analysis., Headline: FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld, source:Yahoo, summary: AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants., Headline: The man behind AstraZeneca’s ‘blockbuster’ cancer drugs, source:Yahoo, summary: As far as life goals go, defeating cancer might be deemed one of the more fanciful., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $65.53, moving -0.7% from the previous trading session., Headline: F-star`s Delayed Acquisition Presents A Risky Opportunity, source:Seeking Alpha, summary: No summary",AZN
108,2023-01-28,"Headline: F-star's Delayed Acquisition Presents A Risky Opportunity, source:SeekingAlpha, summary: FSTX seems undervalued, even at the $7.12 takeover bid. CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. Read more here., Headline: AbbVie: Why The Company Is Still Overvalued, source:Seeking Alpha, summary: No summary",AZN
109,2023-01-29,"Headline: RQ Bio partners with AstraZeneca in Covid antibody fight, source:Yahoo, summary: UK biotech RQ Bio is partnering with AstraZeneca as it races to keep its antibody to protect immunocompromised patients from Covid-19 up to date with the latest variants.  The Anglo-Swedish pharmaceutical company recently launched a trial of a second generation of its Evusheld antibody, as the original appears unable to prevent infection from the XBB 1.5 variant.  The antibodies are used to protect people who do not respond to vaccines, for example, if they have certain cancers., Headline: Could This Vaccine Become Sanofi's Latest Blockbuster?, source:Yahoo, summary: Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants.  Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year., Headline: Veeva Systems: A Leading Provider Of Cloud-Based Solutions For The Pharmaceutical Industry, source:SeekingAlpha, summary: Veeva Systems is a cloud-based software solution provider for the pharmaceutical and life sciences industries. See why VEEV stock is a Buy., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",AZN
110,2023-01-30,"Headline: WHO maintains public health emergency on COVID but sees `inflexion point` ahead, source:Seeking Alpha, summary: No summary, Headline: TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer, source:Business Wire, summary: No summary, Headline: Cantor biotech/biopharma analysts hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: AstraZeneca begins late-stage trial of datopotamab, Keytruda combo for NSC lung cancer, source:Seeking Alpha, summary: No summary, Headline: Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment, source:Alliance News, summary: No summary, Headline: Is AstraZeneca PLC (AZN) a High Growth Stock?, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P […], Headline: Merck (MRK) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings., Headline: 15 Biggest Neuroscience Companies in the World, source:Yahoo, summary: In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to the 5 Biggest Neuroscience Companies in the World. As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health. According […], Headline: Drugmakers prevail in dispute over U.S. discount drug program, source:Yahoo, summary: (Reuters) -Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.  The ruling from a three-judge panel of the 3rd U.S. Circuit Court of Appeals based in Philadelphia is a victory for Sanofi SA, Novo Nordisk AS and AstraZeneca PLc.  The companies had sued the U.S. Department of Health and Human Services (HHS) after it ordered them to stop restricting sales of discounted drugs to so-called contract pharmacies., Headline: UPDATE 1-Drugmakers prevail in dispute over U.S. discount drug program, source:Yahoo, summary: Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.  The ruling from a three-judge panel of the 3rd U.S. Circuit Court of Appeals based in Philadelphia is a victory for Sanofi SA, Novo Nordisk AS and AstraZeneca PLc .  The companies had sued the U.S. Department of Health and Human Services (HHS) after it ordered them to stop restricting sales of discounted drugs to so-called contract pharmacies., Headline: U.S. Appeals Court Sides With Drugmakers on Discount Program, source:Yahoo, summary: The court ruled that drugmakers can limit their shipments of federally discounted drugs to pharmacies, in a blow to hospitals and clinics., Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",AZN
111,2023-01-31,"Headline: Diabetes drug developer Structure Therapeutics sets terms for $125M US IPO, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",AZN
112,2023-02-01,"Headline: AZN Crosses Below Key Moving Average Level, source:Market News Video, summary: No summary, Headline: 3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023, source:Yahoo, summary: Top dividend stocks are capable of delivering above-average returns returns in any type of market.  Which dividend stocks are no-brainer buys for retail investors right now?  AstraZeneca (NASDAQ: AZN), Merck (NYSE: MRK), and Medtronic (NYSE: MDT) are three elite income stocks that have recession-proof businesses, strong growth prospects, and ample free cash flows., Headline: Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints, source:Yahoo, summary: Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.",AZN
113,2023-02-02,"Headline: TEZSPIRE® approved for self-administration in the US with a new pre-filled pen, source:Yahoo, summary: WILMINGTON, Del., February 02, 2023--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1, Headline: GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod, source:Yahoo, summary: GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.",AZN
114,2023-02-05,"Headline: PRESS DIGEST-British Business - Feb 6, source:Yahoo, summary: The following are the top stories on the business pages of British newspapers.  The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned.  - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.",AZN
115,2023-02-06,"Headline: Hutchmed: We Explore Pharma In China, source:SeekingAlpha, summary: HUTCHMED (China) being a part of CK Hutchison Holdings, a huge conglomerate, is developing well. Read more on HCM stock here.",AZN
116,2023-02-07,"Headline: AstraZeneca says Forxiga approved in EU for heart failure, source:Yahoo, summary: AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure., Headline: AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.",AZN
117,2023-02-08,"Headline: AstraZeneca Expected to Swing to 4Q Profit -- Earnings Preview, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC is scheduled to report results for the fourth quarter on Feb 9. Here is what you need to know: SALES FORECAST: Sales at the..., Headline: PepsiCo, AstraZeneca, PayPal earnings: 3 things to watch, source:Yahoo, summary: By Liz Moyer, Headline: AstraZeneca PLC 4Q EPS 58c, source:MarketWatch, summary: Corrections &amp; Amplifications This headline was corrected at 0928 GMT to reflect AstraZeneca 4Q Adj EPS $1.38, not 4Q Adj Loss/Shr $17.00 By Cecilia..., Headline: AstraZeneca Q4 core earnings beat estimates despite easing COVID vaccine demand, source:Yahoo, summary: By Scott Kanowsky, Headline: AstraZeneca Swung to 4Q Profit, But Covid-19 Shot Decline Hit Revenue -- Update, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC on Thursday posted a swing to fourth-quarter profit, though it reported lower revenue due to declining sales of its...",AZN
118,2023-02-09,"Headline: AstraZeneca goes for growth with new drugs as COVID sales wane, source:Yahoo, summary: AstraZeneca on Thursday said it was poised to grow in 2023 and beyond, banking on its burgeoning line-up of cancer, metabolic and rare disease drugs to pick up the pace from dwindling COVID product sales.  CEO Pascal Soriot said the firm was on a path to deliver at least 15 new medicines this decade and said it expects to kick off at least thirty new late-stage clinical trials in 2023.  But like many other industries and its own peers, AstraZeneca has grappled with higher costs linked to the war in Ukraine and the lingering effects of the pandemic in 2022., Headline: As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023, source:CNBC, summary: Demand for Covid-19 vaccines has dropped, but AstraZeneca has ""blockbuster"" projects in development that are set to make billions of dollars, according to its CFO., Headline: AstraZeneca Beat Expectations on 4Q Profit, But Revenue Is a Miss -- Earnings Review, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC reported fourth-quarter results on Thursday. Here is what we watched. REVENUE: Sales at the Anglo-Swedish pharma major..., Headline: FTSE 100: Astrazeneca swings into profit amid double-digit revenue rise, source:Yahoo, summary: AstraZeneca posted adjusted earnings of $1.38 per share on revenue of $12.2bn., Headline: How To Allocate $5,000 Among 5 Dividend Income And Dividend Growth Stocks And ETFs, source:SeekingAlpha, summary: In this article, I will show you a portfolio that consists of 5 picks that provide you with Dividend Income and Dividend Growth. Read more here., Headline: UPDATE 2-European shares gain as upbeat earnings ease recession fears, source:Yahoo, summary: The pan-European STOXX 600 ended up 0.6%, after hitting a near one-year high earlier in the session.  Industrials were the biggest to boost to the index, bolstered by a 6.7% gain in Siemens after the builder of trains and industrial software reported better-than-expected earnings and raised its full-year sales and profit guidance.  AstraZeneca Plc rose 4.1% after the British drugmaker projected growth in 2023 and beyond., Headline: AstraZeneca chief says industry should not pay for NHS Covid costs, source:Yahoo, summary: AstraZeneca’s chief executive said the pharmaceuticals industry should not be made to pay for the “explosion” of NHS costs related to the Covid pandemic, as drugmakers ramp up their criticism of the UK government.  Pascal Soriot said the pricing agreement reached with the industry in 2019 — which stated the NHS would not have to pay more than a 2 per cent increase each year for branded drugs, however much it buys — did not take account of soaring demand from treating Covid patients.  The UK health department’s clawback rose from about 5-10 per cent before the pandemic to 26.5 per cent this year, prompting other pharmaceutical chief executives to warn that it could hit life sciences investment in the UK., Headline: AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab, source:Yahoo, summary: AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales., Headline: AstraZeneca Has a Covid Sales Problem. Its Stock Doesn’t., source:Yahoo, summary: The Anglo-Swedish pharma major reported 1% revenue growth as cancer and cardiovascular therapies offset a decline in sales of its Vaxzevria vaccine., Headline: AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) has reported Q4 core EPS of $1.38, down 17% Y/Y (-5% constant currency). The company clocked Q4 sales of $11.21 billion, -7% (+1% CC), in line with the consensus. The core gross margin of 77% in the fourth quarter was impacted by inventory write-downs and manufacturing termination fees for Evusheld, its COVID-19 treatment. Fourth-quarter revenue was also hurt by a decline in sales of AstraZeneca's COVID-19 vaccine Vaxzevria. ""In 2023, we expect to see another year o, Headline: 2 Top Biotech Stocks to Buy Right Now, source:Yahoo, summary: For today, let's highlight two high-quality pharmaceutical stocks that investors may want to consider buying and holding for the long run.  With over 83,000 employees throughout the world, AstraZeneca (NASDAQ: AZN) is a truly global business.  As you would expect from a large-cap pharmaceutical company, AstraZeneca boasts world-class products., Headline: Market check: Google stock falls, AstraZeneca stock trades higher amid earnings, source:Yahoo, summary: Yahoo Finance Live’s Brad Smith breaks down how stocks are moving in intraday trading., Headline: AstraZeneca snubs Britain over £320m drug factory amid ‘discouraging’ taxes, source:Yahoo, summary: AstraZeneca overlooked Britain for a new $400m (£320m) drug factory because of its “discouraging” tax regime, chief executive Pascal Soriot has said., Headline: Omicron strains remain dominant globally, and the WHO is monitoring four closely, source:Yahoo, summary: The omicron strain of the coronavirus that causes COVID and its descendent lineages are still dominant globally, and XBB.1.5 is under monitoring., Headline: Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates, source:Yahoo, summary: Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers., Headline: Garage demolition underway at AstraZeneca’s future Kendall Square home, source:Yahoo, summary: It's the first step on a years-long, billion-dollar path to build a new research center for the life sciences giant., Headline: AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth, source:Yahoo, summary: AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance., Headline: As Brits reel from a cost-of-living crisis, the UK stock market quietly booms to an all-time high, source:CNBC, summary: The FTSE 100 has hit three all-time highs over the last week, despite continued gloom on the U.K. economy and amid a cost-of-living crisis. , Headline: AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Before I hand the call over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.",AZN
119,2023-02-10,"Headline: UPDATE: Hunt disappointed UK loses new AstraZeneca factory to Ireland, source:Alliance News, summary: No summary, Headline: Medicare mulls rebates in 2025 for drug prices rising faster than inflation, source:Seeking Alpha, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: AstraZeneca (AZN), AbbVie (ABBV), source:TipRanks, summary: No summary, Headline: GLOBAL BROKER RATINGS: LBBW raises Siemens; Jefferies cuts Adidas, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC 2022 Q4 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q4 earnings call., Headline: AZN June 16th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: LONDON MARKET CLOSE: Rate worries keep European stocks in check, source:Alliance News, summary: No summary, Headline: Pharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO, source:Yahoo, summary: AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases., Headline: IN THE KNOW: AstraZeneca late-stage pipeline impresses Barclays, source:Alliance News, summary: No summary, Headline: Jeremy Hunt has made Britain a no-go area for investment, source:Yahoo, summary: The timing couldn’t be more perfect. On Friday, Rishi Sunak and Jeremy Hunt hosted a summit of more than 200 prominent business figures as part of efforts to drum up fresh investment into Britain. And what better backdrop than one of the biggest snubs this Government has ever suffered? AstraZeneca’s usually restrained boss Sir Pascal Soriot confirmed that the pharma giant had chosen to build a new state-of-the-art factory in Dublin rather than the north-west of England because of the Treasury’s, Headline: Sunak is putting Britain’s life sciences success at risk, warns Covid jab creator, source:Yahoo, summary: Rishi Sunak risks squandering Britain's post-pandemic lead in life sciences, one of the creators of the Oxford Covid-19 vaccine has warned, as ministers are hit with an industry backlash over ""discouraging"" tax policies., Headline: AstraZeneca PLC (NASDAQ:AZN) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: AstraZeneca PLC (NASDAQ:AZN) Q4 2022 Earnings Call Transcript February 9, 2023 Operator: Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca’s Full Year and Q4 2022 Results Conference Call for investors and […], Headline: Super Bowl ads boost sales of drugs, yet only two companies advertising this year, source:Seeking Alpha, summary: No summary",AZN
120,2023-02-12,"Headline: AstraZeneca's (LON:AZN) Dividend Will Be $1.45, source:Yahoo, summary: AstraZeneca PLC ( LON:AZN ) will pay a dividend of $1.45 on the 27th of March. Based on this payment, the dividend..., Headline: AstraZeneca: Strong 2022 Growth Bodes Well, source:SeekingAlpha, summary: AstraZeneca's stock might have sagged in January, but it got a boost recently after its 2022 earnings release. Click here to read why Iâd buy AZN., Headline: AstraZeneca (AZN) Declares $0.98 Dividend, source:Fintel, summary: nan",AZN
121,2023-02-13,"Headline: Sophia  expands deal with AstraZeneca to include MM approaches to oncology, source:Thefly.com, summary: No summary, Headline: SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development, source:Business Wire, summary: No summary, Headline: AstraZeneca, SOPHiA team up to use AI, machine learning in cancer drugs development, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca rises Monday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.28% to £114.22 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.20% to $69.71 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...",AZN
122,2023-02-14,"Headline: Compugen: Rilvegostomig expected to progress into Phase 3 this year, source:Thefly.com, summary: No summary, Headline: Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3, source:PR Newswire, summary: No summary, Headline: SVB Securities Sticks to Their Buy Rating for AstraZeneca (AZN), source:TipRanks, summary: No summary, Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.84% to £115.18 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Tuesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.90% higher to $70.34 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: LONDON BROKER RATINGS: Bryan Garnier starts Unilever with 'neutral', source:Alliance News, summary: No summary",AZN
123,2023-02-15,"Headline: GLOBAL BROKER RATINGS: HBSC cuts Michelin; Bryan Garnier likes Danone, source:Alliance News, summary: No summary, Headline: AstraZeneca's Evusheld not recommended by NHS for vulnerable people, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.43% to £115.68 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Panel backs moving opioid antidote Narcan over the counter, source:Associated Press, The, summary: No summary, Headline: Medicare mulls limiting per month costs for generic drugs at $2, source:Seeking Alpha, summary: No summary, Headline: Novo Nordisk: Attractive Market But Likely No Margin Of Safety, source:SeekingAlpha, summary: Novo Nordisk is the only pure-play and a market leader in the diabetes and obesity care space. Click here to read my most recent analysis of NVO stock., Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.92% to $69.69 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: UK drug pricing watchdog declines to recommend AstraZeneca`s COVID therapy Evusheld, source:Seeking Alpha, summary: No summary",AZN
124,2023-02-16,"Headline: MannKind: The Continuing Saga Of What They Say Vs. What They Do, source:SeekingAlpha, summary: As we approach another pivotal point for MannKind I thought it might be good to review the history of the company. See why I rate MNKD stock a Hold now., Headline: AstraZeneca: Reiterate Our Growth Pick, source:SeekingAlpha, summary: AstraZeneca, profit beats expectations, but revenues are down due to lower COVID-19 sales. See why we recommend a buy on AZN stock., Headline: Pfizer, GSK to face FDA AdCom meetings for RSV vaccines from late February, source:Seeking Alpha, summary: No summary, Headline: 3 Stocks To Buy As U.S. Inflation Stays Sticky, source:SeekingAlpha, summary: There was good news and bad news on the US inflation front for January 2023. Read more to see 3 stocks to buy in the current situation., Headline: Merck, AstraZeneca present final results from Phase 3 PROpel trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca, Merck present final results from Phase III PROpel trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC shed 1.78% to £113.62 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100..., Headline: U.K. stocks rise for fourth session, source:MarketWatch, summary: U.K. stocks finished up Thursday, with the FTSE 100 Index rising 0.18% at 8,012.53. Of the FTSE 100 constituents, major international banks company Standard..., Headline: Moderna, Pfizer, BioNTech Covid jab patent dispute heads to 2024 trial, source:Alliance News, summary: No summary, Headline: AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium, source:Yahoo, summary: WILMINGTON, Del., February 16, 2023--Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer (mCRPC) showed LYNPARZA® (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada in combination with abiraterone and prednisone or prednisolone demonstrated median OS of 42.1 months versus 34.7 months for abiraterone plus placebo. This result re, Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 2.50% to $67.95 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",AZN
125,2023-02-17,"Headline: Campbell & CO Investment Adviser LLC Buys 1, Sells 4 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: 9 February Inflation-Busting Ideal Dividend Dogs, source:Seeking Alpha, summary: No summary, Headline: This chart offers one reason that European stocks may continue to outperform U.S. equities, source:MarketWatch, summary: One of the stories for markets this year has been the outperformance of European stocks to U.S. ones, Headline: 10 Sectors Likely To Generate Good Returns In The Next Decade, source:Seeking Alpha, summary: No summary, Headline: UK dividends calendar - next 7 days, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC advanced 1.09% to £114.86 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.50% to $68.97 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Steven Cohen’s Point72 Hedge Fund Backs Salesforce, Broadcom And Meta While Cutting Palo Alto And Workday Stakes, source:Fintel, summary: nan, Headline: COVID vaccine sales to see decline through end of decade as pandemic eases, source:Seeking Alpha, summary: No summary",AZN
126,2023-02-20,"Headline: AstraZeneca rises Monday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.47% to £115.40 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca reports protection against RSV in infants with Beyfortus, source:Alliance News, summary: No summary",AZN
127,2023-02-21,"Headline: LONDON BROKER RATINGS: BoA cuts DS Smith; Jefferies likes JTC, source:Alliance News, summary: No summary, Headline: BRIDGER MANAGEMENT, LLC Buys 1, Sells 4 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of HOWE & RUSLING INC, source:GuruFocus, summary: No summary, Headline: Ex-Dividend Reminder: AstraZeneca, STERIS and Baxter International, source:Dividend Channel, summary: No summary, Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.26% to £115.70 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS, source:Thefly.com, summary: No summary, Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.90% higher to $69.59 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the..., Headline: AstraZeneca Imfinzi, Imjudo combo gets approval in EU to treat liver, lung cancers, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca`s blood cancer drug Calquence`s tablet form gets approval in EU, source:Seeking Alpha, summary: No summary, Headline: TOP NEWS: AstraZeneca wins three approvals in EU for cancer drugs, source:Alliance News, summary: No summary",AZN
128,2023-02-22,"Headline: AstraZeneca says Calquence tablet formulation approved in EU for CLL, source:Thefly.com, summary: No summary, Headline: AstraZeneca reports Imfinzi plus Imjudo approved in EU for NSCLC, source:Thefly.com, summary: No summary, Headline: UK dividends calendar - next 7 days, source:Alliance News, summary: No summary, Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.61% to £115.00 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 1.06% to $68.85 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901, source:PR Newswire, summary: No summary, Headline: LONDON MARKET EARLY CALL: Stocks to rise after uneventful Fed minutes, source:Alliance News, summary: No summary, Headline: AstraZeneca Signs License Agreement With KYM Biosciences for Gastric Cancer Therapy, source:MarketWatch, summary: By Michael Susin AstraZeneca PLC said Thursday that it has entered into an agreement with KYM Biosciences Inc. regarding an exclusive license agreement for a..., Headline: AstraZeneca signs USD63 million agreement to address gastric cancer, source:Alliance News, summary: No summary, Headline: LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down, source:Alliance News, summary: No summary, Headline: AstraZeneca to pay KYM $63M upfront in license deal for potential gastric cancer therapy, source:Seeking Alpha, summary: No summary",AZN
129,2023-02-23,"Headline: AstraZeneca announces license agreement with KYM Biosciences for CMG901, source:Thefly.com, summary: No summary, Headline: LONDON MARKET CLOSE: FTSE 100 struggles, but European peers rise, source:Alliance News, summary: No summary, Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC shed 1.12% to £112.10 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: Interesting AZN Put And Call Options For April 6th, source:Stock Options Channel, summary: No summary, Headline: Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down, source:Yahoo, summary: Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down., Headline: Top Research Reports for Exxon Mobil, Coca-Cola & AstraZeneca, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), The Coca-Cola Company (KO) and AstraZeneca PLC (AZN)., Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.71% to $67.40 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: ADRs End Higher; Alibaba, AstraZeneca Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed higher on Thursday. The S&P/BNY Mellon index of American depositary receipts edged up 0.5% to...",AZN
130,2023-02-24,"Headline: AstraZeneca reports Enhertu approved in China for metastatic breast cancer, source:Thefly.com, summary: No summary, Headline: AstraZeneca completes acquisition of CinCor Pharma, source:Thefly.com, summary: No summary, Headline: Ambrx Biopharma drops 17% to end rally ahead of investor day, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard, source:Yahoo, summary: ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard are included in this Analyst Blog., Headline: TOP NEWS: AstraZeneca closes CinCor buy; Enhertu wins Chinese approval, source:Alliance News, summary: No summary, Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.98% to £111.00 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE..., Headline: SVB Securities Reaffirms Their Buy Rating on AstraZeneca (AZN), source:TipRanks, summary: No summary, Headline: AstraZeneca prices two EUR750 million fixed-rate notes, source:Alliance News, summary: No summary, Headline: Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo, source:Yahoo, summary: FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 1.53% to $66.37 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...",AZN
131,2023-02-26,"Headline: Baron Health Care Fund Q4 2022 Quarterly Letter, source:Seeking Alpha, summary: No summary, Headline: Baron International Growth Fund Q4 2022 Quarterly Letter, source:Seeking Alpha, summary: No summary, Headline: Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca, source:SeekingAlpha, summary: Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here...",AZN
132,2023-02-27,"Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.02% to £110.98 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.65% higher to $66.80 Monday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Are You Looking for a High-Growth Dividend Stock?, source:Yahoo, summary: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.",AZN
133,2023-02-28,"Headline: Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slipped 1.96% to £108.80 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 2.43% to $65.18 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: 11 Most Promising Cancer Stocks According to Analysts, source:Yahoo, summary: In this article, we discuss 11 most promising cancer stocks according to analysts. If you want to see more stocks in this selection, check out 5 Most Promising Cancer Stocks According to Analysts. The market for community oncology services worldwide is projected to experience substantial growth, with an estimated increase from $47.95 billion in 2022 […], Headline: 50 Biggest Public Companies in the World, source:Yahoo, summary: In this article, we will be taking a look at the 50 biggest public companies in the world. To skip our detailed analysis, you can go directly to see the 10 biggest public companies in the world. While much maligned, and often rightly so, the biggest public companies in the world aren’t just intrinsically linked […]",AZN
134,2023-03-01,"Headline: FBI Director says novel coronavirus likely originated from China lab leak, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.59% to £108.16 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: IN BRIEF: AstraZeneca prices three tranche global bond offering, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.05% higher to $65.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials, source:Seeking Alpha, summary: No summary",AZN
135,2023-03-02,"Headline: Prenetics announces formation of scientific advisory board, source:Thefly.com, summary: No summary, Headline: AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC, source:Thefly.com, summary: No summary, Headline: AstraZeneca, Merck provide regulatory update on Lynparza sNDA, source:Thefly.com, summary: No summary, Headline: AstraZeneca (AZN) Shares Cross Below 200 DMA, source:Dividend Channel, summary: No summary, Headline: AstraZeneca (AZN) Receives a Buy from SVB Securities, source:TipRanks, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.44% to £108.64 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: US FDA to discuss AstraZeneca and Merck's Lynparza cancer drug combo, source:Alliance News, summary: No summary, Headline: UPDATE 1-U.S. FDA panel to review expanded use of Merck-AstraZeneca's cancer drug, source:Yahoo, summary: Merck & Co Inc and British drugmaker AstraZeneca PLC said on Thursday that an independent committee of advisers to the U.S. health regulator will review the companies' application for the expanded use of their drug Lynparza to treat an advanced form of prostate cancer.  The U.S. Food and Drug Administration's (FDA) committee is scheduled to meet on April 28.  The companies' are seeking approval of the drug Lynparza in combination with other medications – biraterone and prednisone or prednisolone –for the treatment of a type of treatment-resistant prostate cancer in adult patients., Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.17% to $65.10 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program, source:Yahoo, summary: As previously announced, Valneva SE (NASDAQ: VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions. Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector, Headline: Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023, source:Yahoo, summary: WILMINGTON, Del., March 02, 2023--Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023. The company will present 19 abstracts, including eight oral presentations, across generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), Wilson disease and dermatomyositis.",AZN
136,2023-03-03,"Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.74% to £107.84 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca's Trading Range Makes This Options Trade Appealing, source:Yahoo, summary: AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are going to be in a sideways grind, punishing speculation and..., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.15% higher to $65.20 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...",AZN
137,2023-03-04,"Headline: Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines, source:Seeking Alpha, summary: No summary, Headline: Lexicon Pharma: Advancing A Worthwhile Pipeline But Commercialization Remains A Key Risk, source:SeekingAlpha, summary: Lexicon is getting closer to FDA approval for sotagliflozin. Click here to read my analysis of LXRX stock.",AZN
138,2023-03-05,"Headline: Those who invested in AstraZeneca (LON:AZN) five years ago are up 159%, source:Yahoo, summary: When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares..., Headline: LONDON BRIEFING: Stocks called flat; AstraZeneca positive test results, source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca hails Enhertu phase 2 trial results, source:Alliance News, summary: No summary, Headline: AstraZeneca, Daiichi Sankyo`s Enhertu shows promise in multiple cancer types in trial, source:Seeking Alpha, summary: No summary",AZN
139,2023-03-06,"Headline: AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02, source:Thefly.com, summary: No summary, Headline: AstraZeneca, Daiichi Sankyo announce Enhertu met the prespecified target for ORR, source:Thefly.com, summary: No summary, Headline: AstraZeneca says cancer drug Enhertu showed positive results, source:Yahoo, summary: Enhertu--trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo--had met prespecified criteria for objective response rate and duration of response., Headline: 4 AI Stocks That Are Revolutionizing Healthcare, source:InvestorPlace, summary: No summary, Headline: ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial, source:Yahoo, summary: WILMINGTON, Del., March 06, 2023--Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients., Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.39% to £107.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR underperforms Monday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.98% to $64.56 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) reported high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase 2 trial of Enhertu (trastuzumab deruxtecan) The study met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients. Related: AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer. En, Headline: Genomic Vision launches FiberSmart®, AI-powered software for automating genomic analysis, source:Business Wire, summary: No summary",AZN
140,2023-03-07,"Headline: Mineralys Therapeutics initiated with an Outperform at Evercore ISI, source:Thefly.com, summary: No summary, Headline: Biden to announce plan to keep Medicare solvent beyond 2050, source:Seeking Alpha, summary: No summary, Headline: Ionis: FDA to Review Eplontersen in ATTRv-PN >IONS, source:MarketWatch, summary: By Colin Kellaher Ionis Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration will review its application seeking approval of its..., Headline: Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs, source:Thefly.com, summary: No summary, Headline: Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay, source:Business Wire, summary: No summary, Headline: AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study, source:Yahoo, summary: AstraZeneca (AZN) and Daiichi Sankyo' Enhertu met the pre-specified criteria for objective response rate and duration of response in the DESTINY-PanTumor02 phase II study., Headline: Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares rallied 1.01% to £108.50 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100..., Headline: Ionis, AstraZeneca eplontersen application accepted by FDA for nerve damage disorder, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.42% to $64.29 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ...",AZN
141,2023-03-08,"Headline: Full Year 2022 Sophia Genetics SA Earnings Call, source:Yahoo, summary: Full Year 2022 Sophia Genetics SA Earnings Call, Headline: Genprex`s Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer, source:Seeking Alpha, summary: No summary, Headline: Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer, source:SeekingAlpha, summary: Genprex has a strong financial position with zero debt and a cash balance of $29.52 million. Check out why I'm bullish on GNPX stock., Headline: 3 No-Brainer Stocks to Buy With $400 Right Now, source:Yahoo, summary: A reasonably small amount of money can go a long way when it's invested in innovative businesses., Headline: Roche: Ongoing Pipeline Issues Sap Growth And Increase M&A Likelihood, source:SeekingAlpha, summary: Roche hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Find out our recommendation on RHHBY stock., Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.26% to £108.22 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race, source:Yahoo, summary: Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies., Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.26% to $64.12 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca Imfinzi Phase 3 Trial Returns Positive Results, source:MarketWatch, summary: By Joe Hoppe AstraZeneca PLC said Thursday that a Phase 3 trial showed that its Imfinzi product significantly improved event-free survival in patients with..., Headline: AstraZeneca`s Imfinzi shows event-free survival benefit in lung cancer patients in trial, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca Tagrisso improves overall survival in lung cancer patients in phase 3 trial, source:Seeking Alpha, summary: No summary",AZN
142,2023-03-09,"Headline: AstraZeneca hails trial results of cancer drugs Imfinzi and Tagrisso, source:Alliance News, summary: No summary, Headline: AstraZeneca says Imfinzi significantly improved event-free survival in AEGEAN, source:Thefly.com, summary: No summary, Headline: AstraZeneca says Tagrisso showed `strong` overall survival benefit in trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces AEGEAN trial demonstrated statistical significance, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces ADAURA trial meets secondary endpoint, source:Thefly.com, summary: No summary, Headline: IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer, source:Yahoo, summary: WILMINGTON, Del., March 09, 2023--Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo-controlled trial showed that treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resecta, Headline: TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer, source:Yahoo, summary: WILMINGTON, Del., March 09, 2023--Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent., Headline: 5 Large Drug Stocks to Watch as Sector Picks Up in 2023, source:Yahoo, summary: Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio., Headline: AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients, source:Yahoo, summary: In a trial, lung cancer patients treated with AstraZeneca plc's (NASDAQ: AZN) immunotherapy Imfinzi (durvalumab) pre- and post-surgery lived significantly longer without the disease progressing or recurring than those treated with chemotherapy. The late-stage study compared patients with resectable, early-stage, non-small cell lung cancer treated with Imfinzi and chemotherapy before surgery and as monotherapy after surgery to patients treated with chemotherapy pre-surgery. Topline results from a, Headline: AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) released topline data from the ADAURA Phase 3 trial demonstrating Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The study included the adjuvant treatment of patients with early-stage (IB, II, and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. In May 2020, AstraZeneca anno, Headline: AstraZeneca PLC ADR falls Thursday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.03% to $64.10 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca (AZN) Receives a Buy from SVB Securities, source:TipRanks, summary: No summary",AZN
143,2023-03-10,"Headline: Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Fourth Quarter and Full Year 2022 Results Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available in the Investors section […], Headline: Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi, source:Yahoo, summary: J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article., Headline: AstraZeneca falls Friday, still outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC dropped 1.55% to £106.98 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies, source:Yahoo, summary: Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.14% higher to $64.19 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...",AZN
144,2023-03-13,"Headline: AstraZeneca outperforms market despite losses on the day, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.11% to £106.86 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.54% to $65.18 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session., Headline: Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA Platform, source:SeekingAlpha, summary: Silence Therapeutics is an underfollowed British siRNA company focusing on cardiovascular and autoimmune diseases. Read why we rate SLN stock a speculative Buy.",AZN
145,2023-03-14,"Headline: AstraZeneca remains steady Tuesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC were unchanged Tuesday at £106.86 , on what proved to be an all-around great trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.14% to $65.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg, source:Thefly.com, summary: No summary",AZN
146,2023-03-15,"Headline: LONDON BROKER RATINGS: Jefferies rates Future at 'hold'; Spirent upped, source:Alliance News, summary: No summary, Headline: FOCUS-How GSK plans to replenish its depleted medicine cabinet, source:Yahoo, summary: GSK's chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing an RSV vaccine and promising hepatitis B and asthma treatments - and pledged a tighter focus than his predecessor on infectious disease and HIV.  Tony Wood only took the helm of R&D last August., Headline: GLOBAL BROKER RATINGS: HSBC says 'hold' Terna and Snam, 'buy' Enel, source:Alliance News, summary: No summary, Headline: AstraZeneca falls Wednesday, still outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.39% to £106.44 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE..., Headline: AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?, source:Yahoo, summary: AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER., Headline: Astrazeneca (AZN) Could Be a Great Choice, source:Yahoo, summary: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out., Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.78% to $64.58 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...",AZN
147,2023-03-16,"Headline: JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC advanced 1.45% to £107.98 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 2.17% to $65.98 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ...",AZN
148,2023-03-17,"Headline: Is AstraZeneca PLC (AZN) a Solid Prospective Investment?, source:Yahoo, summary: Artisan Partners, an investment management company, released its “Artisan Global Equity Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTHX returned 15.95%, Advisor Class fund APDHX posted a return of 15.98%, and Institutional Class fund APHHX returned 16.04%, compared to a […], Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.15% to £108.14 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: 2 Steady Stocks to Buy and Hold Forever, source:Yahoo, summary: There is nothing like a bear market to emphasize the importance of investing in solid, reliable, and steady companies that can deliver consistent revenue and earnings for a long time.  Two such companies are AstraZeneca (NASDAQ: AZN) and Visa (NYSE: V).  U.K.-based AstraZeneca is a drugmaker with a vast, diversified portfolio of over three-dozen products across six major segments., Headline: AstraZeneca PLC ADR falls Friday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.56% to $65.61 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $65.61, marking a -0.56% move from the previous day.",AZN
149,2023-03-20,"Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.22% to £107.90 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Monday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.72% to $66.74 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ...",AZN
150,2023-03-21,"Headline: AstraZeneca rises Tuesday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares advanced 1.06% to £109.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.37% higher to $66.99 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Oppenheimer emerging biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary",AZN
151,2023-03-22,"Headline: Here's What is Driving Amgen (AMGN) Stock's Outperformance, source:Yahoo, summary: Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline., Headline: UK dividends calendar - next 7 days, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.66% to £109.76 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.63% to $66.57 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: White House seeking alternative supply chains for pharmaceutical ingredients, source:Seeking Alpha, summary: No summary",AZN
152,2023-03-23,"Headline: TOP NEWS: AstraZeneca's Calquence receives first approval in China, source:Alliance News, summary: No summary, Headline: AstraZeneca`s blood cancer drug Calquence gets conditional approval in China, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca says Calquence conditionally approved in China for first indication, source:Thefly.com, summary: No summary, Headline: 3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030, source:Yahoo, summary: These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount., Headline: These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar, source:Yahoo, summary: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates., Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.20% to £109.98 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR rises Thursday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.04% to $67.26 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: 7 Blue-Chip Stocks to Buy for Capital Preservation, source:Yahoo, summary: The financial sector-driven panic sent investors to the refuge of safe assets, including blue-chip stocks. In general, blue-chip stocks have a low beta and this supports capital preservation. Additionally, most blue-chip stocks have an attractive dividend yield. So, today, my focus is on names that are undervalued. Even if there is a meaningful correction in the broad markets, these blue-chip stocks are likely to remain resilient. Once market sentiments reverse, these stocks can deliver healthy, Headline: BOE: Discounted Global Covered Call Fund, source:SeekingAlpha, summary: BlackRock Enhanced Global Dividend Trust shares some similarities with BDJ but has a sizeable portion of its portfolio outside the US. See why BOE CEF is a Buy., Headline: Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.",AZN
153,2023-03-24,"Headline: FDA draft guidance impacts companies using accelerated approval for oncology drugs, source:Seeking Alpha, summary: No summary, Headline: U.K. stocks continue losing streak, fall for second day, source:MarketWatch, summary: U.K. stocks finished lower Friday, with the FTSE 100 Index falling 1.26% at 7,405.45. Among FTSE 100 constituents, major international banks company Standard..., Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.75% to £110.80 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.97% higher to $67.91 Friday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%, source:Yahoo, summary: Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.",AZN
154,2023-03-26,"Headline: LONDON BRIEFING: Stocks called higher as banking crisis fears ease, source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca hails eplontersen; Enhertu wins another approval, source:Alliance News, summary: No summary",AZN
155,2023-03-27,"Headline: Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints, source:Thefly.com, summary: No summary, Headline: Ionis, AstraZeneca report positive outcomes from eplontersen trial, source:Seeking Alpha, summary: No summary, Headline: Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks, source:Yahoo, summary: WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1, Headline: Oppenheimer emerging biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study, source:Yahoo, summary: Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)., Headline: AstraZeneca PLC ADR rises Monday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.21% to $68.73 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review, source:Yahoo, summary: Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability. At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on t",AZN
156,2023-03-28,"Headline: WHO updates COVID vaccine guidance; low priority for children and adolescents, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.19% to $68.60 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...",AZN
157,2023-03-29,"Headline: AstraZeneca PLC ADR rises Wednesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.06% higher to $68.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively, source:Yahoo, summary: Pieris Pharmaceuticals Inc (NASDAQ: PIRS) reported Q4 earnings and provided updates across its pipeline. The investors are reacting to the further pushback of the timeline for the readout from the Phase 2a study of elarekibep to mid-2024 from prior guidance of the third quarter of 2023. Pieris is collaborating with AstraZeneca Plc (NASDAQ: AZN) to develop elarekibep for asthma patients. AstraZeneca has communicated that completion of the Phase 2a study remains an important priority and that addi, Headline: Astrazeneca (AZN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day., Headline: AstraZeneca Completes KYM Solid Tumors Treatment Deal, source:MarketWatch, summary: By Michael Susin AstraZeneca PLC said Thursday that it has completed an exclusive global license agreement with KYM Biosciences over the CMG901 treatment for..., Headline: LONDON BRIEFING: Stocks add to rebound; SSE ups earnings guidance, source:Alliance News, summary: No summary",AZN
158,2023-03-30,"Headline: AstraZeneca signs exclusive global license deal with KYM Biosciences, source:Alliance News, summary: No summary, Headline: AstraZeneca, KYM Biosciences complete licensing deal for cancer drug CMG901, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca completes agreement with KYM Biosciences for CMG901, source:Thefly.com, summary: No summary, Headline: 7 Growth Stocks That Pay Generous Dividends, source:Yahoo, summary: When it comes to dividend-paying growth stocks, it can be difficult to find names that are both high-growth and high-yield. This makes sense, given that companies with high dividend yields are typically paying out a large portion of their earnings as a dividend, leaving little capital to fund growth. That said, there are quite a few stocks that, while not exactly “high-yield,” have annual yields above that of the S&P 500 (1.69%), plus offer the opportunity for growth. Hitting this “sweet spot,”, Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.82% higher to $69.20 Thursday, on what proved to be an all-around great trading session for the stock market, with the...",AZN
159,2023-03-31,"Headline: Samsung Bioepis` biosimilar to AstraZeneca`s Soliris backed for EU approval, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca Ultomiris gets EMA backing for expanded use, source:Seeking Alpha, summary: No summary, Headline: This is Why  Astrazeneca (AZN) is a Great Dividend Stock, source:Yahoo, summary: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.30% higher to $69.41 Friday, on what proved to be an all-around positive trading session for the stock market, with the...",AZN
160,2023-04-01,"Headline: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Conference Call and Webcast. . A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to […]",AZN
161,2023-04-02,"Headline: AstraZeneca's Ultomiris Recommended for Marketing Authorization in EU, source:MarketWatch, summary: By Michael Susin AstraZeneca PLC said Monday that its treatment for patients with neuromyelitis optica spectrum disorder has been recommended for marketing..., Headline: Harbor Capital Appreciation Fund Buys AstraZeneca, Ups Nvidia Holding, source:GuruFocus, summary: No summary, Headline: TOP NEWS: AstraZeneca's ultomiris recommended for EU approval, source:Alliance News, summary: No summary",AZN
162,2023-04-03,"Headline: AstraZeneca says Ultomiris recommended for approval in EU for NMOSD, source:Thefly.com, summary: No summary, Headline: Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader, source:Thefly.com, summary: No summary, Headline: AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease, source:Yahoo, summary: CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive., Headline: AstraZeneca PLC ADR rises Monday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.72% higher to $69.91 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",AZN
163,2023-04-04,"Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.49% higher to $70.25 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $70.25, moving +0.49% from the previous trading session., Headline: AstraZeneca's Lynparza, Imfinzi Ovarian Cancer Treatment Met Primary Endpoint in Phase 3 Trial, source:MarketWatch, summary: By Joe Hoppe AstraZeneca PLC said Wednesday that its Lynparza and Imfinzi combination met its endpoint in the treatment of patients with advanced ovarian..., Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary, Headline: AstraZeneca Imfinzi, Lynparza combo improves progression-free survival in ovarian cancer trial, source:Seeking Alpha, summary: No summary",AZN
164,2023-04-05,"Headline: AstraZeneca receives positive interim trial results for Imfinzi drug, source:Alliance News, summary: No summary, Headline: AstraZeneca says Lynparza/Imfinzi combo met endpoint in ovarian cancer study, source:Thefly.com, summary: No summary, Headline: UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial, source:Yahoo, summary: AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.  Lynparza, jointly developed with U.S.-based Merck & Co , was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations., Headline: RPT-UPDATE 1-AstraZeneca says drug combo meets goal in late-stage ovarian cancer trial, source:Yahoo, summary: AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.  Lynparza, jointly developed with U.S.-based Merck & Co , was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations., Headline: Drug giant AstraZeneca teams up with Hong Kong Science Park to drive biotech, medical research growth, source:Yahoo, summary: AstraZeneca, one of the world's leading pharmaceutical companies, has signed a second collaboration agreement with Hong Kong Science and Technology Parks (HKSTP) as the city moves to position itself as a trailblazer in life science innovation. Along with the wider Greater Bay Area, Hong Kong aims to attract the best health talent and drive growth in the fields of medical research, drug development, and clinical trials. The collaboration will involve AstraZeneca and HKSTP supporting and providing, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: LONDON MARKET CLOSE: Risk-off mood prevails but FTSE 100 outperforms, source:Alliance News, summary: No summary, Headline: U.K. stocks climb Wednesday, source:MarketWatch, summary: U.K. stocks climbed Wednesday, as the FTSE 100 Index finished up 0.37% at 7,662.94. Of the FTSE 100 constituents, general mining company Polymetal..., Headline: AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) announced topline data from a planned interim analysis of the DUO-O Phase 3 trial of a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy, and bevacizumab. The combo therapy improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Also Read: AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients. In an additional arm, Imfinzi, chemotherapy plu, Headline: UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula, source:Yahoo, summary: A UK court on Wednesday ordered GSK's Tesaro to pay rival AstraZeneca royalties on total sales of ovarian cancer drug Zejula, in a win for the Anglo-Swedish drugmaker.  Tesaro had argued the royalty was payable only on sales that are for uses claimed or covered by the licensed patents, after AstraZeneca filed a UK lawsuit against GSK in 2021, asking for a bigger share of sales from Zejula.  In October 2012, Tesaro entered into license agreements with AstraZeneca, giving it exclusive rights to certain methods of treating patients with Zejula, developed by Tesaro with help from technology licensed from AstraZeneca., Headline: AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal, source:Yahoo, summary: Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer., Headline: AstraZeneca PLC ADR rises Wednesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 2.56% to $72.05 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: IN THE KNOW: AstraZeneca needs competitor data for context - Shore, source:Alliance News, summary: No summary, Headline: Top Analyst Reports for Mastercard, AstraZeneca & Philip Morris, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AstraZeneca PLC (AZN) and Philip Morris International Inc. (PM)., Headline: Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer, source:Yahoo, summary: AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge., Headline: Unusual Call Option Trade in AstraZeneca (AZN)  Worth $1,645.00K, source:Fintel, summary: nan, Headline: WHO chief expects COVID emergency to end this year, source:Seeking Alpha, summary: No summary, Headline: GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says, source:Thefly.com, summary: No summary, Headline: TOP NEWS: AstraZeneca's cancer drug Lynparza approved by NHS England, source:Alliance News, summary: No summary, Headline: LONDON MARKET OPEN: European stocks edge higher in cautious trade, source:Alliance News, summary: No summary, Headline: GSK ordered by UK court to pay more royalties to AstraZeneca on Zejula sales - report, source:Seeking Alpha, summary: No summary",AZN
165,2023-04-06,"Headline: 7 Very Undervalued Penny Stocks to Buy in April 2023, source:InvestorPlace, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: AstraZeneca (AZN), Sanofi (SNY), source:TipRanks, summary: No summary, Headline: Pfizer posts 82% efficacy for maternal RSV vaccine in full data release, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup, source:Yahoo, summary: Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup are included in this Analyst Blog., Headline: FDA forces pre-term birth drug off the market after 12 years, source:Seeking Alpha, summary: No summary, Headline: LONDON MARKET CLOSE: Stocks end shortened week on positive note, source:Alliance News, summary: No summary, Headline: Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates, source:Yahoo, summary: J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.40% higher to $72.34 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: McDonald's, U.K. Pharma Giant Hit New Highs, source:Yahoo, summary: Dow Jones component McDonald's hit new highs Wednesday while U.K. pharma giant AstraZeneca scored a breakout. In addition, MCD stock broke out from a 281.77 buy point, according to MarketSmith. Shares formed a 97-day consolidation and powered higher last month, up nine days in a row before pulling back this week., Headline: Catalyst Watch: Eyes on inflation data, big bank earnings, source:Seeking Alpha, summary: No summary",AZN
166,2023-04-07,"Headline: Estimating The Fair Value Of AstraZeneca PLC (LON:AZN), source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, AstraZeneca fair value estimate is UK£139 AstraZeneca's UK£117..., Headline: 2 Top Biotech Stocks to Buy Right Now, source:Yahoo, summary: Pharmaceutical companies can be great long-term investments.  Because of the major industry risk that comes with patent expirations, investors need to be sure that they are picking pharmaceutical companies with strong product pipelines.  Here are two big pharma stocks with robust product portfolios and pipelines for long-term income investors to consider for their portfolios., Headline: Steven Cohen Loads Up on Esperion Therapeutics as Shares Slide, source:GuruFocus, summary: No summary",AZN
167,2023-04-10,"Headline: GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market, source:Seeking Alpha, summary: No summary, Headline: GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market, source:SeekingAlpha, summary: GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here., Headline: U.S. launches $5B program to speed up development of next-gen COVID vaccines, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer, source:Yahoo, summary: J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog., Headline: AstraZeneca PLC ADR underperforms Monday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.37% to $72.07 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $72.07 in the latest trading session, marking a -0.37% move from the prior day., Headline: Sanofi Gets Full Commercial Control on Virus Medication From AstraZeneca in U.S., source:MarketWatch, summary: By Cecilia Butini Sanofi SA and AstraZeneca PLC said Monday that Sanofi would retain full commercial control on an antibody treatment for respiratory..., Headline: LONDON BRIEFING: Harbour Energy, BP to team up on carbon capture, source:Alliance News, summary: No summary, Headline: AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Sanofi to get commercial control of RSV therapy nirsevimab in US, AstraZeneca to record $0.7B gain, source:Seeking Alpha, summary: No summary, Headline: TOP NEWS: Sanofi wins US drug control from AstraZeneca in Sobi deal, source:Alliance News, summary: No summary",AZN
168,2023-04-11,"Headline: LONDON BROKER RATINGS: Redburn likes Shell; Barclays raises Persimmon, source:Alliance News, summary: No summary, Headline: AstraZeneca updates arrangements with Sobi, Sanofi for nirsevimab in U.S., source:Thefly.com, summary: No summary, Headline: AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023, source:Yahoo, summary: WILMINGTON, Del., April 11, 2023--AstraZeneca will showcase five real-world evidence (RWE) studies from its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio, reinforcing its commitment to advancing science in chronic kidney disease (CKD) and hyperkalemia (HK), at the National Kidney Foundation (NKF) Spring Clinical Meeting April 11-15, 2023., Headline: 12 Best Covid Treatment Stocks to Buy Today, source:Yahoo, summary: In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […], Headline: AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms, source:Yahoo, summary: AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States., Headline: Fusion Pharmaceuticals receives IND clearance for Alpha therapy FPI-2068, source:Thefly.com, summary: No summary",AZN
169,2023-04-12,"Headline: AstraZeneca COVID shot production is expected to resume in India, source:Seeking Alpha, summary: No summary, Headline: These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 2.19% to $73.76 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Fusion Pharma Shares Edge Up 4.3% on FDA Clearance of FPI-2068, source:MarketWatch, summary: By Denny Jacob Fusion Pharmaceuticals Inc. shares edged up 4.3% to $4.35 in aftermarket trading Wednesday after it said the U.S. Food and Drug Administration..., Headline: Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy, source:Yahoo, summary: Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the clearance of investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107) to the U.S. Food and Drug Administration (FDA). Fusion is jointly developing FPI-2068 with AstraZeneca (LSE/STO/Nasdaq: AZN) under the companies' multi-asset collabora, Headline: SK Bioscience Rallies After Clinical Trials of Covid-19 Vaccine Booster, source:MarketWatch, summary: By Kwanwoo Jun SK Bioscience Co Ltd.'s shares rallied Thursday after the global phase 3 clinical trials confirmed the efficacy and safety of its Covid-19...",AZN
170,2023-04-13,"Headline: AstraZeneca price target raised to $85 from $75 at Argus, source:Thefly.com, summary: No summary, Headline: AZN June 2nd Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy, source:Yahoo, summary: Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca., Headline: AstraZeneca Stock Sees Relative Strength Rating Rise To 85, source:Yahoo, summary: AstraZeneca  now clears that threshold, with a jump from 80 to 85 Thursday.  When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.  AstraZeneca ADR is still within a buy range after breaking past a 72.22 buy point in a flat base., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.37% to $74.77 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: TOP NEWS: AstraZeneca Covid antibody neutralises variants of concern, source:Alliance News, summary: No summary",AZN
171,2023-04-14,"Headline: Ghana 1st in world to approve new malaria vaccine by Oxford, source:Seeking Alpha, summary: No summary, Headline: 3 Best Stocks to Buy Now, 4/14/2023, According to Top Analysts, source:TipRanks, summary: No summary, Headline: New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy, source:Yahoo, summary: ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT) announces a poster presentation at AACR 2023 (# 3577 / 2 Poster PET, MRI, and CT Imaging April 18, 2023) of an independent analysis undertaken by AstraZeneca (LSE/STO/Nasdaq: AZN), on data from ImaginAb's IAB-CD8-201 'iCorrelate' Phase II study. The analysis shows baseline and early on-treatment CD8 ImmunoPET/CT may be able to distinguish resp, Headline: IXJ: Healthcare Dashboard For April, source:SeekingAlpha, summary: Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Learn why IXJ ETF is a global alternative to XLV., Headline: AstraZeneca PLC ADR falls Friday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 1.22% to $73.86 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: FTC Alerts Nearly 700 Companies About Potential Penalties for Misleading Claims, source:Yahoo, summary: Marketers will likely review their practices to avoid risking penalties that could stretch into the hundreds of millions of dollars",AZN
172,2023-04-15,"Headline: AstraZeneca presents results from AEGEAN Phase III trial, source:Thefly.com, summary: No summary",AZN
173,2023-04-16,"Headline: IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial, source:Yahoo, summary: WILMINGTON, Del., April 16, 2023--Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC)., Headline: AstraZeneca reports positive results for lung cancer drug combination, source:Alliance News, summary: No summary, Headline: LONDON BRIEFING: Possible offers for Network International, John Wood, source:Alliance News, summary: No summary, Headline: GRAIL, AstraZeneca present new data on methylation assay, source:Thefly.com, summary: No summary",AZN
174,2023-04-17,"Headline: Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?, source:SeekingAlpha, summary: nan, Headline: Astrazeneca (AZN) is a Top Dividend Stock Right Now: Should You Buy?, source:Yahoo, summary: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out., Headline: GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research (AACR) Annual Meeting 2023, source:Business Wire, summary: No summary, Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.31% to $73.63 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting, source:Yahoo, summary: Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today presented data from the First-in-Human (FIH) Phase I trial evaluating C-CAR031 at the 2023 American Association for Cancer Research (AACR) Annual Meeting., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $73.63, marking a -0.31% move from the previous day.",AZN
175,2023-04-18,"Headline: Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Relay Therapeutics (RLAY) and 23andMe Holding (ME), source:TipRanks, summary: No summary, Headline: AstraZeneca confident new COVID antibody protects against known variants, source:Yahoo, summary: AstraZeneca is confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants, its vaccines head said.  Laboratory studies show the antibody, called AZD3152, neutralizes all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, Iskra Reic said in an interview on Tuesday.  AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023., Headline: AstraZeneca PLC ADR rises Tuesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.89% to $75.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: Why AstraZeneca Shares Are Trading Higher Today?, source:Yahoo, summary: AstraZeneca plc's (NASDAQ: AZN) vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show that the antibody, dubbed AZD3152, neutralizes all known variants of COVID-19. AstraZeneca has support from regulators to make the treatment available by the end of this year, Reuters reported citing Iskra Reic's interview. Depending on additional encouraging data and regulator",AZN
176,2023-04-19,"Headline: Citigroup, Ryanair Bemoan Lingering Brexit Woes: New Economy, source:Yahoo, summary: (Bloomberg) -- The new Brexit Deal for Northern Ireland between the UK and the European Union represents progress but isn’t enough to fully eliminate disruption caused by Britain’s exit from the bloc, business leaders said at the Bloomberg New Economy Gateway Europe event near Dublin.Most Read from BloombergWorthless Degrees Are Creating an Unemployable Generation in IndiaAirline Blunder Sells $10,000 Asia-US Business Class Tickets for $300India Passes China as World’s Most Populous Nation, UN S, Headline: Could This Rare-Disease Drug Candidate Become a Blockbuster?, source:Yahoo, summary: This drug candidate could be a great treatment option for patients with a potentially deadly disease., Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.24% to $74.84 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $74.84, marking a -0.24% move from the previous day.",AZN
177,2023-04-20,"Headline: UK shareholder meetings calendar - next 7 days, source:Alliance News, summary: No summary, Headline: UK earnings, trading statements calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick, source:Yahoo, summary: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.41% to $74.53 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",AZN
178,2023-04-21,"Headline: ClearBridge International Value Strategy Q1 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: nan, Headline: Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more, source:Seeking Alpha, summary: No summary, Headline: Merck (MRK) to Report Q1 Earnings: What's in the Cards?, source:Yahoo, summary: Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q1 earnings., Headline: Mineralys: New IPO And A Leader In The Hypertension Drug Development Space, source:SeekingAlpha, summary: nan, Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 1.44% to $75.60 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",AZN
179,2023-04-24,"Headline: AstraZeneca, Ionis announce eplontersen trial met all endpoints, source:Thefly.com, summary: No summary, Headline: AstraZeneca/Sanofi`s RSV preventing therapy Beyfortus gets approval in Canada, source:Seeking Alpha, summary: No summary, Headline: UK earnings, trading statements calendar - next 7 days, source:Alliance News, summary: No summary, Headline: UK shareholder meetings calendar - next 7 days, source:Alliance News, summary: No summary, Headline: NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks, source:Yahoo, summary: WILMINGTON, Del., April 24, 2023--Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.1, Headline: Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?, source:Yahoo, summary: Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs., Headline: AstraZeneca PLC ADR rises Monday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.28% higher to $75.81 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: EU outlines plan to take control of medicine production in health crises, source:Yahoo, summary: Proposal for compulsory licensing risks ire of pharmaceutical groups keen to protect patents and revenue",AZN
180,2023-04-25,"Headline: UK shareholder meetings calendar - next 7 days, source:Alliance News, summary: No summary, Headline: AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?, source:Yahoo, summary: Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs., Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.20% to $75.66 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ...",AZN
181,2023-04-26,"Headline: Novartis iptacopan improves hemoglobin levels in rare blood disorder trial full data, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca's 1Q Sales Expected to Dip -- Earnings Preview, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC is scheduled to report results for the first quarter on Thursday. Here's what you need to know: SALES: The Anglo-Swedish..., Headline: Novartis` iptacopan improves hemoglobin levels in rare blood disorder trial full data, source:Seeking Alpha, summary: No summary, Headline: EU publishes proposed reforms for pharma industry, source:Seeking Alpha, summary: No summary, Headline: Notable earnings before Thursday`s open, source:Seeking Alpha, summary: No summary, Headline: UK earnings, trading statements calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Merck, AstraZeneca dip as FDA reviews cancer drug ahead of AdCom meeting, source:Seeking Alpha, summary: No summary, Headline: Will AstraZeneca Q1 results bring positive surprise?, source:Seeking Alpha, summary: No summary, Headline: U.K. stocks extend losing streak for third session, source:MarketWatch, summary: U.K. stocks finished lower Wednesday, with the FTSE 100 Index dropping 0.49% at 7,852.64. Among FTSE 100 constituents, technical services company..., Headline: LONDON MARKET CLOSE: Tech shines but tepid trade elsewhere, source:Alliance News, summary: No summary, Headline: Pfizer, BioNTech hit new 52-week lows, source:Seeking Alpha, summary: No summary, Headline: Why AstraZeneca (AZN) Might Surprise This Earnings Season, source:Yahoo, summary: AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 2.66% to $73.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: 7 Low-Risk Stocks to Buy if You Only Want to Beat Inflation, source:Yahoo, summary: If you’re looking for some low-risk stocks for inflation-proofing, investing in historically stable companies with robust cash flows and dividends is the best bet right now. A recession is on the cards later this year, and if you are only worried about protecting what you have while having returns that can beat inflation, I would not recommend investing in many of the hotter growth stocks this year. Now don’t get me wrong — growth names are an essential part of your portfolio and they can substa, Headline: GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1, source:Alliance News, summary: No summary, Headline: European markets open lower; banks choppy after results beat expectations, source:CNBC, summary: European markets opened lower Thursday, with concerns over the global banking sector still casting a shadow over investor sentiment., Headline: Aspen Tech plunges to 9-month low on Q3 results; William Blair downgrades stock, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca beats Q1 top and bottom line estimates; reaffirms FY23 outlook, source:Seeking Alpha, summary: No summary, Headline: GET READY: Astra, Barclays, LSEG, Schroders and Unilever at 0700 BST, source:Alliance News, summary: No summary, Headline: LONDON MARKET EARLY CALL: Lower call as US bank sector worries weigh, source:Alliance News, summary: No summary, Headline: AstraZeneca 1Q Revenue Consensus Was $10.60B, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC on Thursday reported a rise in profit for the first quarter, but said a decline in sales of its Covid-19 medicines hurt..., Headline: LONDON BRIEFING: AstraZeneca revenue dips as Covid medicines decline, source:Alliance News, summary: No summary",AZN
182,2023-04-27,"Headline: LONDON MARKET OPEN: Stocks lower amid worries for health of US economy, source:Alliance News, summary: No summary, Headline: AstraZeneca Q1 sales boosted by cancer drugs amid COVID products wane, source:Seeking Alpha, summary: No summary, Headline: TOP NEWS: AstraZeneca profit jumps despite Covid-19 sales decline, source:Alliance News, summary: No summary, Headline: AstraZeneca reports Q1 core EPS $1.92, consensus $1.07, source:Thefly.com, summary: No summary, Headline: AstraZeneca sees FY23 core EPS up high single to low double-digit percentage, source:Thefly.com, summary: No summary, Headline: Astrazeneca: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (AZN), BioMarin Pharmaceutical (BMRN) and Sanofi (SNY), source:TipRanks, summary: No summary, Headline: AstraZeneca beats estimates on strong emerging market sales as COVID wanes, source:Yahoo, summary: LONDON (Reuters) -AstraZeneca on Thursday beat expectations for first-quarter profit and revenue, as buoyant sales of cancer treatment Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling COVID product sales.  The company's sales and outlook highlight the rapid decline of its COVID vaccine, its best-selling product in 2021 at the height of the pandemic, which has struggled to compete with rival shots developed by Pfizer and Moderna.  AstraZeneca's current strategy is focused on areas such as cancer, cardiovascular, kidney, rare and respiratory diseases., Headline: UPDATE 2-AstraZeneca first quarter profit, revenue beat expectations, source:Yahoo, summary: AstraZeneca on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of its roster of drugs in emerging markets.  AstraZeneca's performance in emerging markets was particularly strong, CEO Pascal Soriot said in a statement.  Excluding sales of its COVID-19 products, sales grew 22% to $3.1 billion in emerging markets on a constant currency basis., Headline: 3 Best Stocks to Buy Now, 4/27/2023, According to Top Analysts, source:TipRanks, summary: No summary, Headline: GLOBAL BROKER RATINGS: Berenberg cuts Dassault; HSBC cuts S&N, source:Alliance News, summary: No summary, Headline: AstraZeneca (AZN) Receives a Buy from SVB Securities, source:TipRanks, summary: No summary, Headline: Unusually active option classes on open April 27th, source:Thefly.com, summary: No summary, Headline: AstraZeneca's Profit, Revenue Beat Expectations Despite Covid-19 Slump -- Earnings Review, source:MarketWatch, summary: By Cecilia Butini AstraZeneca PLC reported first-quarter results on Thursday. Here is what we watched. REVENUE: Revenue declined to $10.88 billion from..., Headline: AstraZeneca hunts for more China deals after signing partnerships, source:Yahoo, summary: AstraZeneca is exploring potential deals in China, declaring the market “completely open” to foreign drugmakers.  Pascal Soriot, AstraZeneca’s chief executive, has just returned from two weeks in the country, where the Anglo-Swedish drugmaker has signed three licensing partnerships in recent months.  AstraZeneca is the largest foreign pharmaceutical company by sales in China., Headline: Trending tickers: Meta | Unilever | AstraZeneca | Taylor Wimpey, source:Yahoo, summary: The latest investor updates on stocks that are trending on Thursday., Headline: AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat CC), beating the consensus of $10.75 billion. The company said that total revenue was stable, despite a decline of $1.46 billion from COVID-19 medicines. Excluding COVID-19 medicines, revenue increased by 15%, and product sales increased by 16% Core Gross margin of 83%, up four percentage points,, Headline: Drugmakers scout for deals, ramp up research spending, source:Yahoo, summary: Drugmakers including Merck & Co, AstraZeneca Plc and AbbVie Inc said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.  Several top drugs such as AbbVie flagship Humira have begun to face competition from new rivals or are expected to lose patent protections in the next few years, and deals could be a quick fix to address the loss of revenue from older therapies.  Merck recently announced a $10.8 billion deal to buy Prometheus Biosciences Inc., Headline: AstraZeneca chief warns high tax Britain now ‘very unattractive’, source:Yahoo, summary: High taxes are making Britain ""very unattractive"" for business, the boss of the country's biggest drugmaker has warned, as he said that China was likely to shape the medicines of the future., Headline: AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales, source:Yahoo, summary: AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance., Headline: FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting, source:Yahoo, summary: The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). In 2017, AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) collaborated to co-develop and co-commercialise Lynparza and Koselugo (selumetinib) for multiple cancer types. Ahead of the meeting, the, Headline: Europe stocks markets set for higher open as earnings boost sentiment, source:CNBC, summary: European stock markets are set to open higher on Friday as investors digest corporate earnings. , Headline: AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan, source:Thefly.com, summary: No summary",AZN
183,2023-04-28,"Headline: Merck, AstraZeneca Lynparza wins limited label expansion endorsement, source:Seeking Alpha, summary: No summary, Headline: GLOBAL BROKER RATINGS: HSBC cuts Santander; DZ Bank likes Meta, source:Alliance News, summary: No summary, Headline: Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised, source:Yahoo, summary: Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.76% to $73.22 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study, source:Yahoo, summary: Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue., Headline: AstraZeneca Plc (AZN) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.  The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.",AZN
184,2023-04-29,"Headline: 27 Largest Biotech Companies in the US, source:Yahoo, summary: In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]",AZN
185,2023-04-30,"Headline: GSK struggles to make investors believe its growth story, source:Yahoo, summary: Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise, Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: No summary",AZN
186,2023-05-01,"Headline: AstraZeneca (AZN) Presents at the 2023 American Association for Cancer Research (AACR) - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by AstraZeneca PLC in conjunction with this event., Headline: AstraZeneca ""disappointed"" with US ODAC's guidance on Lynparza, source:Alliance News, summary: No summary, Headline: SVB Securities Remains a Buy on AstraZeneca (AZN), source:TipRanks, summary: No summary, Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",AZN
187,2023-05-02,"Headline: AstraZeneca bemoans ODAC judgement on use of Lynparza drug for cancer, source:Alliance News, summary: No summary, Headline: AstraZeneca says disappointed with FDA Lynparza vote outcome, source:MarketWatch, summary: No summary, Headline: IN BRIEF: AstraZeneca Chair Michel Demare buys GBP230,000 in shares, source:Alliance News, summary: No summary",AZN
188,2023-05-03,"Headline: Fentanyl overdose deaths rose 279%, oxycodone deaths fell in 5 years, source:Seeking Alpha, summary: No summary, Headline: Sernova, AstraZeneca enter collaboration for therapeutic cell applications, source:Thefly.com, summary: No summary, Headline: VGK: 5 Reasons I Like This European ETF, source:TipRanks, summary: No summary, Headline: Sernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell Applications, source:MarketWatch, summary: By Robb M. Stewart Biotechnology company Sernova said Wednesday it entered a preclinical research collaboration with AstraZeneca to evaluate the use of its..., Headline: Sernova Shares Jump With AstraZeneca Collaboration, source:MarketWatch, summary: By Robb M. Stewart Sernova's shares rallied Wednesday after the biotechnology company entered a preclinical research collaboration with AstraZeneca to..., Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.93% to £118.84 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: US approves 1st vaccine for RSV after decades of attempts, source:Associated Press, The, summary: No summary, Headline: Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio, source:Yahoo, summary: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 1.21% to $74.59 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: AZN Stock Today: This Options Trade Boosts AstraZeneca Stock Yield To 21% Annualized, source:Yahoo, summary: AstraZeneca is a group leader that is showing an improving Relative Strength Rating. So, let's look at how a covered call trade on AZN stock might take shape. Income investors can further enhance the yield on the stock through the use of covered calls., Headline: ADRs End Mostly Lower; Sernova Gains on AstraZeneca Collaboration, source:MarketWatch, summary: By Sabela Ojea International stocks trading in New York closed mostly lower Wednesday. The S&P/BNY Mellon index of American depositary receipts fell 0.02% to..., Headline: WHO meeting is set to decide whether to end COVID emergency, source:Seeking Alpha, summary: No summary",AZN
189,2023-05-04,"Headline: AstraZeneca chair says it is paying CEO enough to ward off US rivals, source:Yahoo, summary: The new chair of AstraZeneca believes the drugmaker has extinguished the threat of chief executive Pascal Soriot quitting for lucrative roles in the US, saying that the benefit of increasing his pay in recent years outweighed the criticism from some shareholders.  Under Soriot, who has led AstraZeneca for more than a decade, the group has become the most valuable company on the London market, with a market capitalisation of £185bn.  Sales of its innovative cancer drugs has helped propel the group to three times the size of UK rival GSK., Headline: Baron International Growth Fund Q1 2023 Quarterly Letter, source:SeekingAlpha, summary: Baron International Growth Fund gained 3.75% (Institutional Shares) during the first quarter of 2023. Click here to read the full fund letter., Headline: AstraZeneca chair says increasing CEO`s pay wards of rivals, FT reports, source:Thefly.com, summary: No summary, Headline: Pieris Pharmaceuticals completes safety review for 10 mg dose of elarekibep, source:Thefly.com, summary: No summary, Headline: Q1 2023 Ionis Pharmaceuticals Inc Earnings Call, source:Yahoo, summary: Q1 2023 Ionis Pharmaceuticals Inc Earnings Call, Headline: Ionis Pharma upgraded at Citi after quarterly update, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca management to meet with TD Cowen, source:Thefly.com, summary: No summary, Headline: June 23rd Options Now Available For AstraZeneca (AZN), source:Stock Options Channel, summary: No summary, Headline: AstraZeneca falls Thursday, still outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.29% to £118.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE..., Headline: Baron Health Care Fund Q1 2023 Shareholder Letter, source:SeekingAlpha, summary: Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing., Headline: AstraZeneca PLC ADR falls Thursday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.28% to $74.38 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ...",AZN
190,2023-05-05,"Headline: FibroGen announces MATTERHORN study did not meet primary efficacy endpoint, source:Thefly.com, summary: No summary, Headline: FibroGen stock falls ~10% after roxadustat fails phase 3 trial for anemia, source:Seeking Alpha, summary: No summary, Headline: WHO ends global public health emergency status for COVID-19, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca rises Friday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.61% to £119.22 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.20% to $75.27 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",AZN
191,2023-05-06,"Headline: 3 Low-Volatility Stocks for a Stable Investment Strategy, source:InvestorPlace, summary: No summary, Headline: GSK: Add This Cheap Chip Play To Your Portfolio, source:TalkMarkets, summary: No summary",AZN
192,2023-05-07,"Headline: AstraZeneca, Merck`s Koselugo gets approval in China for rare genetic disorder in kids, source:Seeking Alpha, summary: No summary",AZN
193,2023-05-08,"Headline: AstraZeneca reports Koselugo approved in China for inoperable PN in NF1 patients, source:Thefly.com, summary: No summary, Headline: The 7 Best Mutual Funds to Invest in for May 2023, source:InvestorPlace, summary: No summary, Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.08% higher to $75.33 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg, source:Thefly.com, summary: No summary, Headline: AstraZeneca Gets Broader Approval for Heart Failure Treatment in US, source:MarketWatch, summary: By Christian Moess Laursen AstraZeneca said Tuesday that its Farxiga treatment has been approved in the U.S for use on patients with heart failure. The..., Headline: AstraZeneca Farxiga gets FDA approval to reduce risk of death due to heart failure, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca`s Farxiga gets FDA approval to reduce risk of death due to heart failure, source:Seeking Alpha, summary: No summary",AZN
194,2023-05-09,"Headline: TOP NEWS: AstraZeneca's Farxiga approved in US to treat heart failure, source:Alliance News, summary: No summary, Headline: LONDON BROKER RATINGS: RBC raises Intertek; Davy likes Greencoat UK, source:Alliance News, summary: No summary, Headline: AstraZeneca says Farxiga extended in U.S. to reduce risk of cardiovascular death, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Peel Hunt says 'buy' IAG; RBC lifts Intertek, source:Alliance News, summary: No summary, Headline: AstraZeneca put volume heavy and directionally bearish, source:Thefly.com, summary: No summary, Headline: AstraZeneca outperforms market despite losses on the day, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.07% to £119.14 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE..., Headline: FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients, source:Yahoo, summary: WILMINGTON, Del., May 09, 2023--AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.1 FARXIGA was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF)., Headline: AstraZeneca PLC ADR falls Tuesday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slumped 0.33% to $75.08 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: 15 Biggest Immunotherapy Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […], Headline: AstraZeneca Ultomiris gets expanded approval in EU for rare nervous system disorder, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca's Ultomiris approved in EU for autoimmune disease NMOSD, source:Alliance News, summary: No summary, Headline: AstraZeneca`s Ultomiris gets expanded approval in EU for rare nervous system disorder, source:Seeking Alpha, summary: No summary",AZN
195,2023-05-10,"Headline: AstraZeneca`s Ultomiris approved in EU for adults with NMOSD, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.79% to £118.20 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.28% to $74.87 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Unusual Call Option Trade in Astrazeneca plc - ADR (AZN)  Worth $261.13K, source:Fintel, summary: nan",AZN
196,2023-05-11,"Headline: June 30th Options Now Available For AstraZeneca (AZN), source:Stock Options Channel, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.88% to £119.24 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE..., Headline: Top Healthcare Stocks for May 2023, source:Yahoo, summary: Top healthcare stocks include Azenta Inc. for best value, ShockWave Medical for fastest growth, and Viking Therapeutics for most momentum., Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.19% to $74.73 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript May 10, 2023 Operator: Good day, ladies and gentlemen. And welcome to the Pieris Pharmaceuticals to host First Quarter 2023 Investor Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host Tom Bures, CFO. Sir, the floor is […]",AZN
197,2023-05-12,"Headline: Celcuity gedatolisib combo shows promise in phase 1b trial in breast cancer patients, source:Seeking Alpha, summary: No summary, Headline: Capital One biotech analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns, source:Yahoo, summary: Sanofi said Friday its shot significantly reduced the risk of babies becoming hospitalized with RSV. The results could stoke Sanofi stock., Headline: LaNova Medicines reports global exclusive LM-305 license pact with AstraZeneca, source:Thefly.com, summary: No summary, Headline: LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate, source:PR Newswire, summary: No summary, Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.72% to £120.10 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates, source:Yahoo, summary: Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU., Headline: Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody, source:Yahoo, summary: The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have revealed data from a real-world trial of their candidate nirsevimab, a long-acting antibody. In November, nirsevimab was approved in Europe, dubbed Beyfortus, to prevent RSV-LRTD in newborns and infants during their first RSV season. The phase 3 HARMONIE study recruited over 8,000 infants 12 months and younger. Infants who received a single dose of the a, Headline: AstraZeneca PLC ADR remains steady Friday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR were unchanged Friday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index..., Headline: Directors’ Deals: AstraZeneca chair bets on upward momentum, source:Yahoo, summary: AstraZeneca is the jewel in the FTSE 100’s crown.  The pharmaceutical group now has a market capitalisation of £182bn.  This places it firmly ahead of Shell, the index’s second-largest constituent, with a market cap of £161bn., Headline: 25 Best US Cities for People With Allergies, source:Yahoo, summary: In this article, we will take a look at the 25 best US cities for people with allergies. If you want to see more cities in this selection, go to the 5 Best US Cities for People With Allergies. According to Allied Market Research, the market for allergy treatments was valued at $24.6 billion in […], Headline: Cancer therapies spending set to surge through end of decade, source:Seeking Alpha, summary: No summary",AZN
198,2023-05-13,"Headline: How The Pharmaceutical Industry Is Using AI, source:SeekingAlpha, summary: Industry-leading pharmaceutical firms are adopting AI to drive value for the future of their enterprise. Several companies in the PPH ETF are currently integrating AI into their operations.",AZN
199,2023-05-14,"Headline: Is AstraZeneca Stock a Buy for Growth Investors?, source:Yahoo, summary: Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark.  This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios.  British drugmaker AstraZeneca (NASDAQ: AZN) is one such company.",AZN
200,2023-05-15,"Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.08% to £120.00 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.35% higher to $74.99 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: AI Meets Biotech: Transforming the Drug Development Process, source:InvestorPlace, summary: No summary",AZN
201,2023-05-16,"Headline: AstraZeneca to exit leading U.S. drug industry group PhRMA, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC (LON:AZN) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?, source:Yahoo, summary: AstraZeneca's (LON:AZN) stock is up by 4.2% over the past three months. However, the company's financials look a bit..., Headline: AstraZeneca to leave leading U.S. drug lobby group, source:Yahoo, summary: LONDON (Reuters) -AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.  AstraZeneca decided not to continue its membership after a recent assessment of whether it was ""the most productive and effective use of (company) resources"", a spokesperson for the British drugmaker said in an emailed statement.  PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023., Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.58% to £120.70 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100..., Headline: UPDATE 1-AstraZeneca to leave leading U.S. drug lobby group, source:Yahoo, summary: AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.  AstraZeneca decided not to continue its membership after a recent assessment of whether it was ""the most productive and effective use of (company) resources"", a spokesperson for the British drugmaker said in an emailed statement.  PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.39% higher to $75.28 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?, source:SeekingAlpha, summary: We continue our coverage of AstraZeneca with a 'hold' rating for the next 12 months. Demand for some AZN innovative drugs is high, click for our view., Headline: Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites, source:SeekingAlpha, summary: Pieris' expanding Elarekibep trial finally has active/completed sites. Read more to see my thoughts on PIRS stock and why it is a Buy., Headline: AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial, source:MarketWatch, summary: By Christian Moess Laursen AstraZeneca said Wednesday that trial results showed that its Tagrisso drug in combination with chemotherapy demonstrated strong...",AZN
202,2023-05-17,"Headline: AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression in trial, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca's Tagrisso plus chemotherapy effective against lung cancer, source:Alliance News, summary: No summary, Headline: AstraZeneca announces Tagrisso combination demonstrates statistical significance, source:Thefly.com, summary: No summary, Headline: AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial, source:Yahoo, summary: The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday.  The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso.  The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer., Headline: TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial, source:Yahoo, summary: WILMINGTON, Del., May 17, 2023--Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)., Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares dropped 1.21% to £119.24 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) has reported topline data from the Phase 3 FLAURA2 trial of Tagrisso (osimertinib) in combination with chemotherapy for locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The results showed that Tagrisso plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to Tagrisso alone. Related: Ast, Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slumped 0.77% to $74.70 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: WHO recommends updating COVID shots to add XBB.1 variants, source:Seeking Alpha, summary: No summary",AZN
203,2023-05-18,"Headline: Revvity announces new license agreement with AstraZeneca, source:Thefly.com, summary: No summary, Headline: Revvity licenses gene editing tech to AstraZeneca for cancer, immune-mediated therapies, source:Seeking Alpha, summary: No summary, Headline: Revvity Announces New License Agreement for Next-Generation Base Editing Technology, source:Business Wire, summary: No summary, Headline: FibroGen stock rises after roxadustat matches Sepo in Chinese trial for anemia, source:Seeking Alpha, summary: No summary, Headline: Unusually active option classes on open May 18th, source:Thefly.com, summary: No summary, Headline: Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron, source:Seeking Alpha, summary: No summary, Headline: Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron, source:Seeking Alpha, summary: No summary, Headline: FDA advisers back RSV vaccine for pregnant women that protects their newborns, source:Associated Press, The, summary: No summary, Headline: Baron Health Care Fund Reduced AstraZeneca PLC (AZN) on Competition Concerns, source:Yahoo, summary: Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […], Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.45% to £119.78 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.66% to $74.21 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: The 7 Next Trillion-Dollar Companies to Invest in Now, source:Yahoo, summary: In the last decade, few companies have touched the magic trillion-dollar valuation. Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), and Alphabet (NASDAQ:GOOG, NASDAQ: GOOGL) are the names worth mentioning. While these businesses will continue to create value, I am more interested in finding the next trillion-dollar companies. An interesting point to note is that most of the trillion-dollar valuation companies in the last decade were from the technology sector. Of course, there are potential opportuni",AZN
204,2023-05-19,"Headline: AstraZeneca's China boss says drugmaker will seek to ""love the Communist Party"", source:Yahoo, summary: Global drugmaker AstraZeneca will seek to be a patriotic company in China that ""loves the Communist Party"", its China president said at an event on Friday.  Wang Lei, who is also the company's global executive vice president, made the comments at an event in the eastern city of Wuxi which the firm organised to celebrate its 30th year in China, according to a person familiar with the matter and photos shared with Reuters.  While many local companies have in recent years publicly pledged allegiance to the ruling Chinese Communist Party as President Xi Jinping strengthened the party's role throughout Chinese society and its economy, such messaging is still unusual from foreign companies., Headline: Astra China head says company seeks to `love the Communist Party,` Reuters says, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.27% to £120.10 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: AstraZeneca's China Executive Seeks Loyalty to ""Love the Communist Party"" In China, source:Yahoo, summary: During an event held in the city of Wuxi to commemorate its 30th year in China, AstraZeneca Plc's (NASDAQ: AZN) China president, Wang Lei, said the company will seek to be a patriotic company in China that ""loves the Communist Party."" Wang, who also holds the position of global executive vice president, commented at the event, Reuters reported citing a person familiar with the matter and photos shared. Also Read: One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps. A, Headline: 3 Undervalued Pharma Stocks to Buy for High Total Returns, source:Yahoo, summary: Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors. After an extended bull market, there tends to be a price and time correction phase in various sectors. One secret to successful investing is to identify sectors that have been depressed for an extended period. Stocks in this sector tend to be undervalued, and once sentiments reverse, the rally can be massive. My focus in this column is on undervalued pharma stocks to buy. To, Headline: Why Astrazeneca (AZN) is a Great Dividend Stock Right Now, source:Yahoo, summary: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out., Headline: DeSantis Vs. Disney, Alibaba Spinoffs Cloud Business, Apple Bans Internal ChatGPT Use: Today's Top Stories, source:Yahoo, summary: Bloomberg Alibaba's Cloud Business Spinoff - What's Going On With Alibaba Stock Friday Alibaba Group Holding Limited's (NYSE: BABA) move to fully spin out a potentially transformative $12 billion cloud business has fueled speculation of it succumbing to market or political realities. Analysts value the cloud business at upwards of $30 billion, a prime beneficiary of a post-ChatGPT frenzy mirroring the success of Amazon.Com Inc's (NASDAQ: AMZN) cloud unit Amazon Web Services. Alibaba splurged ten, Headline: Olema Oncology: Best Contrarian Oncology Play For 2023, source:SeekingAlpha, summary: Olema, clinical-stage biopharma, targeting ER+ breast cancer, has promising clinical data and a solid cash position. Click here to read why OLMA stock is a buy., Headline: AstraZeneca PLC ADR rises Friday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.78% higher to $74.79 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: An AstraZeneca executive said the quiet part about China out loud, source:Yahoo, summary: AstraZeneca has big business in China. The British pharmaceutical company is the biggest drugmaker in the country, where it makes 13% of its revenue.",AZN
205,2023-05-21,"Headline: Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal, source:SeekingAlpha, summary: Shanghaiâs LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million plus royalties on sales. Read more here..., Headline: Billions of dollars at stake as FDA shortcut allows half-proven drugs - report, source:Seeking Alpha, summary: No summary, Headline: IN BRIEF: AstraZeneca hires LSEG CFO Anna Manz as non-exec director, source:Alliance News, summary: No summary",AZN
206,2023-05-22,"Headline: Pfizer Yielding 4.5% Is Getting Added To My Dividend Harvesting Portfolio And Maybe The Main Account, source:SeekingAlpha, summary: Pfizer has fallen through the $40 level and looks very enticing as its dividend yield sits at 4.5%. See why I added PFE stock to my portfolio., Headline: AstraZeneca rises Monday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.22% to £120.36 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.45% to $74.45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite...",AZN
207,2023-05-23,"Headline: Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.02% to £120.34 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE..., Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: AstraZeneca PLC ADR falls Tuesday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.51% to $74.07 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD, source:Yahoo, summary: WILMINGTON, Del., May 23, 2023--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to o, Headline: AstraZeneca PLC ADR underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",AZN
208,2023-05-24,"Headline: As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction, source:Benzinga, summary: No summary, Headline: AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter, source:Yahoo, summary: Innoviva Inc's (NASDAQ: INVA) affiliate Entasis Therapeutics Inc received FDA approval for Xacduro (sulbactam and durlobactam for injection), co-packaged as a treatment for hospital-acquired pneumonia. The approval covers patients 18 years and older for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by difficult-to-treat bacteria strains known as Acinetobacter baumannii-calcoaceticus complex. Innoviva acquired Entasis Therapeutics in May 2022 for $2.20 per sha, Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: No summary",AZN
209,2023-05-25,"Headline: AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023, source:Yahoo, summary: WILMINGTON, Del., May 25, 2023--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023., Headline: AstraZeneca: Think Medium-To-Long Term, source:SeekingAlpha, summary: AstraZeneca's price has moved sideways in the past month, after showing good progress for some time. See why AZN stock is still a buy for me., Headline: LONDON BRIEFING: UK retail sales up; Hunt ""comfortable"" with recession, source:Alliance News, summary: No summary, Headline: AstraZeneca's Imfinzi plus Lynparza effective for endometrial cancer, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: No summary, Headline: AstraZeneca Ultomiris gets approval in Japan for expanded use in rare nervous system disorder, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca's Ultomiris gets approval in Japan for expanded use in rare nervous system disorder, source:Seeking Alpha, summary: No summary",AZN
210,2023-05-26,"Headline: AstraZeneca Imfinzi, Lynparza cuts risk of uterus cancer progression in phase 3 trial, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca's Imfinzi, Lynparza cuts risk of uterus cancer progression in phase 3 trial, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer, source:Benzinga, summary: No summary, Headline: AstraZeneca says Ultomiris approved in Japan for prevention of NMOSD relapses, source:Thefly.com, summary: No summary, Headline: Elon Musk's Neuralink gets FDA nod to start human trial of brain implant, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca announces high-level results from DUO-E Phase III trial on Imfinzi, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces results from Imfinzi plus Lynparza trial, source:Thefly.com, summary: No summary, Headline: IN THE KNOW: AstraZeneca's DUO-E positive, but ""mature OS"" data needed, source:Alliance News, summary: No summary, Headline: Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today, source:Benzinga, summary: No summary, Headline: AstraZeneca price target lowered to $80 from $85 at Argus, source:Thefly.com, summary: No summary, Headline: Stocks facing most buy and sell pressure into Russell rebalancing, source:Seeking Alpha, summary: No summary, Headline: TD Cowen pharma/biotech analysts hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Unusually active option classes on open May 26th, source:Thefly.com, summary: No summary, Headline: TOP NEWS: AstraZeneca's Ultomiris wins another approval in Japan, source:Alliance News, summary: No summary, Headline: IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy, source:Yahoo, summary: WILMINGTON, Del., May 26, 2023--Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cance, Headline: Health authorities to target next COVID shot to new strain, WSJ says, source:Thefly.com, summary: No summary, Headline: 12 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain, source:Yahoo, summary: In this article, we discuss 12 best growth stocks to buy and hold in 2023 according to billionaire Rajiv Jain. If you want to see more stocks in this selection, check out 5 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain. Bloomberg reported on May 23 that Rajiv Jain, […]",AZN
211,2023-05-28,"Headline: Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years, source:Yahoo, summary: Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years.  With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS).  As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.",AZN
212,2023-05-29,"Headline: AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal, source:Yahoo, summary: AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer., Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary, Headline: Nestle hires LSEG's Anna Manz as CFO as Rogers ends eight-year term, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: No summary",AZN
213,2023-05-30,"Headline: Bolt Biotherapeutics and AstraZeneca Rare Disease partner in retinal disease R&D, source:Thefly.com, summary: No summary, Headline: Catalyst Pharmaceuticals appoints Thompson to board of directors, source:Thefly.com, summary: No summary, Headline: Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM, source:Business Wire, summary: No summary, Headline: BioLight announces joint cooperation agreement with AstraZeneca's Alexion, source:Thefly.com, summary: No summary, Headline: Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?, source:TalkMarkets, summary: No summary, Headline: AstraZeneca PLC ADR rises Wednesday, outperforms market, source:MarketWatch, summary: No summary",AZN
214,2023-05-31,"Headline: AstraZeneca/Merck's Lynparza gains expanded prostate cancer indication, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca halts bowel disease drug program, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program, source:MarketWatch, summary: By Anthony O. Goriainoff AstraZeneca said Thursday that it was discontinuing the brazikumab inflammatory bowel disease development program after reviewing..., Headline: LONDON BRIEFING: Higher open as US debt limit bill passes House, source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca discontinues brazikumab; Lynparza wins approval, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",AZN
215,2023-06-01,"Headline: AstraZeneca discontinues brazikumab IBD development program, source:Thefly.com, summary: No summary, Headline: AstraZeneca halts AbbVie-partnered bowel disease drug program, source:Seeking Alpha, summary: No summary, Headline: Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA, source:Thefly.com, summary: No summary, Headline: AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer, source:Thefly.com, summary: No summary, Headline: UPDATE 1-AstraZeneca to stop developing Crohn's disease drug, source:Yahoo, summary: British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.  The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and ""the context of a competitive landscape"".  AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan., Headline: Merck and Astra's Lynparza prostate cancer treatment gets US approval, source:Alliance News, summary: No summary, Headline: LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, source:Yahoo, summary: WILMINGTON, Del., June 01, 2023--AstraZeneca and Merck & Co., Inc’s, known as MSD outside the US and Canada, LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC)., Headline: Lexicon Pharmaceuticals Secures Key FDA Approval, But Heavy Lifting Remains, source:SeekingAlpha, summary: Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa. Read why I think LXRX remains as a high-risk proposition for investors., Headline: AstraZeneca (AZN) Discontinues Brazikumab Development, source:Yahoo, summary: AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program., Headline: Germany Is Cooling. 3 Stocks to Put Your Money In., source:MarketWatch, summary: Germany’s industrial machine, diminished or not, still offers attractive names like Siemens, SAP, and Deutsche Telekom., Headline: AstraZeneca's IMFINZI plus chemo improved pathologic response in Phase III trial, source:Thefly.com, summary: No summary, Headline: Cantor Fitzgerald biotech to hold analyst/industry dinner meeting, source:Thefly.com, summary: No summary",AZN
216,2023-06-02,"Headline: AstraZeneca's Imfinzi shows positive response in gastric cancers, source:Seeking Alpha, summary: No summary, Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN), source:TipRanks, summary: No summary, Headline: 3 Nasdaq 100 Stocks That Are Surefire Buys in June, source:Yahoo, summary: These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer., Headline: AstraZeneca says Imfinzi plus chemotherapy showed clinical benefit in trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Friday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.67% to £117.48 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers, source:MarketWatch, summary: By Michael Susin AstraZeneca said late Friday that interim analysis of the phase III study regarding its Imfinzi drug together with chemotherapy..., Headline: AstraZeneca sees positive results for Imfinzi in gastric cancers, source:Alliance News, summary: No summary, Headline: Here's Why Astrazeneca (AZN) is a Strong Value Stock, source:Yahoo, summary: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores., Headline: Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies, source:Yahoo, summary: FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer, Headline: Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study, source:Yahoo, summary: Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks., Headline: FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer, source:Yahoo, summary: Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC., Headline: Top Research Reports for Exxon Mobil, AstraZeneca & Netflix, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX)., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.34% to $72.59 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial, source:Yahoo, summary: WILMINGTON, Del., June 02, 2023--Positive high-level results from a planned interim analysis of the MATTERHORN Phase III trial showed treatment with AstraZeneca’s IMFINZI® (durvalumab) added to standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) neoadjuvant (before surgery) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone fo",AZN
217,2023-06-03,"Headline: SVB Securities Sticks to Their Buy Rating for AstraZeneca (AZN), source:TipRanks, summary: No summary, Headline: AstraZeneca interim analysis of DUO-O trial shows statistically significant PFS, source:Thefly.com, summary: No summary, Headline: LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial, source:Yahoo, summary: WILMINGTON, Del., June 03, 2023--Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® (olaparib), IMFINZI® (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutation",AZN
218,2023-06-04,"Headline: AstraZeneca defies geopolitics to bet on China, source:Yahoo, summary: AstraZeneca’s chief executive returned from a recent trip to China exuberant about an “explosion” of biotech companies in the country and the potential for his business to deliver drugs discovered there to the world.  Pascal Soriot said the market was “completely open” for pharma investment.  “It’s hard to not be impressed by the progress that has been made in China over the last few years,” he added on a press call in April., Headline: AstraZeneca says TAGRISSO achieved 'unprecedent' survival in EGFRm, source:Thefly.com, summary: No summary, Headline: Wall Street Breakfast: The Week Ahead, source:SeekingAlpha, summary: Investors head into next week with the debt ceiling crisis resolved for the near term., Headline: AstraZeneca’s cancer pill Tagrisso halves mortality risk in lung cancer, source:Seeking Alpha, summary: No summary, Headline: TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial, source:Yahoo, summary: WILMINGTON, Del., June 04, 2023--Positive results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent., Headline: AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients, source:Yahoo, summary: AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.  The drug has regulatory approvals across multiple geographies for certain patients with so-called non small cell lung cancer (NSCLC) who have a mutation of the EGFR gene.  The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer, said Susan Galbraith, executive VP of oncology R&D at AstraZeneca in a statement., Headline: GLOBAL BRIEFING: Saudi Arabia to cut oil output to boost prices, source:Alliance News, summary: No summary, Headline: AstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria Met, source:MarketWatch, summary: By Elena Vardon AstraZeneca said Monday that a phase four trial for its Andexxa drug for patients experiencing intracranial haemorrhage will be stopped early...",AZN
219,2023-06-05,"Headline: AstraZeneca stops Andexxa trial early, Tagrisso reduces death risk, source:Alliance News, summary: No summary, Headline: Cantor Fitzgerald biotech to hold analyst/industry dinner meeting, source:Thefly.com, summary: No summary, Headline: AstraZeneca says Andexxa trial stopped early after hitting pre-specified target, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces ANNEXA-I trial will be stopped early, source:Thefly.com, summary: No summary, Headline: AstraZeneca reports interim analysis from DESTINY-PanTumor02 trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca says Enhertu showed ORR of 37.1% in DESTINY-PanTumor02 Phase 2 trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces updates results from TROPION-Lung02 Phase Ib trial, source:Thefly.com, summary: No summary, Headline: At BIO 2023, Canada Showcases Multiple Strengths as a Biopharma Powerhouse, source:Business Wire, summary: No summary, Headline: ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors, source:Business Wire, summary: No summary, Headline: Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial, source:Business Wire, summary: No summary, Headline: AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial, source:MarketWatch, summary: By Elena Vardon AstraZeneca said Monday that the phase II trial for its cancer drug Enhertu showed clinically meaningful and durable responses across..., Headline: Stocks Mixed, Week Ahead, OPEC Cuts, Palo Alto Networks Joins S&P 500, AstraZeneca Lung Cancer Trial - 5 Things To Know, source:Yahoo, summary: Stock futures edge higher as jobs report, debt deal boost global markets; Week Ahead: inflation data, Treasury bond sales in focus; Saudi Arabia agrees steep production cuts as OPEC seeks to 'stabilize' global markets; Palo Alto Networks leaps on S&P 500 inclusion, DISH Networks slumps and AstraZeneca unveils 'unprecedented' data from late-stage lung cancer trial., Headline: ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care, source:Yahoo, summary: WILMINGTON, Del., June 05, 2023--ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of ANDEXXA (andexanet alfa) in patients on oral FXa inhibitor treatment including apixaban and rivaroxaban experiencing an intracranial hemorrhage, will be stopped early.1 The decision is based on achieving pre-specified stopping criteria of superior hemostatic efficacy, the ability to limit the expansion of a potentially life-threatening bleed in the brain, versus usual care.1,2, Headline: AstraZeneca PLC (LON:AZN) is largely controlled by institutional shareholders who own 87% of the company, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their..., Headline: AstraZeneca and Daiichi Sankyo report progress in cancer drug trials, source:Alliance News, summary: No summary, Headline: ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors, source:Yahoo, summary: WILMINGTON, Del., June 05, 2023--Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients., Headline: AstraZeneca rises Monday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.39% to £117.94 Monday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100..., Headline: Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial, source:Yahoo, summary: WILMINGTON, Del., June 05, 2023--Updated results from the TROPION-Lung02 Phase Ib trial showed, with additional enrolment and follow-up from the initial presentation, that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterat, Headline: $100 Invested In AstraZeneca 10 Years Ago Would Be Worth This Much Today, source:Benzinga, summary: No summary, Headline: Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term, source:Yahoo, summary: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores., Headline: AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients, source:Yahoo, summary: AstraZeneca plc's (NASDAQ: AZN) Tagrisso (osimertinib) cuts the risk of death by 51% in patients with a certain form of lung cancer diagnosed early enough to remove their tumor surgically, trial data showed. Data from the ADAURA Phase 3 trial showed Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small ce, Headline: AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal, source:Yahoo, summary: At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.84% higher to $73.20 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...",AZN
220,2023-06-06,"Headline: AstraZeneca PLC (AZN) ASCO Investor Event, source:SeekingAlpha, summary: AstraZeneca PLC (NASDAQ:NASDAQ:AZN) ASCO Investor Event June 5, 2023 7:00 PM ETCorporateParticipantsAndy Barnett - VP Global Head of IRRoy Herbst - Deputy Director, Yale Cancer CenterPascal..., Headline: ASCO, source:SeekingAlpha, summary: The following slide deck was published by AstraZeneca PLC in conjunction with this event., Headline: AstraZeneca rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.32% to £118.32 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE..., Headline: UPDATE 1-US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy, source:Yahoo, summary: The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infections in infants.  The RSV prevention antibody, nirsevimab, showed an overall favorable safety profile in clinical trials, FDA staff said in documents published ahead of the health regulator's advisory committee meeting on Thursday., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.27% higher to $73.40 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Genomic Vision Provides Strategy Update, source:Business Wire, summary: No summary, Headline: This Is What Whales Are Betting On AstraZeneca, source:Benzinga, summary: No summary, Headline: Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway', source:Benzinga, summary: No summary",AZN
221,2023-06-07,"Headline: Zentalis price target raised to $50 from $45 at Stifel, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.66% to £117.54 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR falls Wednesday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.12% to $73.31 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: Iberdrola plans to invest EUR4.00 billion in digitalisation by 2030, source:Alliance News, summary: No summary, Headline: FDA panel back approval of AstraZeneca, Sanofi RSV drug, Bloomberg says, source:Thefly.com, summary: No summary",AZN
222,2023-06-08,"Headline: AstraZeneca/Sanofi's RSV drug recommended by FDA AdCom, source:Thefly.com, summary: No summary, Headline: AstraZeneca, Sanofi win FDA advisory committee backing for RSV therapy nirsevimab, source:Seeking Alpha, summary: No summary, Headline: Unusually active option classes on open June 8th, source:Thefly.com, summary: No summary, Headline: AZN July 28th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: AstraZeneca falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.03% to £117.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the..., Headline: Top Healthcare Stocks for June 2023, source:Yahoo, summary: Top healthcare stocks include Theravance Biopharma for best value, Dr Reddy's Laboratories for fastest growth, and Viking Therapeutics for most momentum., Headline: FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSV, source:CNBC, summary: If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV. , Headline: FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection, source:MarketWatch, summary: Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi and AstraZeneca to..., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 1.28% to $74.25 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: UPDATE 3-US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy, source:Yahoo, summary: The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.  The advisers voted unanimously in favor of using the antibody, nirsevimab, in newborns and infants to prevent infections in their first RSV season.  In a separate 19-2 vote, the panel backed the therapy's use in children aged up to two years who are vulnerable to severe illness through their second RSV season., Headline: AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee, source:Alliance News, summary: No summary, Headline: AstraZeneca Reaches Agreement With Quell Therapeutics for Treg Cell Therapies, source:MarketWatch, summary: By Anthony O. Goriainoff AstraZeneca said Friday that it has reached an agreement to develop, manufacture and commercialize engineered T-regulatory, or Treg,..., Headline: AstraZeneca Says Nirsevimab Recommended for RSV Prevention in Infants by FDA Body, source:MarketWatch, summary: By Joe Hoppe AstraZeneca said Friday that its nirsevimab antibody has been recommended for the prevention of respiratory syncytial virus, a lower respiratory..., Headline: LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout, source:Alliance News, summary: No summary",AZN
223,2023-06-09,"Headline: TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data, source:Alliance News, summary: No summary, Headline: US FDA committee recommends Sanofi's RSV disease treatment in infants, source:Alliance News, summary: No summary, Headline: AstraZeneca reports danicopan met primary endpoint in Phase 3 ALPHA trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces Treg cell therapy agreement with Quell Therapeutics, source:Thefly.com, summary: No summary, Headline: UK cell therapy start-up agrees AstraZeneca partnership worth up to $2bn, source:Yahoo, summary: One of the most promising UK biotech start-ups, Quell Therapeutics, has signed a research collaboration and licensing deal with AstraZeneca to develop treatments for two autoimmune diseases.  The pharma giant will pay Quell $85mn upfront and up to $2bn more if it meets various development and commercialisation milestones over the next few years.  The technology developed by Quell allows the manipulation of a patient’s immune response by genetically engineering “regulatory T-cells” or Tregs., Headline: AstraZeneca in pact with Quell Therapeutics for Treg cell therapies, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca (NASDAQ:AZN), Sanofi RSV Antibody Wins FDA Advisors’ Nod, source:TipRanks, summary: No summary, Headline: AstraZeneca outperforms market despite losses on the day, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.32% to £117.12 Friday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100..., Headline: Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon, source:Yahoo, summary: The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The committee also voted 19 to 2 in support of nirsevimab's favorable benefit-risk profile for children up to 24 months of age who remain vulnerable to, Headline: AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes, source:Yahoo, summary: AstraZeneca plc (NASDAQ: AZN) has entered into a collaboration, exclusive option, and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies for Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications. Under the terms of the agreement, Quell’s proprietary toolbox of Treg cell engineering modules, including its Foxp3 Phenotype Lock, will be leveraged to develop autologous multi-modular Treg cell therapy candidates for major autoim, Headline: AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder, source:Yahoo, summary: AstraZeneca Plc (NASDAQ: AZN) released data from the Phase 3 ALPHA trial of danicopan as an add-on to the standard of care for paroxysmal nocturnal hemoglobinuria (PNH). The data showed that danicopan as an add-on to the standard of care C5 inhibitor therapy Ultomiris (ravulizumab) or Soliris (eculizumab) demonstrated a statistically significant and clinically meaningful increase in hemoglobin levels and maintained disease control in PNH patients, compared to placebo plus established C5 inhibito, Headline: Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories, source:Yahoo, summary: Financial Times Privacy Breach Risk in Nvidia's AI Technology Stirs Concern Among Researchers Researchers found that an Nvidia Corp (NASDAQ: NVDA) artificial intelligence software feature is susceptible to manipulation leading to the compromise of private information. Robust Intelligence analysts found that the ""NeMo Framework,"" which allows developers to work with a range of large language models, could easily break through so-called safety guardrails. After using the Nvidia system on their own, Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.26% to $74.06 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite..., Headline: New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control, source:Yahoo, summary: Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies evaluating crovalimab compared to eculizumab, a current standard of care in paroxysmal nocturnal hemoglobinuria (PNH), were presented at the European Hematology Association Hybrid Congress. In the COMMODORE 2 study, 79.3% of participants randomized to be treated with crovalimab achieved hemolysis control from week five to week 25 compared with 79.0% with AstraZeneca Plc's (NASDAQ: AZN) Soliris (eculizum, Headline: FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody, source:Yahoo, summary: The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.",AZN
224,2023-06-10,"Headline: AI Meets Biotech: Transforming the Drug Development Process, source:InvestorPlace, summary: No summary",AZN
225,2023-06-11,"Headline: Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground, source:TalkMarkets, summary: No summary, Headline: AstraZeneca breast cancer drug capivasertib gets priority review in US, source:Alliance News, summary: No summary",AZN
226,2023-06-12,"Headline: AstraZeneca's capivasertib-Faslodex combination granted Priority Review in U.S., source:Thefly.com, summary: No summary, Headline: AstraZeneca announces FDA acceptance, priority review for capivasertib NDA, source:Thefly.com, summary: No summary, Headline: AstraZeneca (AZN) Receives a Buy from Bank of America Securities, source:TipRanks, summary: No summary, Headline: Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer, source:Yahoo, summary: WILMINGTON, Del., June 12, 2023--AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with FASLODEX® (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen., Headline: AstraZeneca rises Monday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC advanced 1.01% to £118.30 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies, source:Yahoo, summary: AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million., Headline: AstraZeneca PLC ADR underperforms Monday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.28% to $73.85 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $73.85, moving -0.28% from the previous trading session., Headline: AstraZeneca's Soliris Treatment Approved in China for Adults With gMG, source:MarketWatch, summary: By Joe Hoppe AstraZeneca said Tuesday that its Soliris disease treatment has been approved in China for adults with refractory generalized myasthenia gravis,..., Headline: AstraZeneca wins approval in China for Soliris in myasthenia gravis, source:Alliance News, summary: No summary",AZN
227,2023-06-13,"Headline: Pharma chiefs warn red tape and NHS levy risk Britain missing out on billions, source:Yahoo, summary: Britain risks missing out on billions of pounds of pharmaceutical investment because bosses are struggling with red tape and a sky-high NHS levy, an industry group has warned., Headline: AstraZeneca reports Soliris approved in China for adults with refractory gMG, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces partnership with Vanguard Renewables, source:Thefly.com, summary: No summary, Headline: Unusually active option classes on open June 13th, source:Thefly.com, summary: No summary, Headline: AstraZeneca to decarbonize its U.S. footprint by turning cow manure into renewable natural gas, source:MarketWatch, summary: In a first for the pharma sector, AstraZeneca will tap renewable natural gas for its U.S. manufacturing sites by the end of 2026., Headline: Top 20 Most Profitable Pharmaceutical Companies In The World, source:Yahoo, summary: In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading […], Headline: AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites, source:Yahoo, summary: WILMINGTON, Del., June 13, 2023--In a first-of-its-kind collaboration, AstraZeneca is partnering with Vanguard Renewables to deliver renewable natural gas to all its U.S. sites., Headline: AstraZeneca turns to cows to cut U.S. carbon footprint, source:Yahoo, summary: Drugmaker AstraZeneca is switching to biogas produced from cow manure and food waste in the United States, it said on Tuesday, in a deal to cut its carbon emissions there.  The Anglo-Swedish drugmaker said the long-term agreement with Massachusetts-based Vanguard Renewables would enable it to transition to biogas from natural gas and cut its emissions across its U.S. research and manufacturing sites.  ""Doing the right thing costs a little bit more, but it is not punitive,"" said Pascal Soriot, chief executive of AstraZeneca, which makes 26 medicines in the U.S., Headline: AstraZeneca falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.76% to £117.40 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review, source:Yahoo, summary: The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.38% higher to $74.13 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $74.13, moving +0.38% from the previous trading session., Headline: Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating, source:Benzinga, summary: No summary, Headline: AstraZeneca put volume heavy and directionally bearish, source:Thefly.com, summary: No summary",AZN
228,2023-06-14,"Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC shed 1.96% to £115.10 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: U.K. stocks continue winning streak, climb for third session, source:DowJones, summary: U.K. stocks finished higher Wednesday, with the FTSE 100 Index increasing 0.10% at 7,602.74. Among FTSE 100 constituents, medical equipment/supplies company..., Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 1.83% to $72.77 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...",AZN
229,2023-06-15,"Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares rose 1.53% to £116.86 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index..., Headline: LONDON MARKET CLOSE: Europe mixed after ECB hike and hawkish Fed, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC ADR rises Thursday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 2.54% to $74.62 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: FDA panel recommends updated COVID-19 vaccines targeting XBB.1.5 subvariant, source:Thefly.com, summary: No summary",AZN
230,2023-06-16,"Headline: Unusually active option classes on open June 16th, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.87% to £117.88 Friday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: 2 Best Biotech Stocks to Buy Right Now, source:Yahoo, summary: When done right, investing in pharmaceutical companies can be a lucrative endeavor.  This is because as long as there are diseases and infections, medicines and vaccines will always remain in high demand.  Dating back to Astra's founding in 1913 in Sweden, AstraZeneca (NASDAQ: AZN) has more than a century of corporate history., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.80% higher to $75.22 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ..., Headline: Biologic drugs will lead European pharmas to surpass US counterparts in sales, source:Seeking Alpha, summary: No summary",AZN
231,2023-06-18,"Headline: Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas, source:SeekingAlpha, summary: San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Read more here..., Headline: How HS2 haunts ambitious plans for Britain’s golden triangle, source:Yahoo, summary: The rivalry between Oxford and Cambridge stretches back centuries, with each university town famously dismissing their opposite as “the other place”., Headline: AstraZeneca drafts plan to spin off China business amid tensions, source:Yahoo, summary: Anglo-Swedish drugmaker views listing a separate unit in Hong Kong as potential shelter from global strife, Headline: AstraZeneca planning China business spin off -FT, source:Yahoo, summary: The company would seek to be a patriotic company in China that ""loves the Communist Party"", its China president said in May. Last year, the country accounted for 13% of AstraZeneca's total sales, and the company is China's biggest drugmaker.  The spin off could protect AstraZeneca from tensions between China and other global powers, while the company retained control of the business, the FT's report said.  AstraZeneca said it did not comment on ""rumours or speculations around future strategy or M&A."", Headline: LONDON MARKET EARLY CALL: Stocks to fall but pound rises ahead of BoE, source:Alliance News, summary: No summary, Headline: PRESS: AstraZeneca drafts plan to spin-off in China - FT, source:Alliance News, summary: No summary, Headline: Why is AstraZeneca (NASDAQ:AZN) Mulling Spin-Off of China Business?, source:TipRanks, summary: No summary, Headline: AZN Stock: China Business Spin-Off in the Works; Politics at Play, source:TipRanks, summary: No summary, Headline: LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys, source:Alliance News, summary: No summary, Headline: AstraZeneca weighs China unit spinoff amid geopolitical risks - report, source:Seeking Alpha, summary: No summary",AZN
232,2023-06-19,"Headline: AstraZeneca could spin off China business, source:Yahoo, summary: AstraZeneca is protecting itself from US-China tensions.  Plus, corporate America has poured a lot of money into diversity plans over the past three years, but now it’s pulling back.  US secretary of state Antony Blinken is wrapping up a trip to China., Headline: LONDON MARKET OPEN: Stocks falter amid weaker outlook for China, source:Alliance News, summary: No summary, Headline: AstraZeneca could break out and separately list China business, FT reports, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares shed 1.20% to £116.46 Monday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index..., Headline: AstraZeneca/China: break-up deal would reflect necessity not choice, source:Yahoo, summary: China is known for its prowess in gymnastics.  As tensions heighten between the US and China, AstraZeneca may offer its own twist by carving out its Chinese business.  Chief executive Pascal Soriot has pushed AstraZeneca harder and faster into China than any other big foreign drugmaker., Headline: AstraZeneca plots to sell AI drug unit to the Chinese, source:Yahoo, summary: AstraZeneca’s pioneering artificial intelligence (AI) research centre could fall into foreign ownership under reported plans for the drugs giant to spin off and separately list its Chinese division.",AZN
233,2023-06-20,"Headline: Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court , source:CNBC, summary: The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control. , Headline: AstraZeneca: What's Next? (Rating Downgrade), source:SeekingAlpha, summary: AstraZeneca is considering spinning off its China operations and listing a separate division in Hong Kong or Shanghai. Read why we're neutral on AZN stock., Headline: AstraZeneca outperforms market despite losses on the day, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.09% to £116.36 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE..., Headline: AstraZeneca call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions, source:Yahoo, summary: European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting geopolitical tensions. Last month, during an event held in Wuxi to commemorate its 30th year in China, AstraZeneca's China president, Wang Lei, said the company will seek to be a patriotic company in China that ""loves the Communist Party."" In 2022, China accounted for 13% of the company's overall sales. The s, Headline: Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories, source:Yahoo, summary: Bloomberg Spotify to Launch New Expensive Subscription Plan, 'Supremium,' Amid Competition with Apple and Amazon Spotify Technology S.A. (NYSE: SPOT) is eying a more expensive subscription option likely to include high-fidelity audio to drive more revenue and appease investors. Dubbed ""Supremium,"" the new tier will be Spotify's most expensive plan and likely offer a HiFi feature it first announced it was working on in 2021. To augment its current ""Premium"" tier, Spotify will offer subscribers ex, Headline: AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business, source:Yahoo, summary: AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China., Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 1.69% to $73.95 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite..., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $73.95, marking a -1.69% move from the previous day.",AZN
234,2023-06-21,"Headline: Pieris Pharma Shares Halted as Partner Discontinues Asthma Treatment Trial, source:MarketWatch, summary: By Adriano Marchese Pieris Pharmaceuticals shares were halted in premarket trading after its partner AstraZeneca decided to discontinue and cease dosing in..., Headline: Pieris sinks 60% as AstraZeneca halts mid-stage trial for Asthma candidate, source:Seeking Alpha, summary: No summary, Headline: Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis, source:Benzinga, summary: No summary, Headline: What Does AstraZeneca's Debt Look Like?, source:Benzinga, summary: No summary, Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.43% to £115.86 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE..., Headline: $1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today, source:Benzinga, summary: No summary, Headline: AstraZeneca PLC ADR falls Wednesday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.77% to $73.38 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer, source:Yahoo, summary: Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC., Headline: SandboxAQ to launch 'AQBioSim' division to focus on A.I.-assisted drug development, source:CNBC, summary: Jack Hidary, SandboxAQ CEO, joins 'Last Call' to discuss the use case for A.I. in the healthcare industry and how the technology is being utilized to develop life saving drugs.",AZN
235,2023-06-22,"Headline: Novo Nordisk falls after safety signal linked to weight loss drug class, source:Seeking Alpha, summary: No summary, Headline: European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide, source:Benzinga, summary: No summary, Headline: Interesting AZN Put And Call Options For August 4th, source:Stock Options Channel, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.12% to £116.00 Thursday, on what proved to be an all-around rough trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Thursday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.78% higher to $73.95 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Is AstraZeneca a Top Stock to Buy Right Now?, source:Yahoo, summary: The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead., Headline: Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst, source:Benzinga, summary: No summary",AZN
236,2023-06-23,"Headline: Unusually active option classes on open June 23rd, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC shed 1.53% to £114.22 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100..., Headline: IN THE KNOW: GSK inks Zantac settlement but ""not a full stop"" on saga, source:Alliance News, summary: No summary, Headline: This Is What Whales Are Betting On AstraZeneca, source:Benzinga, summary: No summary, Headline: Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate, source:Yahoo, summary: Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 2.47% to $72.12 Friday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite...",AZN
237,2023-06-25,"Headline: Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company, source:SeekingAlpha, summary: The biotech world had a busy week. Click to read about the latest Deals and Financings & Trials and Approvals in biotech., Headline: What is behind big pharma's underperformance?, source:Seeking Alpha, summary: No summary, Headline: Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer, source:Business Wire, summary: No summary, Headline: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer, source:Business Wire, summary: No summary, Headline: EU committee recommends expanded approval for AstraZeneca's Soliris, source:Alliance News, summary: No summary",AZN
238,2023-06-26,"Headline: Innate Pharma announces first patient dosed in MATISSE trial, source:Thefly.com, summary: No summary, Headline: Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead, source:TalkMarkets, summary: No summary, Headline: AstraZeneca's Soliris recommended for EU approval by CHMP for children with gMG, source:Thefly.com, summary: No summary, Headline: Interesting AZN Put Options For August 18th, source:Stock Options Channel, summary: No summary, Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slid 1.14% to £112.92 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100..., Headline: Amazon targets Ohio for big AWS operations expansion, source:Seeking Alpha, summary: No summary, Headline: Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics, source:Benzinga, summary: No summary, Headline: AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease, source:Yahoo, summary: The European Union has recommended for marketing authorization of AstraZeneca Plc's (NASDAQ: AZN) Soliris (eculizumab) for expanded use in refractory generalized myasthenia gravis (gMG) in children and adolescents. gMG is a rare, chronic autoimmune neuromuscular disease causing severe weakness and loss of muscle function. Soliris was first approved in the EU in 2017 for certain adults with gMG and is also approved for certain adults with gMG in the U.S., China, and Japan. If approved, Soliris wo, Headline: AstraZeneca PLC ADR falls Monday, still outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.54% to $71.73 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite..., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $71.73, moving -0.54% from the previous trading session., Headline: AstraZeneca put volume heavy and directionally bearish, source:Thefly.com, summary: No summary, Headline: AstraZeneca's diabetes combination treatment approved in China, source:Alliance News, summary: No summary",AZN
239,2023-06-27,"Headline: AstraZeneca says Xigduo XR approved in China for adults with type-2 diabetes, source:Thefly.com, summary: No summary, Headline: Largest borrow rate increases among liquid names, source:Thefly.com, summary: No summary, Headline: AIM ImmunoTech announces approval in the Netherlands to begin Phase 1b/2 study, source:Thefly.com, summary: No summary, Headline: Price Over Earnings Overview: AstraZeneca, source:Benzinga, summary: No summary, Headline: AstraZeneca falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.90% to £111.90 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.08% to $71.67 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $71.67 in the latest trading session, marking a -0.08% move from the prior day., Headline: AstraZeneca Unusual Options Activity For June 28, source:Benzinga, summary: No summary",AZN
240,2023-06-28,"Headline: AstraZeneca announces $400M investment in AZ Forest program, source:Thefly.com, summary: No summary, Headline: AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health, source:Yahoo, summary: CAMBRIDGE, United Kingdom, June 28, 2023--Expansion of AZ Forest for climate action and human health, Headline: IN BRIEF: AstraZeneca invests USD400 million in reforestation, source:Alliance News, summary: No summary, Headline: Genprex jumps ~15% on third FDA fast track tag for lead asset, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.39% to £112.34 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: How to Find Strong Medical Stocks Slated for Positive Earnings Surprises, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.99% to $70.96 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...",AZN
241,2023-06-29,"Headline: AstraZeneca says Imfinzi/Imjudo show sustained OS benefit in HIMALAYA trial, source:Thefly.com, summary: No summary, Headline: AstraZeneca: Imfinzi + Imjudo demonstrate meaningful OS benefit for HCC patients, source:Thefly.com, summary: No summary, Headline: AstraZeneca's Advanced Liver Cancer Treatment Data Shows Improved Survival Rates, source:MarketWatch, summary: By Michael Susin AstraZeneca said Thursday that phase III studies showed that Imfinzi plus Imjudo provided a sustained and clinically meaningful overall..., Headline: AstraZeneca Sees Positive Phase 3 Trial Data for Imfinzi Cancer Treatment, source:MarketWatch, summary: By Chris Wack AstraZeneca said a Phase III trial showed its Imfinzi durvalumab plus Imjudo demonstrated a sustained, clinically meaningful overall survival..., Headline: SEC charges five individuals with insider trading before Alexion-Portola merger, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.02% to £112.36 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer, source:Benzinga, summary: No summary, Headline: IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial, source:Yahoo, summary: WILMINGTON, Del., June 29, 2023--Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment., Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.16% to $70.85 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...",AZN
242,2023-06-30,"Headline: Medicare revises guidance on drug price negotiations amid lawsuits, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca rises Friday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.36% to £112.76 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.02% to $71.57 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ...",AZN
243,2023-07-01,"Headline: 4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip, source:Yahoo, summary: It's been a wild two years for Wall Street.  After rocketing to record-closing highs in 2021, all three major stock indexes stumbled into a bear market last year.  The innovation-focused Nasdaq Composite (NASDAQINDEX: ^IXIC) was hardest hit, with the index shedding a third of its value.",AZN
244,2023-07-02,"Headline: Europe stocks close slightly lower after strong first half; mining stocks up 2%, source:CNBC, summary: European stock markets closed slightly lower on Monday, shortly after ending the first half of the year 8.8% higher., Headline: Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial, source:Business Wire, summary: No summary, Headline: AstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer Patients, source:MarketWatch, summary: By Anthony O. Goriainoff AstraZeneca said Monday that its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell..., Headline: TOP NEWS: AstraZeneca, Daiichi hail datopotamab lung cancer trial, source:Alliance News, summary: No summary",AZN
245,2023-07-03,"Headline: How a Swedish start-up reignited the search for an Alzheimer’s drug, source:Yahoo, summary: A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise, Headline: LONDON MARKET OPEN: Stocks start second half in green amid PMIs, source:Alliance News, summary: No summary, Headline: These Stocks Are Moving the Most Today: Tesla, AstraZeneca, and More, source:MarketWatch, summary: Stocks closed in the green Monday to start off the shortened holiday week., Headline: Tesla shares rally on delivery numbers, AstraZeneca stock slumps on drug trial, and other stocks on the move, source:MarketWatch, summary: Tesla and AstraZeneca stock head in opposite directions., Headline: AstraZeneca shares slump after Phase 3 lung cancer drug study, source:MarketWatch, summary: AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors., Headline: AstraZeneca says TROPION-Lung01 Phase 3 trial met dual primary endpoint, source:Thefly.com, summary: No summary, Headline: AstraZeneca (NASDAQ: AZN) Slumps Over Concerns about Lung Cancer Drug Trial, source:TipRanks, summary: No summary, Headline: Russia and Saudi Arabia cut oil supplies in effort to bolster prices, source:Yahoo, summary: Oil prices have pushed higher as Saudi Arabia and Russia announced twin moves to cut supplies., Headline: LONDON MARKET MIDDAY: Miners and oil majors lead FTSE 100 march, source:Alliance News, summary: No summary, Headline: AZN and VBIV among pre-market losers, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca shares dip after lung cancer drug trial update 'disappoints' hopes, source:Yahoo, summary: Investing.com -- AstraZeneca (LON:AZN) has announced that its experimental precision drug has shown improvement in slowing the progression of lung cancer in a late-stage trial, however, shares slipped on Monday after analysts noted that the findings disappointed expectations., Headline: AstraZeneca Lung Cancer Treatment Meets Dual Primary Endpoint in First Phase 3 Trial Results, source:MarketWatch, summary: By Ben Glickman AstraZeneca said its treatment for lung cancer met one of its dual primary endpoints in the first batch of results for a Phase 3 trial. The..., Headline: AstraZeneca Drops on Concern Over Lung Cancer Trial, source:Yahoo, summary: (Bloomberg) -- AstraZeneca Plc shares fell as results from a high-level study of a new cancer medicine raised concern the drug might not work as well as anticipated.Most Read from BloombergTesla and BYD Post Record Sales on Surge in Electric-Car DemandIt’s Getting a Lot Harder to Chase the Stock Rally From Here OnFrench Riots Begin to Abate Even as Economic Costs MountSingapore’s Star Banker Creates a Succession Dilemma for DBSThe drug helped patients with the most common form of lung cancer liv, Headline: Stocks making the biggest moves in the premarket: Tesla, Apple, AstraZeneca and more, source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Tesla, XPeng, Nio rise premarket; AstraZeneca, AMC Entertainment fall, source:Yahoo, summary: Investing.com -- U.S. futures inched lower at the start of a holiday-shortened week that includes the release of some key economic data, including the monthly employment report., Headline: AstraZeneca shares drop as lung cancer trial update lags expectations, source:Yahoo, summary: AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped.  The drug, datopotamab deruxtecan, which is being jointly developed with Japan's Daiichi Sankyo, was shown to prolong progression-free survival compared with standard chemotherapy in patients whose non-small cell lung cancer had returned after one or two prior treatment attempts, AstraZeneca said.  The British drugmaker also said some trial participants had died of interstitial lung disease, or scarring of lung tissue, but added that the drug's safety profile was in line with observations during previous clinical trials., Headline: Unusually active option classes on open July 3rd, source:Thefly.com, summary: No summary, Headline: AstraZeneca shares fall after cancer drug trial disappoints investors, source:Yahoo, summary: AstraZeneca failed to meet investor expectations for a new lung cancer drug, despite announcing positive results showing a statistically significant improvement over chemotherapy.  Shares in the Anglo-Swedish drugmaker fell 5 per cent on Monday morning after it published the first results from its phase 3 trial for datopotamab deruxtecan, which it is developing with Daiichi Sankyo.  Investors were hoping that the drug would become as successful as Enhertu, another cancer treatment AstraZeneca developed with the Japanese group, and the companies have been investing heavily in trials for different types of cancer., Headline: AstraZeneca 'glossing over' patient deaths in trial 'shameful,' Feuerstein says, source:Thefly.com, summary: No summary, Headline: Video: Nasdaq 100 Movers: AZN, TSLA, source:Market News Video, summary: No summary, Headline: AstraZeneca Unusual Options Activity, source:Benzinga, summary: No summary, Headline: AstraZeneca reports mixed Phase 3 data for lung cancer drug, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday, source:Benzinga, summary: No summary, Headline: AZN Crosses Below Key Moving Average Level, source:Market News Video, summary: No summary, Headline: AstraZeneca Stock (NASDAQ:AZN) Dives as Phase Three Data Disappoints, source:TipRanks, summary: No summary, Headline: Stocks to Watch Monday: Tesla, Apple, Nio, AstraZeneca, source:Yahoo, summary: **↗️** [**Tesla (TSLA)**](https://www.wsj.com/market-data/quotes/TSLA): The electric carmaker's stock rose 6.5% premarket after the company posted [a record quarter for sales.](https://www.wsj.com/articles/tesla-deliveries-to-show-whether-price-cuts-are-paying-off-2f2aac93) Other U., Headline: Stocks making the biggest moves midday: Tesla, Rivian, XPeng and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial, source:Yahoo, summary: WILMINGTON, Del., July 03, 2023--Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy., Headline: AstraZeneca Losses Leave The FTSE In The Red To Start July, source:TalkMarkets, summary: No summary, Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slipped 8.00% to £103.74 Monday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100..., Headline: U.K. stocks drop Monday, source:MarketWatch, summary: U.K. stocks finished down Monday, with the FTSE 100 Index decreasing 0.06% at 7,527.26. Among FTSE 100 constituents, biotechnology company AstraZeneca PLC..., Headline: LONDON MARKET CLOSE: Blue chips lose early shine as US treads water, source:Alliance News, summary: No summary, Headline: European stocks decrease for first time in four days, source:MarketWatch, summary: European stocks fell Monday, as the Stoxx Europe 600 index closed down 0.21% to 460.98. The German DAX weakened 0.41% to 16,081.04, the French CAC 40 index..., Headline: European Stocks Rise, AstraZeneca Drops After Lung-Cancer Trial Update, source:Yahoo, summary: European stock markets were mostly in the green on Monday, despite eurozone data suggesting a decline in manufacturing activity in June.  London-listed pharmaceutical company AstraZeneca was among the biggest decliners as the results of a study on a lung-cancer treatment disappointed investors.  AstraZeneca (ticker: AZN) was down nearly 6% in London after it reported results for its datopotamab deruxtecan treatment in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial., Headline: AstraZeneca drug hits PFS, but no 'clinically meaningful,' says Credit Suisse, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: No summary, Headline: Midday movers: Tesla, AstraZeneca, Carnival Corp. and more, source:Yahoo, summary: Investing.com -- Stocks are rising in light trading on a shortened market day in the U.S. session. Here are the market movers for July 3., Headline: Tesla, Rivian rise; Apple, AstraZeneca fall, Monday, 7/3/2023, source:Associated Press, The, summary: No summary, Headline: AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment, source:Yahoo, summary: AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled., Headline: AstraZeneca Stock Sinks as Cancer Drug Results Disappoint Investors, source:Yahoo, summary: 'For the dual primary endpoint of overall survival (OS), the data were not mature,' AstraZeneca said in its news release., Headline: Health Care Slips as AstraZeneca Slides -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell amid development setbacks for some major drugmakers. AstraZeneca and Daiichi Sankyo shares plunged after the British drugmaker and..., Headline: AstraZeneca Stock Is Sinking. A Cancer Drug Showed Disappointing Results., source:Yahoo, summary: American depositary receipts of AstraZeneca were falling Monday after the drugmaker reported disappointing results from a Phase 3 trial of a lung- cancer drug., Headline: AstraZeneca: Today's Hit On Lung Cancer Data - Justified Or Overblown?, source:SeekingAlpha, summary: AstraZeneca stock took a hit today after the company released data from a key lung cancer study. See whether today's selloff in AZN was justified., Headline: ADRs End Mostly Higher; AstraZeneca, Novartis Trade Actively, source:MarketWatch, summary: By Denny Jacob International stocks trading in New York closed mostly higher on Monday. The S&P/BNY Mellon index of American depositary receipts edged up..., Headline: These Were Monday's 2 Stock Movers That Investors Cared About the Most, source:Yahoo, summary: Modest gains came for the Nasdaq Composite (NASDAQINDEX: ^IXIC), Dow Jones Industrial Average (DJINDICES: ^DJI), and S&P 500 (SNPINDEX: ^GSPC) alike, as a favorable summer sentiment among many investors continued to build momentum.  Coinbase Global (NASDAQ: COIN) got a big boost as institutional investors look to have the U.S. Securities and Exchange Commission grant approval for some interesting new investments., Headline: Europe stocks close slightly higher as investors await earnings season; OMV shares up 7%, source:CNBC, summary: European markets closed slightly higher Tuesday, with investors in a cautious mood ahead of data releases and the start of second-quarter earnings season.",AZN
246,2023-07-04,"Headline: LONDON BROKER RATINGS: Dunelm, AstraZeneca and Persimmon cut, source:Alliance News, summary: No summary, Headline: AstraZeneca selloff on lung cancer data overdone, says Berenberg, source:Thefly.com, summary: No summary, Headline: AstraZeneca downgraded to Hold from Buy at Deutsche Bank, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Deutsche Bank cuts Astrazeneca to 'hold', source:Alliance News, summary: No summary, Headline: LONDON MARKET MIDDAY: Stocks higher amid US holiday-thinned trade, source:Alliance News, summary: No summary, Headline: LONDON MARKET CLOSE: Tepid close after quiet day with US market closed, source:Alliance News, summary: No summary, Headline: U.K. stocks continue losing streak, fall for second day, source:MarketWatch, summary: U.K. stocks finished lower Tuesday, with the FTSE 100 Index dropping 0.10% at 7,519.72. Of the FTSE 100 constituents, major international banks company..., Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC rallied 1.99% to £105.80 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results, source:Yahoo, summary: While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival., Headline: Europe stocks set for lower open as economic gloom returns; Fed minutes due, source:CNBC, summary: European markets were set to dip at the open amid concerns over the economic outlook. , Headline: Biotech Blues: Stay Balanced Through July Earnings Season, source:TalkMarkets, summary: No summary",AZN
247,2023-07-05,"Headline: LONDON BROKER RATINGS: UBS likes Pearson; Liberum cuts Naked Wine, source:Alliance News, summary: No summary, Headline: AstraZeneca weakness a buying opportunity, says TD Cowen, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Kepler Cheuvreux cuts Deutsche Boerse to 'hold', source:Alliance News, summary: No summary, Headline: Stocks making the biggest moves in the premarket: Rivian, UPS, Coinbase and more, source:CNBC, summary: These are the stocks posting the largest moves premarket., Headline: Moderna strikes deal to develop mRNA drugs in China , source:CNBC, summary: The deal is the biotech company's first agreement with China after the Asian nation repeatedly refused to accept mRNA vaccines from U.S.-based manufacturers. , Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.38% to £106.20 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE..., Headline: U.K. stocks weaken for third day, source:MarketWatch, summary: U.K. stocks fell Wednesday, as the FTSE 100 Index finished down 1.03% at 7,442.10. Among FTSE 100 constituents, food retail company Ocado Group PLC saw the..., Headline: AstraZeneca, Moderna Stocks Rise, source:Yahoo, summary: Two large drugmakers are advancing in early trading Wednesday. + AstraZeneca's New-York listed ADR rose 2.6% shortly after the open; shares in the drugmaker sold off Monday after it reported mixed results in a trial for an experimental cancer drug., Headline: AstraZeneca PLC ADR rises Wednesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 2.77% to $67.06 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ..., Headline: Moderna announces China investment as country opens doors to foreign pharma, source:Yahoo, summary: China signals a warmer welcome for Western pharma giants just as Treasury Secretary Janey Yellen leaves for Beijing., Headline: Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Liquidia Technologies (LQDA) and AstraZeneca (AZN), source:TipRanks, summary: No summary",AZN
248,2023-07-06,"Headline: Interesting AZN Put And Call Options For November 17th, source:Stock Options Channel, summary: No summary, Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares slipped 2.75% to £103.28 Thursday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100..., Headline: Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine, source:Yahoo, summary: Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above., Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 2.46% to $65.41 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: A Look Into AstraZeneca's Debt, source:Benzinga, summary: No summary",AZN
249,2023-07-07,"Headline: LONDON MARKET CLOSE: FTSE 100 ends rough week in tepid fashion, source:Alliance News, summary: No summary, Headline: U.K. stocks extend negative streak for fifth day, source:MarketWatch, summary: U.K. stocks finished down Friday, with the FTSE 100 Index falling 0.32% at 7,256.94. Of the FTSE 100 constituents, publishing company RELX PLC saw the..., Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares slipped 2.11% to £101.10 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index..., Headline: Here's Why Astrazeneca (AZN) is a Strong Value Stock, source:Yahoo, summary: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores., Headline: Top Analyst Reports for BHP Group, AstraZeneca & Boeing, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including BHP Group Limited (BHP), AstraZeneca PLC (AZN) and The Boeing Company (BA)., Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.86% to $64.85 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite..., Headline: Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $64.85 in the latest trading session, marking a -0.86% move from the prior day.",AZN
250,2023-07-09,"Headline: Goldman Sachs sees rays of hope in underperforming health sector, source:Seeking Alpha, summary: No summary, Headline: B. Riley biotechnology analysts to hold an analyst/industry conference call, source:Thefly.com, summary: No summary",AZN
251,2023-07-10,"Headline: Ionis Pharmaceuticals announces 'positive' results from Phase 3 NEURO-TTRansform, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Monday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.69% to £101.80 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: The Zacks Analyst Blog Highlights BHP Group, AstraZeneca, The Boeing, Diageo and General Mills, source:Yahoo, summary: BHP Group, AstraZeneca, The Boeing, Diageo and General Mills are part of the Zacks top Analyst Blog.",AZN
252,2023-07-11,"Headline: 50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis, source:Benzinga, summary: No summary, Headline: AstraZeneca falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.96% to £100.82 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study, source:Yahoo, summary: Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)., Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.51% to $64.86 Tuesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed at $64.86 in the latest trading session, marking a -0.51% move from the prior day., Headline: LONDON BRIEFING: UK banks pass stress test; Wetherspoon trades well, source:Alliance News, summary: No summary, Headline: LONDON MARKET OPEN: FTSE 100 higher as UK banks pass BoE stress tests, source:Alliance News, summary: No summary",AZN
253,2023-07-12,"Headline: LONDON BROKER RATINGS: UBS raises AstraZeneca; RBC cuts Bunzl, source:Alliance News, summary: No summary, Headline: AstraZeneca upgraded to Buy from Neutral at UBS, source:Thefly.com, summary: No summary, Headline: AstraZeneca's Enhertu approved in China for HER2-low metastatic breast cancer, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Raymond James cuts Activision to market perform, source:Alliance News, summary: No summary, Headline: LianBio announces clinical supply agreement with AstraZeneca, source:Thefly.com, summary: No summary, Headline: Astra, Daiichi get China approval for Enhertu breast cancer treatment, source:Alliance News, summary: No summary, Headline: IN THE KNOW: UBS backs AstraZeneca despite underwhelming Dato-DXd data, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC rose 1.65% to £102.48 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Wednesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 2.48% to $66.47 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: This Is What Whales Are Betting On AstraZeneca, source:Benzinga, summary: No summary",AZN
254,2023-07-13,"Headline: PepsiCo, Walt Disney, Delta rise premarket; Carvana, Coinbase SoFi fall, source:Yahoo, summary: Investing.com -- U.S. futures traded higher Thursday, continuing the recent positive sentiment ahead of the latest data on producer prices, with investors looking for more clues guiding future Federal Reserve monetary policy., Headline: AZN September 1st Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: AstraZeneca price target lowered to 12,600 GBp from 13,200 GBp at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.80% to £103.30 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Nvidia Just Confirmed an Emerging AI Boom in Biotech, source:InvestorPlace, summary: No summary, Headline: 10 Buyable Inflation-Busting July Dividend Stocks, source:SeekingAlpha, summary: Top 10 Inflation-Busting Dividend stocks boasted net gains from 21.29% to 52.44% per YCharts forward-looking data 7/11/23. Read more to see my exclusive lists., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 1.87% to $67.71 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely, source:Alliance News, summary: No summary, Headline: AstraZeneca initiated with a Buy at HSBC, source:Thefly.com, summary: No summary, Headline: LONDON MARKET OPEN: Stocks mixed ahead of US bank earnings, source:Alliance News, summary: No summary",AZN
255,2023-07-14,"Headline: LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK, source:Alliance News, summary: No summary, Headline: AstraZeneca outperforms market despite losses on the day, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.06% to £103.24 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100..., Headline: More Challenges Await AbbVie Following A Disappointing Quarter, source:SeekingAlpha, summary: AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 0.49% to $67.38 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",AZN
256,2023-07-15,"Headline: Renalytix: Commercializing First AI Kidney Disease Diagnostic Tool, source:SeekingAlpha, summary: Renalytix's lead product, KidneyIntelX, an AI diagnostic tool for kidney disease, has received FDA approval. Find out why RNLX stock is a Strong Buy.",AZN
257,2023-07-16,"Headline: HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna, source:Seeking Alpha, summary: No summary, Headline: Buy/Sell: Wall Street's top 10 stock calls this week, source:Thefly.com, summary: No summary, Headline: AstraZeneca's nirsevimab approved as RSV treatment for babies, infants, source:Seeking Alpha, summary: No summary",AZN
258,2023-07-17,"Headline: AstraZeneca PLC ADR falls Monday, underperforms market, source:MarketWatch, summary: No summary, Headline: 3 Doomed Biotech Stocks Destined for Disaster, source:InvestorPlace, summary: No summary, Headline: The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market, source:Benzinga, summary: No summary, Headline: FDA approves AstraZeneca's Beyfortus for prevention of RSV in neonates, infants, source:Thefly.com, summary: No summary, Headline: Sanofi, AstraZeneca confirm FDA approves Beyfortus for RSV disease in infants, source:Thefly.com, summary: No summary, Headline: New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season, source:Associated Press, The, summary: No summary, Headline: FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV, source:CNBC, summary: RSV is the leading cause of hospitalization among children less than a year old, according to scientists., Headline: FDA approves Sanofi and AstraZeneca infant RSV vaccine, source:MarketWatch, summary: The U.S. Food and Drug Administration on Monday approved a Sanofi and AstraZeneca PLC respiratory syncytial virus vaccine for newborns and infants. The RSV..., Headline: Newly approved RSV drug for infants provides all-season protection with 1 shot, source:United Press International, summary: No summary, Headline: US FDA approves AstraZeneca and Sanofi's Beyfortus for RSV in infants, source:Alliance News, summary: No summary, Headline: FDA Approves First RSV Drug to Protect All Infants From Virus, source:Yahoo, summary: While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Astrazeneca (AZN) closed at $67.05, marking a -0.49% move from the previous day., Headline: Rishi Sunak to meet bosses at inaugural Business Council gathering, source:Alliance News, summary: No summary, Headline: AstraZeneca (NASDAQ:AZN) and Sanofi Secure FDA Green Light, source:TipRanks, summary: No summary",AZN
259,2023-07-18,"Headline: The Tech Stock Rally Has Reached a Critical Moment. Watch Tesla, Netflix Earnings., source:MarketWatch, summary: AT&T hit by report about lead on cables, Eli Lilly’s Alzheimer’s drug shows promise in latest trial, and other news to start your day., Headline: Pieris Pharmaceuticals announces restructuring, to reduce workforce by 70%, source:Thefly.com, summary: No summary, Headline: NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories, source:Benzinga, summary: No summary, Headline: Pieris Pharma to Cut 70% of Workforce, Explore Strategic Options, source:MarketWatch, summary: By Ben Glickman Pieris Pharmaceuticals said Tuesday it would cut about 70% of its workforce and explore strategic options after AstraZeneca terminated a..., Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.78% to £102.80 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants, source:Yahoo, summary: The FDA approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA’s (NASDAQ: SNY) Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants. The approval covers newborns and infants during or entering their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus was approved in the European Union in November 2022 to prevent RSV LRTD in, Headline: Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants, source:Yahoo, summary: Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season., Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 0.42% to $66.77 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ..., Headline: Why Pieris Pharmaceuticals Shares Shooting Higher Today?, source:Yahoo, summary: Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company provided a strategic update. The company says the update follows recent events that have impacted its inhaled respiratory franchise, including AstraZeneca Plc's (NASDAQ: AZN) discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the company of its decision to terminate the parties' R&D collaboration agreement, hand back elarekibep, and discontinue the remaining discove",AZN
260,2023-07-19,"Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares advanced 2.16% to £105.02 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR rises Wednesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.17% to $67.55 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Pieris lays off most staff after AstraZeneca pulls out of partnership, source:Yahoo, summary: Pieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale.",AZN
261,2023-07-20,"Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC rallied 1.85% to £106.96 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR rises Thursday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR advanced 1.50% to $68.56 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones..., Headline: SK Chemicals' Shares Climb After AstraZeneca Deal, source:MarketWatch, summary: By Kwanwoo Jun SK Chemicals' shares climbed Friday after it won a contract with biopharmaceuticals giant AstraZeneca. Shares of the South Korean..., Headline: Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility, source:Benzinga, summary: No summary, Headline: Earnings week ahead: Microsoft, Google, Meta, Boeing, Coca-Cola and more, source:Seeking Alpha, summary: No summary",AZN
262,2023-07-21,"Headline: Pfizer price target lowered to $42 from $43 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: The Bristol-Myers Squibb Phenomenon: A Game Changer In The Pharmaceutical Industry, source:SeekingAlpha, summary: On July 27, 2023, Bristol-Myers Squibb will release its financial report for the second quarter of 2023. Read more to see a detailed analysis on BMY stock., Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.69% to £107.70 Friday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100..., Headline: Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody, source:Yahoo, summary: FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results., Headline: AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?, source:Yahoo, summary: AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity., Headline: Sanofi expects infant RSV shot to roll out before respiratory virus season this fall, source:CNBC, summary: Sanofi said it is working with a CDC panel to include Beyfortus on the childhood immunization schedule and the Vaccines for Children Program., Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rallied 1.14% to $69.34 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",AZN
263,2023-07-23,"Headline: 4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys, source:SeekingAlpha, summary: Barronâs Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here., Headline: Big Pharma Bets Big on China, source:Yahoo, summary: China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere.",AZN
264,2023-07-24,"Headline: AstraZeneca rises Monday, still underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.09% to £107.80 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary, Headline: AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?, source:Yahoo, summary: Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs., Headline: AstraZeneca PLC ADR falls Monday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.61% to $68.92 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ..., Headline: Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Astrazeneca (AZN) closed the most recent trading day at $68.92, moving -0.61% from the previous trading session.",AZN
265,2023-07-25,"Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: No summary, Headline: IN BRIEF: OTAQ names interim finance chief with incumbent to move on, source:Alliance News, summary: No summary",AZN
266,2023-07-26,"Headline: LIVE: FTSE 100 and European stocks mixed ahead of Fed interest rates decision, source:Yahoo, summary: A look at how the major markets are performing on Wednesday., Headline: Probe over suicide risk linked to weight loss drugs expands to U.K. – Reuters, source:Seeking Alpha, summary: No summary, Headline: UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks , source:CNBC, summary: The probe into potentially life-threatening side effects comes as the drugs skyrocket in popularity in the U.S. and draw heightened investor interest., Headline: Merck (MRK) to Report Q2 Earnings: What's in the Cards?, source:Yahoo, summary: Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q2 earnings., Headline: ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial, source:Business Wire, summary: No summary",AZN
267,2023-07-27,"Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: No summary, Headline: AstraZeneca: Enhertu showed clinically meaningful PFS, OS in DESTINY-PanTumor02, source:Thefly.com, summary: No summary, Headline: AstraZeneca says Soliris approved in EU for children with refractory gMG, source:Thefly.com, summary: No summary, Headline: Starpharma: Patience Needed, But A Lot To Like, source:SeekingAlpha, summary: The news on Starpharma share price is challenging as a significant shareholder exits. Read more about SPHRF here., Headline: Notable earnings before Friday's open, source:Seeking Alpha, summary: No summary, Headline: UK earnings, trading statements calendar - next 7 days, source:Alliance News, summary: No summary, Headline: ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial, source:Yahoo, summary: WILMINGTON, Del., July 27, 2023--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2-expressing advanced solid tumors, two secondary endpoints of the trial., Headline: Why AstraZeneca (AZN) Might Surprise This Earnings Season, source:Yahoo, summary: AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: IN BRIEF: Astra drug approved while another shows promise, source:Alliance News, summary: No summary, Headline: 50 Most Valuable Companies in the World by Market Cap, source:Yahoo, summary: In this article, we will be taking a look at the 50 most valuable companies in the world by market cap. If you want to skip our detailed analysis of the most valuable industries, you can go directly to 10 Most Valuable Companies in the World by Market Cap. The most valuable companies in the […], Headline: GLOBAL BRIEFING: Yen rises as BoJ adjusts yield curve control, source:Alliance News, summary: No summary, Headline: AstraZeneca beats Q2 top and bottom line estimates; reaffirms FY23 outlook, source:Seeking Alpha, summary: No summary, Headline: GET READY: AstraZeneca, AIB, IAG, Intertek and NatWest at 0700 BST, source:Alliance News, summary: No summary, Headline: Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more, source:Seeking Alpha, summary: No summary, Headline: LONDON MARKET EARLY CALL: Stocks to fall; yen firms after BoJ move, source:Alliance News, summary: No summary, Headline: AstraZeneca PLC 2Q EPS $1.17, source:MarketWatch, summary: By Joe Hoppe AstraZeneca on Friday reported a significant rise in second-quarter net profit, but missed market forecasts, and backed its full-year guidance...., Headline: Europe stocks set for lower open; Bank of Japan jolts markets by easing YCC stance, source:CNBC, summary: European stock markets are heading for a lower open Friday after the Bank of Japan rattled markets. , Headline: AstraZeneca's Alexion to Buy Gene Therapies Portfolio for Up to $1 Bln From Pfizer, source:MarketWatch, summary: By Anthony O. Goriainoff AstraZeneca said Friday that its Alexion division will buy a portfolio of preclinical rare-disease gene therapies from Pfizer for up..., Headline: LONDON BRIEFING: NatWest posts interim growth; IAG swings to profit, source:Alliance News, summary: No summary, Headline: TOP NEWS: AstraZeneca profit surges as Alexion agrees Pfizer deal, source:Alliance News, summary: No summary, Headline: LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green, source:Alliance News, summary: No summary",AZN
268,2023-07-28,"Headline: AstraZeneca Shares Rise After 2Q Revenue, Earnings Beat Market Views -- Update, source:MarketWatch, summary: By Joe Hoppe AstraZeneca shares rose Friday after the company reported a significant rise in second-quarter revenue and earnings per share, ahead of market..., Headline: European stocks mixed; strong AstraZeneca numbers help U.K. outperform, source:Yahoo, summary: European stock markets traded in a mixed fashion Friday, as investors digested a week of corporate earnings, important central bank decisions and economic data.  AstraZeneca stock rose 3.5% after the drugmaker delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales., Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: Astrazeneca: Q2 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Earnings Scheduled For July 28, 2023, source:Benzinga, summary: No summary, Headline: Alexion to acquire portfolio of rare disease gene therapies from Pfizer, source:Thefly.com, summary: No summary, Headline: AstraZeneca reports Q2 core EPS $2.15, consensus $1.97, source:Thefly.com, summary: No summary, Headline: AstraZeneca backs FY23 view of core EPS up high single-to low double-digit, source:Thefly.com, summary: No summary, Headline: AstraZeneca unit in $1B deal with Pfizer for gene therapies, source:Seeking Alpha, summary: No summary, Headline: US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon, source:Benzinga, summary: No summary, Headline: UPDATE 3-AstraZeneca Q2 results beat estimates; COVID vaccine sales evaporate, source:Yahoo, summary: AstraZeneca on Friday delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales.  The Anglo-Swedish drugmaker posted an adjusted profit of $2.15 per share, up 25% and exceeding the $1.98 per share expected in company-compiled consensus estimates.  Total revenue in the quarter was $11.4 billion, up 6% and beating company-compiled analyst estimates of $10.97 billion., Headline: Ionis expands collaboration with AstraZeneca for eplontersen, source:Thefly.com, summary: No summary, Headline: AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up, source:Yahoo, summary: LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of COVID-19 vaccine sales.  Shares in the Anglo-Swedish drugmaker, which has a strong line-up of cancer, metabolic and rare disease drugs, rose as much as 4.8%, before settling back to 3.9% by 1052 GMT, making the stock the largest weighted gainer on the FTSE 100.  Sentiment was boosted by Chief Executive Pascal Soriot's positive remarks on the company's data from a key lung cancer trial, an AstraZeneca shareholder and an analyst told Reuters., Headline: AstraZeneca to buy Pfizer's rare disease gene therapy portfolio for up to $1 billion, source:Yahoo, summary: AstraZeneca bought Alexion in 2021.  It focuses on rare diseases and plans to close the deal in the third quarter, the British drugmaker said.  The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on Alexion and AstraZeneca's capabilities in genomic medicine, it said., Headline: UPDATE 1-AstraZeneca to buy Pfizer's rare disease gene therapy portfolio for up to $1 bln, source:Yahoo, summary: AstraZeneca said on Friday its unit Alexion has agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales.  AstraZeneca bought Alexion in 2021.  It focuses on rare diseases and plans to close the deal in the third quarter, the British drugmaker said., Headline: AstraZeneca beats estimates with strong cancer and diabetes drug sales, source:Yahoo, summary: Strong sales of drugs for cancer and diabetes helped AstraZeneca beat expectations in the second quarter, as the drugmaker expands its genomic medicine business with a $1bn deal to buy assets from Pfizer.  Pascal Soriot, AstraZeneca’s chief executive, said eight medicines delivered more than $1bn of revenue in the first half, with each area of the business, except Covid-19 therapies, growing by double digits year-on-year.  “We look forward to sharing the data with the medical community at an upcoming medical congress and are proceeding to file the data with the US Food and Drug Administration,” he said., Headline: AstraZeneca-Ionis deal for eplontersen expands to Latin America, source:Seeking Alpha, summary: No summary, Headline: Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more , source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: AstraZeneca (NASDAQ:AZN) Soars on Q2 Beat; Enters Into $1B Gene Therapy Deal with Pfizer (NYSE:PFE), source:TipRanks, summary: No summary, Headline: 6 stocks to watch on Friday: Palantir, Chevron, Ford, AstraZeneca and more, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC 2023 Q2 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by AstraZeneca PLC in conjunction with their 2023 Q2 earnings call., Headline: AstraZeneca CEO says lung cancer drug trial data 'very encouraging', source:Yahoo, summary: AstraZeneca Chief Executive Pascal Soriot said on Friday the company is ""very encouraged"" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as ""clinically meaningful"".  The drugmaker's shares fell by as much as 8% earlier this month, after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan., Headline: Unusually active option classes on open July 28th, source:Thefly.com, summary: No summary, Headline: UPDATE 2-AstraZeneca CEO says lung cancer drug trial data 'very encouraging', source:Yahoo, summary: AstraZeneca Chief Executive Pascal Soriot said on Friday the company is ""very encouraged"" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as ""clinically meaningful"".  The drugmaker's shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan.  Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further., Headline: Trending tickers: IAG | NatWest | AstraZeneca | Intel, source:Yahoo, summary: A look at the stocks making headlines on Friday., Headline: European Stock Futures Surge After ECB Meeting, source:TalkMarkets, summary: No summary, Headline: AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies, source:MarketWatch, summary: Stock gains 5% after AstraZeneca's second-quarter results top analyst expectations., Headline: Stocks Surge, Tech Rallies On Strong Earnings, Inflation Softens: What's Driving Markets Friday?, source:Benzinga, summary: No summary, Headline: AstraZeneca's Covid vaccine sales drop to zero as health officials back safer mRNA jabs, source:Yahoo, summary: Sales of the Oxford AstraZeneca Covid vaccine have fallen to zero as health officials switch their backing to safer jabs., Headline: Compared to Estimates, Astrazeneca (AZN) Q2 Earnings: A Look at Key Metrics, source:Yahoo, summary: The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals., Headline: AstraZeneca beats Q2 earnings estimates, sees strong sales of cancer treatment drugs, source:Yahoo, summary: Pharma manufacturer AstraZeneca reports a second-quarter earnings beat, offsetting its losses tied to slowing COVID-19 vaccine sales. AstraZeneca CFO Aradhana Sarin joins Yahoo Finance Live to discuss the value of gene therapy treatment for rare diseases, the company's guidance regarding China, and expectations for its cancer treatment drug Dato-DXd. ""What you see this quarter is really a reflection of all the investments we've made in innovation and new products over the decade,"" Sarin said., Headline: UK economy left behind as US heads for 'immaculate soft landing', source:Yahoo, summary: The US economy is poised to make an “immaculate soft landing” from the inflation crisis leaving the British economy behind., Headline: Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III, source:Yahoo, summary: AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results., Headline: AstraZeneca Shares Surge After Revenue Beat, source:Yahoo, summary: AstraZeneca's shares rose on Friday after it announced the purchase of Pfizer's rare disease portfolio for up to $1 billion and reported better-than-expected financial results on strong sales of its cancer drugs., Headline: AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales, source:Yahoo, summary: AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance., Headline: iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories, source:Yahoo, summary: Bloomberg DoorDash Embraces AI Chatbot to Revolutionize Food Ordering and Gain Competitive Edge DoorDash Inc (NYSE: DASH) has leveraged an artificial intelligence-based chatbot to speed up ordering and help customers find food options. The Uber Technologies Inc (NYSE: UBER) rival is working on a system called DashAI that it's testing in a limited capacity. The technology will help customers to get personalized restaurant recommendations with simple text prompts, adding an edge over its peers. Be, Headline: AstraZeneca plays up China, downplays patent loss in latest earnings: CFO, source:Yahoo, summary: AstraZeneca (AZN) reported strong earnings Friday, including $22 billion, or 4% revenue growth, in the first half of the year, and kept its 2023 forecast stable., Headline: AstraZeneca Plc (AZN) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.  Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca.  Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.",AZN
269,2023-07-29,"Headline: Analysts Are Bullish on Top Healthcare Stocks: Amplifon S.p.A. (GB:0N61), AstraZeneca (GB:AZN), source:TipRanks, summary: No summary, Headline: AstraZeneca: Solid Earnings Report Reinforces Medium To Long-Term Upside, source:SeekingAlpha, summary: AstraZeneca's H1 2023 results show robust growth, with revenues ex-COVID-19 medicines increasing by 16% YoY. Read more about AZN stock here., Headline: AstraZeneca PLC (NASDAQ:AZN) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: AstraZeneca PLC (NASDAQ:AZN) Q2 2023 Earnings Call Transcript July 28, 2023 AstraZeneca PLC misses on earnings expectations. Reported EPS is $0.86 EPS, expectations were $0.98. Operator: Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and […], Headline: RSV treatment market to surge past $9B by 2029, source:Seeking Alpha, summary: No summary",AZN
270,2023-07-30,"Headline: Baron International Growth Fund Q2 2023 Shareholder Letter, source:SeekingAlpha, summary: Baron International Growth Fund gained 3.45% (Institutional Shares) during the second quarter of 2023. Click here to read the full fund letter., Headline: AstraZeneca: Robust Performance And Promising Growth Initiatives, source:SeekingAlpha, summary: AstraZeneca's Q2 2023 financial performance showed a 6% increase in total revenue. Read more to see what makes me bullish on AZN stock., Headline: AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade), source:Seeking Alpha, summary: No summary",AZN
271,2023-07-31,"Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: Ionis Pharmacompletes enrollment for Phase 3 CARDIO-TTRansform study, source:Thefly.com, summary: No summary, Headline: Viatris launches first generic of AstraZeneca asthma drug Symbicort, source:Seeking Alpha, summary: No summary, Headline: 3 Pharma Stocks to Buy for Their Promising Progress, source:Yahoo, summary: Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakthrough that could potentially revolutionize healthcare. Today’s article sheds light on three high-potential pharma stocks that hold strong promise for the future. These companies are among the cream of the crop regarding R&D pipeline size as of 2023, demonstrating a powerful blend of innovation and, Headline: Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook, source:Benzinga, summary: No summary",AZN
272,2023-08-01,"Headline: AstraZeneca PLC ADR falls Tuesday, still outperforms market, source:MarketWatch, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and AstraZeneca (AZN), source:TipRanks, summary: No summary, Headline: Zentalis appoints Freeman as Chief Strategy Officer, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: LBBW says 'buy' Vodafone; DZ raises Intel, source:Alliance News, summary: No summary, Headline: Astrazeneca plc - ADR (AZN) Declares $0.46 Dividend, source:Fintel, summary: nan",AZN
273,2023-08-02,"Headline: AstraZeneca PLC ADR outperforms market despite losses on the day, source:MarketWatch, summary: No summary, Headline: Stick to U.S. stocks that offer experience over hope, Goldman says, source:Seeking Alpha, summary: No summary, Headline: The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets, source:Yahoo, summary: Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in the Petri Dish: a $1 billion deal for Pfizer gene therapies, a succession plan for a founder-led biotech organization, and a new Longwood Fund spinout with assets from GSK., Headline: AstraZeneca and Sanofi RSV drug wins support of CDC panel, Bloomberg says, source:Thefly.com, summary: No summary, Headline: AstraZeneca, Sanofi RSV treatment Beyfortus priced at $495, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca, Sanofi RSV treatment Beyfortus endorsed by CDC panel (updated), source:Seeking Alpha, summary: No summary, Headline: Sanofi says CDC panel unanimously recommends use of Beyfortus for infants, source:Thefly.com, summary: No summary",AZN
274,2023-08-03,"Headline: Infant RSV shot wins backing of CDC advisors, paving way for fall availability, source:CNBC, summary: Sanofi has said the companies are prepared to roll the shot out before RSV season this fall and do not foresee any challenges meeting demand. , Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slipped 1.77% to £109.00 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slipped 1.14% to $69.67 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: CDC panel says babies should get new drug that prevents RSV, source:MarketWatch, summary: Infants should get a new drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, heath..., Headline: Sanofi, AstraZeneca RSV Treatment for Infants Gets U.S. CDC Panel Recommendation, source:MarketWatch, summary: By Cecilia Butini Sanofi and AstraZeneca's preventative treatment for respiratory syncytial virus was recommended for use by an independent health expert...",AZN
275,2023-08-04,"Headline: IN BRIEF: Sanofi wins US CDC recommendation for Beyfortus in RSV, source:Alliance News, summary: No summary, Headline: UK dividends calendar - next 7 days, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Friday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.09% to £109.10 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: 5 Healthcare Stocks to Buy Now, According to Analysts – August 2023, source:TipRanks, summary: No summary, Headline: CDC Recommends New Sanofi, AstraZeneca Shot to Prevent RSV in Babies, source:Yahoo, summary: The Centers for Disease Control and Prevention recommended a new  Sanofi  and  AstraZeneca  injection for all newborns in the U.S. to prevent cases of respiratory syncytial virus, making the drug the latest in a series of tools against the virus to roll out this fall.  Following a meeting of an expert outside advisory committee, which voted unanimously to support use of the medicine, the CDC said late Thursday it recommends routine use of the medicine in babies younger than eight months old.  Sanofi  (ticker: SNY) American depositary receipt was 1.1% higher in early trading, while  AstraZeneca  (AZN) ADR was down 0.2%., Headline: AstraZeneca PLC ADR falls Friday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.39% to $69.40 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite..., Headline: Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations, source:TalkMarkets, summary: No summary",AZN
276,2023-08-06,"Headline: AstraZeneca price target raised to 12,700 GBp from 12,600 GBp at Morgan Stanley, source:Thefly.com, summary: No summary",AZN
277,2023-08-07,"Headline: IN THE KNOW: Wegovy study key share price driver for Novo - Barclays, source:Alliance News, summary: No summary, Headline: Nvidia Just Confirmed an Emerging AI Boom in Biotech, source:InvestorPlace, summary: No summary, Headline: AstraZeneca falls Monday, underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched down 0.22% to £108.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca PLC ADR underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.76% higher to $69.93 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Future Prospects For Johnson & Johnson Following Strong Q2 Performance, source:SeekingAlpha, summary: Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. Read why JNJ stock is a hold.",AZN
278,2023-08-08,"Headline: Is This Blue Chip Dividend Stock a Buy for Growth Investors?, source:Yahoo, summary: An investor who put $3,000 into AstraZeneca (NASDAQ: AZN) five years ago and reinvested dividends would have $6,200 today.  The same amount put into the S&P 500 would be worth only $5,200 with dividends reinvested.  Let's examine AstraZeneca's fundamentals and valuation to decide., Headline: China's CanSino in mRNA vaccine deal with AstraZeneca, source:Yahoo, summary: CanSino Biologics has agreed with AstraZeneca to provide ""contract development and manufacturing services"" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.  In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca.  AstraZeneca did not have an immediate comment on the announcement., Headline: U.K. stocks drop for second session, source:MarketWatch, summary: U.K. stocks dropped Tuesday, as the FTSE 100 Index finished down 0.36% at 7,527.42. Of the FTSE 100 constituents, investment advisors company abrdn PLC saw..., Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC advanced 1.32% to £110.30 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca inks mRNA vaccine deal with China's CanSino, source:Seeking Alpha, summary: No summary, Headline: 3 Stocks That Are Still A Buy On China's Recovery Story, source:SeekingAlpha, summary: China's economic recovery has turned out to be slower than expected. Read why strong domestic consumption indicates that there are still pockets of recovery., Headline: AstraZeneca PLC ADR rises Tuesday, outperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.79% higher to $70.48 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ..., Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary",AZN
279,2023-08-09,"Headline: AstraZeneca signs vaccine deal with China's CanSino Biologics, FT reports, source:Thefly.com, summary: No summary, Headline: Statkraft Strikes Swedish Wind Power Purchase Deal with AstraZeneca, source:MarketWatch, summary: By Dominic Chopping Renewable energy producer Statkraft said it has entered a wind power agreement with AstraZeneca that sees the Anglo-Swedish pharma giant..., Headline: UPDATE 1-China's CanSino in mRNA vaccine deal with AstraZeneca, source:Yahoo, summary: CanSino Biologics has agreed with AstraZeneca to provide ""contract development and manufacturing services"" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.  In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca., Headline: AstraZeneca signs vaccine deal with China’s CanSino, source:Yahoo, summary: Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’, Headline: UK dividends calendar - next 7 days, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: AstraZeneca rises Wednesday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares advanced 1.38% to £111.82 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE..., Headline: AstraZeneca declares goes ex-dividend tomorrow, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: The AstraZeneca PLC ADR rose 1.14% to $71.28 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: Dr. Reddy's launches generic version of Kombiglyze XR in US, source:Seeking Alpha, summary: No summary",AZN
280,2023-08-10,"Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: No summary, Headline: LONDON MARKET MIDDAY: FTSE 100 flat, peers and pound up before US data, source:Alliance News, summary: No summary, Headline: Q2 2023 Ionis Pharmaceuticals Inc Earnings Call, source:Yahoo, summary: Q2 2023 Ionis Pharmaceuticals Inc Earnings Call, Headline: Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk, source:SeekingAlpha, summary: Organon & Co. formed via Merck & Co.'s spinout of its Established Brands, reported its Q2 2023 earnings on 8th August. Read more about OGN stock here., Headline: AstraZeneca rises Thursday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.47% to £111.62 Thursday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: These 10 medications are likely targets for Medicare price negotiations this fall, source:CNBC, summary: It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets., Headline: Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates, source:Yahoo, summary: Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.",AZN
281,2023-08-11,"Headline: AstraZeneca PLC ADR outperforms market on strong trading day, source:MarketWatch, summary: No summary, Headline: Is Most-Watched Stock AstraZeneca PLC (AZN) Worth Betting on Now?, source:Yahoo, summary: No summary, Headline: Hutchmed: Attractive Chinese R&D Giant, source:SeekingAlpha, summary: Hutchmed (China) Limited shows promise for growth with a range of products in clinical trials and collaborations. Click here to read an analysis on HCM stock., Headline: Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership, source:TalkMarkets, summary: No summary",AZN
282,2023-08-13,"Headline: Week In Review: BeiGene And BMS Close BeiGene-Celgene PD-1 Partnership, source:SeekingAlpha, summary: What are the pivotal collaborations and transformative partnerships reshaping China's biopharma sector this week? Click here to find out. , Headline: AstraZeneca (LON:AZN) shareholders have earned a 16% CAGR over the last five years, source:Yahoo, summary: When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...",AZN
283,2023-08-14,"Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: No summary, Headline: Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics, source:SeekingAlpha, summary: Coya Therapeutics aims to target inflammation-related diseases, like ALS, with Treg-enhancing therapeutics. Click here to read my analysis of COYA stock., Headline: China Looks to Attract Foreign Investment as Its Economy Struggles, source:Yahoo, summary: (Bloomberg) -- China’s latest attempt to reverse the nation’s foreign investment slump includes pledges to offer overseas firms better tax treatment and make it easier for them to obtain visas, as officials try to allay fears about doing business in the world’s second-largest economy. Most Read from BloombergOutsider Milei Upends Argentina’s Election With Primary WinAmerica’s Fastest Growing City Is Embracing ‘Yellowstone’ ManiaZuckerberg Says ‘Time to Move On’ From Musk Cage FightRuble Sinks to",AZN
284,2023-08-15,"Headline: AstraZeneca PLC ADR underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary, Headline: Murphy Canyon to hold meeting on planned buy of interest in AZD1656, source:Alliance News, summary: No summary",AZN
285,2023-08-16,"Headline: AstraZeneca PLC ADR outperforms competitors on strong trading day, source:MarketWatch, summary: No summary, Headline: Cheaper Alternatives of Weight-Loss Drugs? Chinese Pharma Companies Are Working On a Local Version, source:Benzinga, summary: No summary, Headline: AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030, source:Yahoo, summary: WILMINGTON, Del., August 16, 2023--AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), September 9-12, 2023.",AZN
286,2023-08-17,"Headline: TAKING AIM: Shore impressed by C4X Discovery's promising portfolio, source:Alliance News, summary: No summary, Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.79% to £107.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the FTSE..., Headline: AstraZeneca PLC ADR outperforms competitors despite losses on the day, source:MarketWatch, summary: The AstraZeneca PLC ADR sank 0.85% to $69.12 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ..., Headline: TOP NEWS: AstraZeneca hails heart-focused Forxiga approval in China, source:Alliance News, summary: No summary",AZN
287,2023-08-18,"Headline: AstraZeneca call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC slid 1.24% to £106.58 Friday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index..., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.95% to $68.46 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",AZN
288,2023-08-20,"Headline: AstraZeneca hails new data on Forxiga's impact on heart failure, source:Alliance News, summary: No summary",AZN
289,2023-08-21,"Headline: AstraZeneca to present 19 abstracts at upcoming ESC Congress, source:Thefly.com, summary: No summary, Headline: The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023, source:Yahoo, summary: There are sectors in the economy that go through an extended period of trending sideways to lower. A good example is the pharmaceutical sector. In the last 10 years, the S&P Pharmaceuticals Select Industry Index has delivered annualized total returns of 2.65%. Furthermore, the index has annualized total returns in the last five years of -2.63%, clearly indicating an extended bear market among pharma stocks. Covid-19 did translate into buying action in selected pharma stocks. However, the interes, Headline: AstraZeneca rises Monday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.15% to £106.74 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100..., Headline: 5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace, source:Yahoo, summary: Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio., Headline: Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS, source:Yahoo, summary: UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations., Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.61% higher to $68.88 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: FDA approves Pfizer maternal RSV vaccine for infants, source:CNBC, summary: Pfizer hopes that its respiratory syncytial virus vaccine will be available to the public by the end of October or the beginning of November. , Headline: FDA approves RSV vaccine for moms-to-be to guard their newborns, source:Associated Press, The, summary: No summary, Headline: US approves Pfizer's maternal vaccine to prevent RSV in infants, source:Alliance News, summary: No summary, Headline: Pay for FTSE 100 bosses jumps 16% as wider wages behind inflation, source:Alliance News, summary: No summary",AZN
290,2023-08-22,"Headline: 3 Big Reasons Why Fed's Powell Can Be Hawkish At Jackson Hole On Aug 25, source:SeekingAlpha, summary: The annual economic symposium at Jackson Hole is awaited for insights into Fed's next policy actions. Read why I think Powell will likely continue to be hawkish., Headline: FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth, source:Benzinga, summary: No summary, Headline: Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca, source:Yahoo, summary: Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article, Headline: AstraZeneca rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched up 0.22% to £106.98 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: AstraZeneca PLC ADR falls Tuesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR dropped 0.16% to $68.77 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: 3 Sorry Pharma Stocks to Sell in August Before It’s Too Late, source:Yahoo, summary: Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery. Not every company can deliver consistent growth and profits, but those who beat the trend will have their shares pop somewhere in the double digits in share appreciation. A few years ago, the advent of the Covid-19 pandemic saw stocks in various industries plummet. Still, pharmaceutical shares began to rise to astronomic levels due to increased, Headline: Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?, source:Yahoo, summary: No summary, Headline: Daiichi Sankyo and AstraZeneca's Enhertu wins new approval in Japan, source:Alliance News, summary: No summary",AZN
291,2023-08-23,"Headline: Five metrics for AI trendspotting, source:Seeking Alpha, summary: No summary, Headline: LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data, source:Alliance News, summary: No summary, Headline: AstraZeneca rises Wednesday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.67% to £107.70 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: AstraZeneca sued in London over adverse events linked to COVID shot, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca facing two London lawsuits over COVID-19 vaccines, source:Yahoo, summary: AstraZeneca is facing two London lawsuits, including one from the husband of a woman who died after receiving the Anglo-Swedish drugmaker's COVID-19 vaccine, in the first of potentially dozens of cases brought in England.  Britain was the first country to roll out the at-cost AstraZeneca COVID-19 vaccine in early 2021, although it later restricted the use of it among under 40s due to the small risk of blood clots.  Anish Tailor, whose wife Alpa died in March 2021 after receiving her first dose of the vaccine, filed a product liability claim against AstraZeneca at London's High Court on Aug. 4, according to court records., Headline: AstraZeneca PLC ADR rises Wednesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.48% higher to $69.10 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: U.K. Dividend Stocks Portfolio Review: Summer 2023, source:SeekingAlpha, summary: The UK Dividend Stocks Portfolio invests exclusively in dividend-paying FTSE All-Share stocks, producing over ten years to July-end a total return of 76.8%., Headline: Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition, source:SeekingAlpha, summary: Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround., Headline: AstraZeneca Prostate Cancer, Generalized Myasthenia Gravis Treatments Get Approval in Japan, source:MarketWatch, summary: By Michael Susin AstraZeneca's prostate-cancer treatment Lynparza has been approved in Japan, while Soliris has been approved for expanded use to treat..., Headline: AstraZeneca says Soliris and Lynparza approved in Japan, source:Alliance News, summary: No summary",AZN
292,2023-08-24,"Headline: AstraZeneca says Lynparza combo approved in Japan for certain mCRPC, source:Thefly.com, summary: No summary, Headline: AstraZeneca says Soliris approved in Japan for pediatric gMG, source:Thefly.com, summary: No summary, Headline: Merck, AstraZeneca: LYNPARZA/(abi/pred) combination approved in Japan, source:Thefly.com, summary: No summary, Headline: GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus, source:Benzinga, summary: No summary, Headline: AstraZeneca Under Legal Lens, Faces Two COVID-19 Vaccine Lawsuits In London, source:Benzinga, summary: No summary, Headline: Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico, source:Seeking Alpha, summary: No summary, Headline: Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories, source:Benzinga, summary: No summary, Headline: The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab, source:Yahoo, summary: A Watertown biotech trimmed its pipeline again, setting aside all of its experimental drugs except one. It's the second time the company has cut programs this year. Plus other life sciences news you may have missed., Headline: AZN October 6th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan, source:Alliance News, summary: No summary, Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.19% to £107.50 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: AstraZeneca PLC ADR underperforms Thursday when compared to competitors, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 1.75% to $67.89 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ...",AZN
293,2023-08-25,"Headline: AstraZeneca files challenge to aspects of Inflation Reduction Act, source:Thefly.com, summary: No summary, Headline: AstraZeneca Files Legal Challenge to Some Drug-Price Provisions of IRA, source:MarketWatch, summary: By Will Feuer AstraZeneca said it has filed a legal challenge to certain aspects of the drug price negotiation provisions of the Inflation Reduction Act,..., Headline: Affirm, Netflix, AstraZeneca rise premarket; Nordstrom, Hawaiian Electric fall, source:Yahoo, summary: Investing.com -- U.S. futures traded higher Friday, bouncing after the previous session’s substantial losses ahead of Fed chief Jerome Powell’s key speech at the Jackson Hole gathering., Headline: As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit — even if their drugs aren’t on the list, source:MarketWatch, summary: No summary, Headline: AstraZeneca latest drugmaker to challenge Medicare drug price negotiation, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients, source:Yahoo, summary: WILMINGTON, Del., August 25, 2023--To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA). The drug price negotiation provisions of the IRA run headlong into the goals of the Orphan Drug Act (ODA), a federal statute designed to encourage manufacturers to invest in new therapies for rare diseases., Headline: UPDATE 2-AstraZeneca sues US over Medicare drug price negotiation plans, source:Yahoo, summary: AstraZeneca said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices.  The British drugmaker, which filed its complaint in a Delaware district court, joins other drugmakers and business groups claiming that the program would restrict the development of new medicines.  The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson, Merck & Co, Bristol Myers Squibb and privately-held Boehringer Ingelheim., Headline: AstraZeneca sues US over Medicare drug price negotiation plans, source:Yahoo, summary: The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson, Merck & Co, Bristol Myers Squibb and privately-held Boehringer Ingelheim.  The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA).  AstraZeneca said it was filing the legal challenge to ""protect timely access to medicines for orphan indications"" in the United States., Headline: AstraZeneca falls Friday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.84% to £106.60 Friday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government, source:Benzinga, summary: No summary, Headline: Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation, source:Yahoo, summary: FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue., Headline: AstraZeneca sues US government over drug price reforms, source:Yahoo, summary: Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines, Headline: AstraZeneca files lawsuit against U.S. over drug pricing, source:Yahoo, summary: AstraZeneca (AZN) joins Johnson & Johnson (JNJ), Merck (MRK), and Bristol-Myers (BMY) in a lawsuit against the U.S. Department of Health and Human Services (HHS) over certain provisions on prices found in President Biden's Inflation Reduction Act (IRA). Yahoo Finance Health Care Reporter Anjalee Khemlani joins the Live show to break down the lawsuit and what to expect moving forward., Headline: AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan, source:Yahoo, summary: AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis., Headline: AstraZeneca becomes first international company to file Medicare drug pricing suit, source:Yahoo, summary: AstraZeneca joins as the sixth pharma company, and the first non-US company, to file suit against the Biden Administration over Medicare drug pricing., Headline: AstraZeneca PLC ADR rises Friday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.53% higher to $68.25 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases, source:Yahoo, summary: Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it. And that in turn makes it more difficult for a company to develop and test effective treatments. With so much less known about rare diseases than common ones, scientists may find themselves groping blindly trying to develop drugs and treatments. Rare diseases have less financial incentive as well. Fewer people having a disease means fewer patients that a treatment can be sold to. Th, Headline: AstraZeneca sues US over drug pricing laws, source:Yahoo, summary: Covid vaccine maker AstraZeneca has sued the US government over legislation designed to lower prescription drug prices.",AZN
294,2023-08-26,"Headline: Ken Fisher’s Top 15 Healthcare Stock Picks, source:Yahoo, summary: In this article, we discuss the top 15 healthcare stock picks of Ken Fisher. If you want to skip our detailed discussion about the healthcare industry, head directly to Ken Fisher’s Top 5 Healthcare Stock Picks. The healthcare sector was forever changed by the COVID-19 pandemic. While it highlighted the weaknesses in the global medical […]",AZN
295,2023-08-27,"Headline: Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca, source:SeekingAlpha, summary: WIR China and Poland partner to create a new drug distribution network. Click here to read more about the past week's new deals, financings, and approvals. ",AZN
296,2023-08-28,"Headline: Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work, source:SeekingAlpha, summary: I expect Lexicon Pharmaceuticals to continue to increase its SG&A spending to support Inpefa. Read more to see why LXRX stock is a Buy., Headline: Oncology Market's Huge Potential Puts These Stocks in Focus, source:Yahoo, summary: The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment., Headline: AstraZeneca PLC ADR rises Monday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.57% higher to $68.64 Monday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: See which drugs President Biden is targeting first for Medicare price-lowering talks, source:Associated Press, The, summary: No summary, Headline: 10 drugs targeted for Medicare price negotiations as Biden pitches cost reductions, source:Associated Press, The, summary: No summary, Headline: Republicans say Medicare drug negotiations will mean fewer new meds, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary",AZN
297,2023-08-29,"Headline: Biden unveils first 10 drugs subject to Medicare price negotiation, source:Thefly.com, summary: No summary, Headline: Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings, source:Benzinga, summary: No summary, Headline: Biden administration unveils first 10 drugs subject to Medicare price negotiations, source:CNBC, summary: The announcement of the 10 drugs kicks off a Medicare negotiation process that aims to make costly medications more affordable for older Americans. , Headline: Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations, source:MarketWatch, summary: Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications..., Headline: Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle, source:Benzinga, summary: No summary, Headline: IN THE KNOW: US drug pricing an ""important catalyst"" for AstraZeneca, source:Alliance News, summary: No summary, Headline: White House names first 10 drugs eligible for Medicare price negotiations, source:United Press International, summary: No summary, Headline: Biden administration announces first 10 drugs eligible for Medicare price negotiations, source:United Press International, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Biden Administration targets drugs from J&J, Merck for controversial Medicare price negotiations, source:Yahoo, summary: The Biden administration revealed the first 10 drugs that will face the Medicare negotiation process under the Inflation Reduction Act., Headline: AstraZeneca rises Tuesday, still underperforms market, source:MarketWatch, summary: AstraZeneca PLC shares rallied 1.35% to £108.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100..., Headline: The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca, source:Yahoo, summary: Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog., Headline: Expensive Drugs Targeted for First U.S. Price Negotiations, source:Yahoo, summary: Lower prices would take effect in 2026 depending on the talks between the U.S. and drugmakers and the outcome of industry lawsuits., Headline: AstraZeneca PLC ADR rises Tuesday, still underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.73% higher to $69.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the...",AZN
298,2023-08-30,"Headline: AstraZeneca falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.65% to £107.34 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Medicare drug price negotiations may have a muted impact on drugmakers in the near term, source:CNBC, summary: Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives. , Headline: Medicare price negotiation list: What it means for pharma companies, source:Yahoo, summary: On Tuesday, the Biden administration listed ten drugs subject to Medicare price negotiations. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the list and how this may impact the pharmaceutical companies who profit from these drugs.   The ten drugs and pharma companies impacted are:  Eliquis - Bristol-Myers Squibb (BMY), Pfizer (PFE) Jardiance - Boehringer Ingelheim, Eli Lilly (LLY) Xarelto- Bayer (BAYRY), Johnson & Johnson (JNJ) Januvia - Merck (MRK) Farxiga - AstraZeneca (AZN) Entresto - Novartis (NVS) Enbrel - Amgen (AMGN) Imbruvica - Johnson & Johnson (JNJ), AbbVie (ABBV) Stelara - Johnson & Johnson (JNJ) Fiasp, NovoLog - Novo Nordisk (NVO), Headline: AstraZeneca PLC ADR falls Wednesday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR slid 0.40% to $68.86 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ..., Headline: Roche downgraded to Neutral from Buy at BofA, source:Thefly.com, summary: No summary",AZN
299,2023-08-31,"Headline: CanSino Biologics on AstraZeneca Deal, Earnings, source:Yahoo, summary: Xuefeng Yu, Chairman, Co-Founder & CEO at CanSino Biologics, discusses collaboration plans with pharmaceutical companies including AstraZeneca as well as the company's first half results. He speaks with Rishaad Salamat, David Ingles and Yvonne Man on ""Bloomberg Markets Asia""., Headline: ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers, source:Business Wire, summary: No summary, Headline: China's CanSino seeks more vaccine contracts after AstraZenca deal, source:Yahoo, summary: China's CanSino Biologics , which recently announced a contract manufacturing deal to support AstraZenca's  messenger RNA (mRNA) technology vaccine programme, is in talks with more firms on similar deals, its CEO said, as it seeks new revenue streams to make up for plummeting COVID vaccine demand.  CanSino begun researching mRNA technology in 2018 and has built a facility in Shanghai that can produce up to 200 million doses a year, giving it the capacity to provide similar services to other companies, CanSino's CEO and co-founder Xuefeng Yu told Reuters in an interview.  ""This is the first step,"" he said, describing the AstraZenca deal announced earlier this month as ""a business model""., Headline: AstraZeneca Enhertu granted Breakthrough Therapy status for two indications, source:Seeking Alpha, summary: No summary, Headline: Novo Nordisk: Super Focused Pharma Company For The Long Run, source:SeekingAlpha, summary: Novo Nordisk is one of the most qualitative big pharma companies globally. Read why I am bullish on NVO stock with the long-term investment horizon here., Headline: Amazon continues hot streak as analysts eye AWS event in the fall as a potential catalyst, source:Seeking Alpha, summary: No summary, Headline: AstraZeneca falls Thursday, underperforms market, source:MarketWatch, summary: Shares of AstraZeneca PLC inched down 0.67% to £106.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the..., Headline: Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet, source:Benzinga, summary: No summary, Headline: Big Pharma's biggest ally gets trolled on X for attacking Medicare drug pricing list, source:Yahoo, summary: Drug lobbying firm PhRMA faced backlash on social media for its attempt to call Medicare pricing negotiations unfair., Headline: AstraZeneca PLC ADR falls Thursday, underperforms market, source:MarketWatch, summary: The AstraZeneca PLC ADR shed 1.51% to $67.82 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ..., Headline: Why this S.F. company says Big Pharma deal is big win for patients, source:Yahoo, summary: It's no picnic for chronic disease patients — or, really, anyone — to gather their medical records from multiple doctor offices.  Now the 100-employee, San Francisco-based company, which has raised more than $100 million over nine years, has a new partnership with AstraZeneca plc (NASDAQ: AZN) to expand its platform into cancer.  The company isn't disclosing the value of the deal or how it came together, but it says the information it gathers on behalf of patients ultimately could provide insights that allow paying customers such as AstraZeneca and dozens of other biopharma partners like Genentech Inc. to make better medicines.",AZN
300,2023-09-01,"Headline: AstraZeneca rises Friday, outperforms market, source:MarketWatch, summary: AstraZeneca PLC shares inched up 0.36% to £107.00 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100..., Headline: Judge withdraws from Medicare drug price case after stock ownership is revealed, source:CNBC, summary: Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program., Headline: AstraZeneca PLC ADR underperforms Friday when compared to competitors despite daily gains, source:MarketWatch, summary: The AstraZeneca PLC ADR inched 0.47% higher to $68.14 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",AZN
